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Preface 
i 
Preface 
The industrial PhD project presented within this thesis has been a joint collaboration 
between H. Lundbeck A/S Department of Chemical Technology & Implementation and 
the Technical University of Denmark (DTU) at the department of Chemical and 
Biochemical Engineering in the Combustion and Harmful Emission Control (CHEC) 
research center. The project took place in the period from August 2011 to July 2014. 
Most of the laboratory work was conducted at Lundbeck, except for a six (6) month 
research period at the Massachusetts Institute of Technology (MIT) at the Department of 
Chemical Engineering in the Klavs Jensen research group. 
The thesis is divided into several chapters and a short outline for each chapter is 
given below. The chapters containing original research with experimental sections have 
all been written in the appropriate manuscript format for the journals to which they are to 
be submitted for publication. 
Chapter 1:  A brief introduction to the pharmaceutical industry, including the 
motivations for a shift towards flow chemistry and the chemical 
engineering aspects of continuous production. 
Chapter 2:  A general discussion on the different aspects of Grignard 
chemistry, with a focus on flow chemistry. 
Chapter 3:  This chapter provides a kinetic study of a Grignard addition 
reaction investigated using flow chemistry. The studied chemistry 
contains consecutive-competitive reactions. 
Chapter 4:  The first part of the main case study, in which a flow reactor setup 
has been used to perform a base liberation of an alkyl halide salt 
needed for Grignard reagent formation. 
Chapter 5:  The second part of the main case study, in which a continuous 
reactor setup has been used for the formation of a Grignard reagent. 
Chapter 6:  The third part of the main study, in which a Grignard addition to a 
ketone has been carried out in a continuous reactor setup. 
Multi-step synthesis of an active pharmaceutical ingredient is 
demonstrated. 
Chapter 7:  This chapter demonstrates the scale-up of a laboratory continuous 
reactor setup used for a Grignard addition reaction that includes 
handling of solid material. 
Chapter 8:  This chapter combines the Grignard chemistry demonstrated in the 
previous experimental chapters. It provides a methodology for 
reactor design and decision-making processes related to the 
development of Grignard chemistry in flow. 
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Abstract 
The pharmaceutical industry has experienced many changes over the last few 
decades. Continuous production has been promoted as one of the more promising 
methods for making the industry more efficient and sustainable. The primary focus of this 
thesis is on the performance of Grignard chemistry in continuous reactor setups. Grignard 
chemistry encompasses a very powerful reaction type frequently applied in the 
pharmaceutical industry, for the formation of new carbon-carbon bonds. Three Grignard 
addition reactions have been studied, all having very different behaviors related to aspects 
of reaction engineering. 
A double Grignard addition (two different Grignard reagents) to a lactone was 
studied with continuous production in mind. The complexity of the reaction was 
investigated kinetically in order to optimize a potential flow setup. The investigation 
indicated that reaction temperatures below -40 qC could suppress the formation of an 
undesired bis-addition product by stabilizing the mono-addition adduct. 
A Grignard addition to a poorly soluble tricyclic ketone, previously studied in the 
laboratory, was transferred to full-scale production. Successful upscaling of the laboratory 
setup to full-scale production equipment enabled complete replacement of the existing 
batch production of this intermediate. 
The crowning achievement in this work was the realization of continuous laboratory 
reactor setups capable of manufacturing the entire GMP portion of the synthesis of 
melitracen HCl at H. Lundbeck A/S. The formation of a carbon-carbon bond between a 
tricyclic ketone and a Grignard reagent was the primary objective, this being the first step 
in GMP synthesis. The process was optimized to include one-step hydrolysis and 
dehydration, followed by phase separation of the product-containing organic phase, which 
was then precipitated with hydrogen chloride to obtain the final API. The Grignard 
reagent was also produced in a continuous laboratory setup involving handling of solid 
magnesium turnings. Likewise, the alkyl halide used in the formation of the Grignard 
reagent was produced continuously. The three segmented units were able to be coupled to 
construct a single continuous reactor facility for manufacturing melitracen HCl. 
The study of Grignard addition reactions to the three different substrates investigated 
in this thesis has culminated in a methodology by which reaction engineering decisions 
can be guided. The methodology provides suggestions on when and how decisions should 
be made on continuous production methods for Grignard chemistry within pharmaceutical 
manufacturing. Physicochemical properties, such as solubility, were found to be critical. 
However, from a business perspective, issues such as the current lifecycle of the API and 
GMP can make a potential reactor setup non-feasible. If the pharmaceutical industry is to 
adapt to recent trends towards end-to-end and on-demand pharmaceutical production, 
access to standard reactor units for commonly-used chemical transformations and 
methods for timely decision-making are essential. The methodology described herein 
provides an approach to fulfilling this need for Grignard chemistry in flow reactors. 
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Dansk Resumé 
Den farmaceutiske industri har oplevet mange ændringer i løbet de sidste årtier. 
Kontinuert produktion har været betragtet som en af de mere lovende metoder at gøre 
branchen mere effektiv og bæredygtig. Det primære fokus for denne afhandling har været 
på Grignard kemi med udførsel i kontinuerte reaktor opsætninger. Grignard kemi er 
meget nyttig former for reaktioner, ofte anvendt i farmaceutiske industri til dannelsen af 
nye kulstof-kulstofbindinger. Tre Grignard additionsreaktioner er blevet undersøgt, alle 
med meget forskellige opførelse relateret til ingeniørmæssige reaktionsaspekter. 
En dobbelt Grignard addition (to forskellige Grignard reagenser) til en lactone blev 
studeret med henblik på kontinuert produktion. Kompleksiteten af reaktionen blev 
undersøgt kinetisk, for at optimere et potentielt kontinuert reaktorsystem. Undersøgelsen 
viste, at reaktionstemperaturer under -40 qC kunne undertrykke dannelsen af uønskede 
bisadditionsprodukt, ved stabilisering af den mellemliggende monoaddition addukt. 
En Grignard additon til en lavt opløselige tricyklisk keton, tidligere studeret i 
laboratoriet, blev overført til fuldskala produktion. Succesfuld opskalering af 
laboratorium opsætningen til en større fuldskala produktionsopsætning muligjorde en 
fuldstændig erstatning af den ældre batch produktion af dette mellemprodukt. 
Hovedstudiet var muliggørelsen af kontinuerte laboratorium reaktoropsætninger, som 
kan producere alle GMP syntesetrinene af melitracen HCl hos H. Lundbeck A/S. 
Dannelsen af en kulstof-kulstofbinding imellem en tricyklisk keton og et Grignard 
reagens var det primære formål, som er det første syntesetrin underlagt GMP. Processen 
var optimeret til at omfatte en ét-trins hydrolyse og afvanding, efterfulgt af en 
faseadskillelse af organisk produktfase fra vandigt affald, produktfasen blev efterfølgende 
fældet med HCl til det endelige API. Dannelse af Grignard reagenset blev også påvist i en 
kontinuert laboratorieopstilling, der involverer faststofhåndtering af magnesium spåner. 
Ligeledes var dannelsen af alkylhalidet som blev brugt til Grignard reagenset fremstillet i 
en kontinuerlig reaktoropsætning. Potentielt, kunne de tre segmenterede opsætninger 
være koblet sammen til en enkelt kontinuert reaktoropsætning til dannelse af melitracen 
HCl. 
Studiet af Grignard additionsreaktioner til tre forskellige substrater som er dækket i 
afhandlingen, har kulmineret til en metodologi for beslutningstagen for ingengiørmæssige 
reaktionsovervejelser. Metoden indeholder forslag om hvornår og hvordan der tages 
beslutning for kontinuerte produktionsmetoder for Grignard kemi inden for den 
farmaceutiske produktion. Fysisk-kemiske egenskaber, så som opløselighed, blev fundet 
kritiske. Desuden, er mere bløde problemer som det nuværende livscyklus status af API 
og GMP relaterede emner bidrager til afgørelse, hvis en økonomisk attraktiv 
reaktorløsning skal etableres. Hvis den farmaceutiske industri skal tilpasse sig den seneste 
tendens med end-to-end og on-demand farmaceutisk produktion, er det nødvendigt at 
have standard reaktorenheder for almindeligt anvendte kemiske omdannelser, og metoder 
til tidlig og hurtig beslutningstagen. Den udviklede metodik beskrevet i denne afhandling 
giver en god afdækning af Grignard kemi i flow reaktorer. 
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Chapter 1 
1 The Pharmaceutical Industry and Continuous Production 
1.1 Introduction 
The pharmaceutical industry is highly complex, including many cross-disciplinary 
fields of science and business. In the last couple of decades the industry has experienced 
great changes due to the incipient introduction of continuous production methods and 
reinterpretation of regulations, a process that is still ongoing. The pharmaceutical industry 
as a whole is classified by the different methods by which the active pharmaceutical 
ingredient (API) is produced, either organic chemical synthesis (small molecules) or 
biochemical methods such as fermentation (macromolecules). Besides this overall 
classification, the pharmaceutical industry is further divided into generic companies and 
research-based companies. Throughout this thesis, the term pharmaceutical industry 
refers to the research-based part of the industry, mostly focusing on organic chemical 
synthesis companies. This first chapter provides an introduction to and overview of the 
pharmaceutical industry, covering the transformation it has undergone in the last few 
decades. Understanding the pharmaceutical industry in more detail helps to identify the 
challenges presently faced by the production part of the industry.1,2 
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1.2 H. Lundbeck A/S 
H. Lundbeck A/S (Lundbeck in short form) is a research-based pharmaceutical 
company using organic synthesis to manufacture APIs. Lundbeck focuses on treatments 
for the central nervous system (CNS), a strategy that was established back in 1987. 
Lundbeck was founded in 1915 as a trading company, but has gradually moved towards 
its present dedication to CNS treatments. The employment of Eduard Goldsmith in 1924 
initiated this pharmaceutical production and Lundbeck began to produce pharmaceuticals 
in the 1930s. It was P.V. Petersen who changed the target to CNS and Lundbeck became 
a research company with several APIs produced in-house. Today, Lundbeck is one of the 
leading companies in CNS treatments, with almost 6000 employees worldwide. The 
headquarters and main research & development (R&D) facilities are located in Valby, 
Denmark and the production of APIs is carried out in Lumsås, Denmark and Padua, Italy. 
Tableting facilities are situated in Valby, Denmark and Nice, France.3,4 
For several years, the main source of revenue came from a refinement of the API 
citalopram. A method was developed to separate the racemic mixture into the active 
S-isomer (escitalopram) and the R-isomer, resulting in a new period of patent protection. 
Escitalopram (Cipralex®) has gone off-patent within the last few years, but it has been 
replaced with new promising APIs (nalmefene (Selincro®) and vortioxetine 
(Brintellix®)) to ensure continuous revenue for Lundbeck. As a research-dependent 
pharmaceutical company, development of new APIs is a key parameter for staying in 
business. Besides the R&D of new APIs, constant optimization of production is necessary 
to remain competitive while maintaining production in developed countries with 
expensive labor costs. Lundbeck was quick to embrace the opportunities for alternative 
manufacturing procedures (e.g. continuous production) that became possible in 2004, 
when the Food and Drug Administration (FDA) of the United States (US) reviewed 
current manufacturing methods based on efficiency within the pharmaceutical industry. 
At present, Lundbeck has three full-scale continuous reactor setups in operation, with 
each one being capable of producing three different starting materials used in API 
syntheses. Approaches have furthermore moved from segmented synthetic steps to 
potential multistep syntheses, following the same trend as generally seen in flow 
chemistry. Lundbeck’s main manufacturing methods still rely on batch production, as is 
the case for most pharmaceutical companies.3,4 
1.3 An Overview of the Pharmaceutical Industry 
The pharmaceutical industry is one of the most complex chemical industries and 
includes multidisciplinary interaction between many sciences. The industry relies heavily 
on the development of new drugs and protection through different intellectual property 
(IP) rights. IP is commonly achieved through patents, providing a company with 20 years 
of protection of the invention.5–11 Different patent protections are commonly used in the 
pharmaceutical industry; in particular, patents on structure are highly favored in 
comparison to process patents, which are often hard to enforce.  
The process for developing a new drug candidate for pharmaceutical production is 
expensive and long. A normal development period of approximately 10 years is not 
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uncommon, which only leaves 10 years for making profit.5,12–14 The cost of developing 
one drug that survives until launch and production release additionally has to cover the 
large number of target compounds that have been discarded.8 
In the early discovery period, thousands of potential APIs are synthesized, where 
many of these are discarded early in the process due to toxicity and/or lack of biological 
activity. Approaching the clinical trials, the number of potential APIs is narrowed down 
to less than 10, a number that keeps on decreasing to even less when the phase I studies 
are begun. The phase I study is also the first human trial (in healthy people), which is why 
the cost of testing increases significantly. In phase II, often one or two candidates remain 
and the clinical trials start to include patients with the disease to which the APIs are 
targeted. In phase III, the final verification of efficacy is demonstrated and the APIs are 
filed for production if positive results are achieved. The accumulation of costs steadily 
increases throughout the trial periods, since promising APIs are discarded and in general 
expenses become larger due to more demanding testing and documentation of their 
effects. During phase I, approximately 100 healthy people participate, phase II requires 
400-500 patients and phase III requires up to 5000. For each phase, the requirements for 
success become higher. The amount of the APIs used also increases during development, 
from a few mg to hundreds of kg. An overview of a typical development progress is 
illustrated in figure 1.1.8,10,11,15,16 
As the clinical trials progress, the transfer from R&D to routine production slowly 
begins. During phase I and phase II, the full-scale synthetic route is decided on and 
optimized. At the beginning of phase III, very few alterations to the production method 
are accepted. The limited options for alteration during the beginning of phase III are a 
consequence of the initiation of carcinogenic studies, used to document long-term 
exposure to the API. 
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Figure 1.1: General overview of drug development up to launch.8,10,11,15,16  
The development of new APIs comes with larger expenses in order to regain the 
losses from the thousands of potential drug candidates that were discarded.8 In the last 
few decades, discovery of new APIs has become more challenging and R&D investments 
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have increased steadily, as has development time. The combination of increased R&D 
efforts and decreasing numbers of new APIs pushes up the total cost of development.12 
Figure 1.2 shows the trends in the pharmaceutical industry. In the last couple of years, a 
small increase in the number of New Molecular Entities (NMEs) has been observed and 
over a 20-year period the annual average number of NMEs was approximately 25.17 
 
Figure 1.2: Development within the pharmaceutical industry for the period from 1998 to 2008.18 
The pharmaceutical industry faces a great challenge in increased development costs, 
since the industry still relies on the development of new APIs and IP protections to stay in 
business. It is common that once an API goes off-patent, 90% of the market share can be 
lost within a year.10,11,19 The first and most simple way to increase revenue is by 
producing under patent protection for a longer period of time. Expanding the production 
time under patent protection requires the product to reach the market earlier (i.e. 
shortening the development time) or the patent to be prolonged. Both concepts are rather 
unlikely to occur in most situations and alternative ways should be found. Another 
alternative is efficiency of production (e.g. process intensification and process 
optimization), hence manufacturing APIs at a lower cost than the original methods 
through novel solutions.20 A common cost structure in the pharmaceutical industry is 
given in figure 1.3, illustrating the importance of R&D to companies but also elucidating 
the huge expenses related to manufacturing that could potentially be reduced.21 It is not 
uncommon for R&D spending on product development to be even higher12 (30-35%). 
The raw material is often the most expensive part of the manufacturing costs, accounting 
for 30-80%. The remaining manufacturing expenses are operational, distributed between 
labor, plant costs, quality assurance & control, waste treatment, logistics & transport and 
changing & cleaning.22 
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Figure 1.3: The cost distribution in a typical pharmaceutical company.21 
As the challenges for discovering new APIs have increased, collaborations across 
boundaries have emerged. Cross-collaborations between academia and industry as well as 
joint ventures between large pharmaceutical companies have arisen. Joint ventures 
between big pharmaceutical companies for the development of new APIs are often seen 
due to the shared risk, meanwhile accepting the downsides of sharing profit. This trend is 
also supported by the fact that new API development has increased in the academic 
environment, with a subsequent modification in the pharmaceutical R&D 
department.10,23,24 Welch et al.25 provide a good overview of the benefits and downsides 
of different approaches to collaboration. During the last two decades, significant merging 
of large pharmaceutical companies has occurred. In 2010, 10 of the biggest 
pharmaceutical companies could be traced back to 57 companies in 1990.18 
Due to the consequences that badly-produced medicines can impose on patients, the 
pharmaceutical industry is perhaps the most strictly regulated chemical industry. The 
industry subscribes to the concept of GXP, which is a general acronym for Good Practice 
related to a certain area X. Production has to comply with Good Manufacturing Practice 
(GMP), where it is the current GMP (cGMP) version that must be met, as the description 
is frequently revisited and updated. Enforcement of the rules is handled by the regulatory 
authorities, the three major ones in the world being the US FDA, the European Medicines 
Agency (EMA) and the Japanese Ministry of Health. All three agencies disseminate the 
guidelines provided by the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH is a 
professional organization consisting of the regulatory authorities and the pharmaceutical 
industry in these three regions.19,26,27 
Regulatory control and documentation rules are very strict and once the 
manufacturing process for an API has been filed and approved, optimizing the process by 
alteration becomes very difficult and is often associated with expensive and time-
consuming refiling. As a consequence of these strict regulations to protect patients, the 
industry has impeded its own opportunities for innovation. In 2004, the FDA broke with 
the general GMP rules of the time and started the debate on how the pharmaceutical 
industry could still comply with high quality assurance but allow innovative thinking at 
the same time.21,28 
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As the new regulatory aspects were brought into effect, new control strategies 
became necessary. Before 2004, the standard procedure for the release of APIs and drugs 
was through quality analysis by well-defined procedures. Out-of-trend (OOT) or 
out-of-specification (OOS) APIs were easily detected, since each batch required a release 
analysis before further processing. Continuous manufacturing does not have the same 
control of material as batch methods and alternative ways to assure quality have to be 
established. Process Analytical Technology (PAT) and Quality-by-Design (QbD) are 
potential methods for achieving the desired quality control. The concepts of QbD and 
PAT are closely related, as PATs are often used to ensure that a reactor setup’s 
performance is in accordance with the specified QbD description when operated. 
Development of spectroscopic equipment and measurement methods has progressed 
strongly and today serves as a very important tool for PATs. Spectroscopic measuring has 
become very popular due to its non-disruptive methods, from which highly specific data 
can also be extracted. The measurements are often combined with chemometric data 
treatment, as the raw data are not always easily interpreted. The more commonly used 
non-disruptive spectroscopic methods include near-infrared (NIR), infrared (IR), Raman 
and ultraviolet measurement (UV-vis). In the process of developing a QbD reactor setup, 
Design of Experiments (DoE) is often used to optimize performance based on static 
calculation and modelling of the investigated parameters. Simpler measurement methods 
like temperature, mass flow and pH controllers are commonly applied and prove 
sufficient and important for QbD in many instances. The above-mentioned methods have 
been used in the food industry for several years before being merged into the 
pharmaceutical industry.1,15,19,29,30 
Discussions on how the pharmaceutical industry can keep up with modern thinking 
and efficiency have been the target of many debates and publications throughout the last 
decade.22,31–34 Stakeholders in the pharmaceutical industry broadly acknowledge that the 
current state does not comply with modern thinking and actions are already being taken to 
meet these concepts. Many issues, aspects and concerns have been raised in order to gain 
a better overview of the challenges the industry is facing. In 2005, interested parties from 
the American Chemical Society (ACS), the Green Chemistry Institute (GCI) and leading 
global pharmaceutical companies formed the ACS GCI pharmaceutical roundtable 
committee.31 The primary interest of the committee is how the pharmaceutical industry 
can remain efficient and competitive and in 2007 the committee came up with ten key 
issues (Table 1.1). The highest ranked key area was continuous processing,31,35 a topic 
that since the beginning of the century has attracted great attention within organic 
synthesis chemistry.32–34,36–43 However, continuous pharmaceutical production is not an 
entirely new concept. V.V. Popov44 suggested back in the 1970s that continuous 
production could be of great importance for the pharmaceutical industry. 
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Table 1.1: Ten key issues suggested by the ACS GCI Roundtable to be important for the pharmaceutical 
industry.31 
Rank Main Key Areas Sub-Areas/Aspects Votes 
1 Continuous Processing Primary, Secondary, Semi-continuous 12 
2 Bioprocesses Biotechnology, Fermentations, Biocatalysis, 
GMOs 
11 
3 Separations and Reaction 
Technologies 
Membranes, Crystallization 11 
4 Solvent Selection, 
Recycling and 
Optimization 
Property modelling, Volume optimization, 
Recycling technologies, In-process 
recycling, Regulatory aspects 
10 
5 Process Intensification Technology, Process, Hybrid systems 9 
6 Integration of Life Cycle 
Assessment (LCA) 
Lifecycle thinking, Total cost assessment, 
Carbon/eco-footprinting, Social LCA, 
Streamlined tools 
4 
7 Integration of Chemistry 
and Engineering 
Business strategy, Links with education 4 
8 Scale-up Aspects Mass and energy transfer, Kinetics and 
others 
3 
9 Process Energy Intensity Baseline for pharmaceuticals, Estimation, 
Energy optimization 
1 
10 Mass and Energy 
Integration 
Process integration, Process synthesis, 
Combined heat and power 
0 
 
In an effort to provide sustainability for the pharmaceutical industry, a number of 
reviews have been published. GlaxoSmithKline (GSK) reviewed their use of solvents and 
reagents to understand whether better and more clever decisions on reagents and solvents 
could be made for both production and early candidate development.45–47 The ACS GCI 
pharmaceutical roundtable35 assessed the distribution of consumed material for API 
production, revealing that reactants only accounted for 7% of the Process Mass Intensity 
(PMI). The PMI survey showed that solvents and water accounted for 56% and 32% 
respectively, which is in good agreement with the E-factor comparison of different 
chemical industries (Table 1.2) made by Sheldon.48 An overview on how the fine 
chemical and pharmaceutical industries (7 and 17 companies, respectively) were dealing 
with green chemistry and sustainability was provided by Watson.49 
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Table 1.2: The E-factor for a selected number of chemical industries.48 
Industry Segment Product Tonnage 
(T) 
E-Factor 
(kgwaste/kgproduct) 
Oil Refining 106-108 <0.1 
Bulk Chemicals 104-106 <1-5 
Fine Chemicals 102-104 5-50 
Pharmaceuticals 10-103 25-100 
 
AstraZeneca, Pfizer and GSK50 mapped the number of different synthesis routes and 
chemical transformations that are most frequently used in the synthesis of small molecule 
APIs (<550 MW). The survey shows that, on average, eight chemical transformations 
were necessary to achieve the final product of the 128 syntheses investigated. Roughley et 
al.51 did a similar survey and Pfizer52 provided an overview of reaction types and methods 
used in GMP bulk production. Formation of new carbon-carbon bonds accounted for 
roughly 11-14% of all chemical transformations, with Grignard reactions accounting for 
approximately 6-9% of this number.50–52 Lonza53 provided a survey of 86 synthesis steps 
in which it was concluded that 63% involved solid material handling. The ACS GCI 
pharmaceutical roundtable31 provided an estimate of the frequency of different unit 
operations used in pharmaceutical chemistry (Figure 1.4). Mapping and categorizing the 
industry have helped to visualize potential areas where a change of mind-set and common 
routines could be made. 
 
Figure 1.4: Frequency of unit operations applied in the pharmaceutical industry.31 
1.3.1 Batch or Continuous Production 
Batch productions have been the workhorse of the pharmaceutical industry for many 
decades. In particular, the authorities’ definition of how APIs should be manufactured and 
R&D scientists’ preferred synthesis methods in the laboratory have been major driving 
forces for the prevalence of batch methods. The biggest advantage of a batch reactor may 
very well be its multipurpose functionality (e.g. reaction, separation, crystallization and 
distillation), providing great flexibility for manufacturing. Combined with the fact that 
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development of new APIs mostly proceeds via batch syntheses, the natural choice for 
scaling of a synthesis is often the batch reactors.19,22,32 
Continuous production methods are quite the contrary to using batch reactors. The 
continuous reactors employed are often highly specific for the intended process and often 
only capable of performing a single operation. The specificity of continuous reactors is 
among the things that make continuous reactors highly efficient. Continuous reactors are 
often significantly smaller in dimension compared to batch reactors. The smaller 
dimensions improve the mass and heat transfer performance of continuous reactors, 
resulting in more stable operating conditions. A major drawback of continuous reactors is 
their limited capability for handling solid reactants and special designs or precautions are 
often necessary. Control strategies also become an important factor when dealing with 
continuous manufacturing.19,22,32,54,55 
Comparison of batch technologies with continuous processing elucidates why batch 
reactors are still in use in the pharmaceutical industry, despite the many great advantages 
of flow chemistry. As seen in table 1.3, both production technologies have advantages 
and disadvantages and the choice of one over the other should be based on optimal 
performance of the given reaction or chemistry.19,32,56,57 
Table 1.3: Comparison of batch and continuous process technologies; (+) and (-) indicate positive or negative 
influence.56,a 
Criterion Batch Process Continuous Process 
Product Quality Variable (-) Constant (+) 
Optimal Product Quantities Small: On-demand Medium/Large: In store 
Process Flexibility High, Multipurpose (+) Low, Dedicated (-) 
Automation Low, but complex High, Straightforward 
Labor Cost High (-) Low (+) 
bProcess Control Needs Low (+) High (-) 
Set-Up Times Long (-) Minimal (+) 
Cleaning Laborious (-) In-Design (+) 
Start-Up and Shutdown Not Applicable Complex (-) 
Long Reaction Times Possible (+) Difficult (-) 
Investment Low (+) High (-) 
Maintenance and Troubleshooting Common Equipment (+) Often Customized (-) 
aThe table is modified for clarification. 
bThe original source56 has the opposite statement, but this is assumed to be a misprint and 
has been corrected. 
 
Calabrese and Pissavini57 provided an economic assessment of flow chemistry over 
batch processing for a nitration reaction. The Novartis-MIT collaboration58 gave rise to an 
economic comparison between a batch and a continuous process for a selected API 
synthesis. 
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1.4 Reaction Engineering Aspects Related to Flow Chemistry 
Chemical reaction engineering plays a very important part in the effort to transform 
the traditional pharmaceutical batch industry into modern time-continuous process 
methods. In particular, understanding the potentials and limitations of flow reactors is 
necessary for attempting to make flow reactor setups for production purposes. 
The continuous stirred tank reactor (CSTR) and the plug flow reactor (PFR) are 
perhaps the two most important reactor modules to understand, since many of the other 
more specialized reactor configurations can be described based on these. One of the main 
differences distinguishing continuous reactors from batch reactors is that the reaction 
takes place over space (reactor volume) instead of time. For flow reactors, reaction time 
then becomes correlated to reactor volume (V) and volumetric flow rate (v), to give the 
residence time (τ).59,60 
 ߬ ൌ ௏௩ 1.1 
Describing a chemical system is done on the basis of the mass balance, which after 
rearranging gives the design equations for the different reactors. For ideal reactors under 
steady state conditions, the design equations for a CSTR and a PFR are given in equations 
1.2 and 1.3, respectively. 
 ܸ ൌ ிೕబିிೕି௥ೕ  1.2 
 
ௗிೕ
ௗ௏ ൌ െݎ௝ 1.3 
The design equations are based on the reactor volume (V), the molar flow rate (F) to 
a given species (j) and the rate of reaction (-r). The molar flow rate is also described as 
concentration (Cj) multiplied by the volumetric flow rate (v). The design equation for the 
PFR is comparable to the design equation for a batch reactor.59 The rate of reaction is 
determined by the rate constants and the chemistry to be carried out in the reactor. In 
many situations, the elementary rate law is sufficient for describing the system.59 
One of the significant differences between a PFR and a CSTR is the mixing behavior. 
The PFR will in an ideal situation have no axial mixing, resulting in no back mixing. For 
the CSTR, the picture is completely the opposite and under ideal conditions the mixture 
within the reactor is the same as in the outlet. For real systems, ideal behavior is rarely 
observed even in a tubular flow regime, but the effect of this non-ideality can often be 
neglected. Residence time distribution (RTD) is a common method for expressing the 
effect of non-ideality.59,60 
In addition to the RTD, the mixing occurring in the two reactor types is based on 
different technologies. The CSTR is in general equipped with a mechanical stirring 
mechanism, such as an impeller or similar device, for mixing in the reactor vessel. The 
PFR in its simplest version relies on internal forces alone for mixing. The mixing 
performance of the PFR can be enhanced with static mixers (mechanical forces), resulting 
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in better mixing performance.61–65 To describe mixing, the dimensionless Reynolds (Re) 
number is widely applied, which describes the relation between internal and viscous 
forces. For pipes, the Re is defined by the density (ρ), the viscosity (μ), the flow velocity 
(v) and the hydraulic diameter (DH). For an impeller-stirred vessel, the Re is often defined 
by the density (ρ), the viscosity (μ), the impeller diameter (D) and the rotational speed of 
the impeller (N). Large Re values equate to a tubular flow regime (RePFR > 3000, ReCSTR 
> 104).59,66,67 
 ܴ݁௉ிோ ൌ ఘ௩஽ಹఓ  1.4 
 ܴ݁஼ௌ்ோ ൌ ఘே஽
మ
ఓ  1.5 
The way of defining the average reaction time in a continuous reactor by τ (equation 
1.1) gives rise to some general assumptions on the limitations of the system related to 
dimensions, mixing and reaction times. If the desire is to have good mixing, the PFR 
faces challenges for slow reactions.22 In order to obtain large Re numbers, the flow rate 
must be high and in the case of slow reactions a very long PFR is required that will 
additionally result in a large drop in pressure. Since the mixing in a CSTR is not 
influenced by the flow rate, the CSTR is preferred over the PFR for slow reactions in 
many situations.22,43,68 
Since the Re number for a PFR will in many situations result in non-tubular flow 
regimes, other dimensionless numbers have been defined to assist with the decision on 
PFR related to mixing performance and its influence on the reaction. One of the most 
important is the Bodenstein (Bo) number, which describes the convective flow to 
dispersion. Bo is defined by the average flow velocity (ū), the reactor length (L) and the 
dispersion coefficient (D). The dispersion coefficient accounts for both the diffusion 
coefficient and the convection. Bo has been applied in small scale systems in 
particular.32,66,69 
 ܤ݋ ൌ ௨௅ࡰ  1.6 
Other interesting numbers that should be mentioned are the Damköhler (Da) number 
and the Dean (De) number, where Da describes the reaction time-scale versus the 
residence time and the De number describes the vortices in curved pipes.66,70,71 Similar to 
the dimensionless numbers discussed for mass transfer, heat transfer is just as important a 
topic. The Péclet (Pe), Nusselt (Nu) and Prandtl (Pa) numbers are some of the more 
important numbers; for a deeper discussion of the topic on dimensionless numbers and 
general mass and heat transport phenomena, see Bird et al.66 
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To benefit from the design equations, an understanding of the chemistry and the 
kinetics taking place is important, especially when dealing with competitive reactions, 
either consecutive (1.7) or in parallel (1.8).59 In these two equations, A, B and C are 
reactants, P is the desired product with rate constant kP and I is the undesired product with 
the rate constant kI. 
 ܣ ൅ ܤ
௞ುሱሮܲ
ܣ ൅ ܲ ௞಺՜ ܫ
 1.7 
 ܣ ൅ ܤ
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ܣ ൅ ܥ ௞಺՜ ܫ
 1.8 
A number of studies have been carried out in order to better understand how to 
manipulate these kinds of reaction challenge.63,70,72–74 
A couple of the more conceptual reactor configurations for continuous production 
deserve more detailed description. Multiple injection points PFR is, in its most simple 
configuration, a number of PFRs connected in series. This kind of reactor configuration is 
often used in situations where it is desirable to keep one of the reactants at a low 
concentration (e.g. competitive reactions, exothermic reactions).75–80 Another commonly 
applied configuration is multiple CSTRs in series. This type of configuration is often used 
to narrow down the RTD of the CSTR. A common application for this configuration is for 
slow reactions that are mixing sensitive.59,81,82 Similar to multiple CSTRs is the 
oscillatory flow reactor (OFR). This consists of a tubular reactor divided into a number of 
cavities by baffles. An oscillating motion makes the small cavities behave like small 
CSTRs, hence at laminar flow-through a tubular flow regime can be achieved. Besides 
the mixing sensitive reactions, this conceptual reactor has been used for crystallisation.83–
87 The filter reactor is another conceptual reactor design. This reactor is well stirred, 
similar to a CSTR, but with a filter at the outlet to retain solid material. This type of 
reactor has an advantage for any reaction that requires retaining solid material; one 
example could be a solid reactant with low solubility where the product has high 
solubility.88–90 
1.5 Process Scale-up from Laboratory to Full-Scale 
In transferring from the laboratory development of APIs to full-scale production, 
there is a huge change in the way the chemistry is performed to achieve the desired API. 
In the laboratory search for new APIs, exotic synthesis routes are used, often with narrow 
operating windows. A direct transfer is therefore often not possible if the process is to be 
economically feasible. On average, 5-8 synthetic steps are used for commercially 
available products.50–52 Besides the challenge of modifying the chemistry, the largest 
difficulties are the physical phenomena (e.g. mass and heat transfer) observed in a larger 
reactor. Table 1.4 gives an understanding of how, in particular, the surface to volume 
ratio changes from the laboratory to a production size batch reactor. Furthermore, 
parameters such as stirring intensity are effected by the scaling.1,19,59,91 
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Table 1.4: Scale-up from laboratory to production size equipment for batch reactors. 
 Laboratory 
Development 
Laboratory 
Scale-Up 
Pilot 
Plant 
Production 
Active Volume (L) 0.5 50 500 5000 
Diameter (m) 0.086 0.399 0.86 1.85 
Height (m) 0.086 0.399 0.86 1.85 
Surface Area (m2) 0.029 0.625 2.904 13.440 
Surface/Volume (m-1) 58.1 12.5 5.8 2.7 
 
In comparison to the batch reactor scale-up, a similar calculation can be done for 
tubular flow reactors (Table 1.5). 
Table 1.5: Comparison of laboratory to production size equipment for PFR with 10 min residence time. 
 Laboratory 
Development 
Laboratory 
Scale-Up 
Production 
(Small) 
Production 
(Large) 
Flow rate (mL/min) 1 50 500 1000 
Diameter ID (inch) 1/16 3/8 1 1 ½ 
Length (m) 5.1 7.0 9.9 8.8 
Volume (L) 0.01 0.5 5 10 
Surface Area (m2) 0.025 0.210 0.787 1.050 
Surface/Volume (m-1) 25.2 4.2 1.6 1.0 
 
As shown in table 1.4 and table 1.5, scale-up of a batch reactor and a tubular flow 
reactor does not have much effect on the surface to volume ratio, but the center to wall 
ratio is very different. Continuous stirred tank reactors (CSTRs) are placed somewhere in 
between batch reactors and PFRs upon scaling. 
  
39
Chapter 1 
14 
1.6 Summary 
The pharmaceutical industry has in recent decades experienced changes in the way 
the industry is observed. The number of new pharmaceuticals being developed has 
generally decreased and many of the previous blockbusters have gone off-patent. At the 
same time, generic manufacturers keep putting pressure on research and development-
based companies by manufacturing off-patent pharmaceuticals more cheaply. Focusing 
on sustainability and greener processes has also pushed the industry into new directions 
of more efficient production. Stakeholders in the pharmaceutical industry have generally 
acknowledged that changes are necessary and the authorities have slightly relaxed the 
regulatory documentation related to production. It is believed by many that continuous 
production is one of the key parameters that can make the industry more efficient. The 
pharmaceutical industry still relies heavily on development by batch processing and the 
shift towards continuous production is a slow process. Continuous processing is a whole 
new discipline within the pharmaceutical industry and new technologies and terms such 
as Quality-by-Design, including spectroscopic on-line measuring for control strategies, 
have become common. Additionally, cross-disciplinary collaboration between 
pharmaceutical development and manufacturing departments is essential if a successful 
transformation to continuous processing is to take place. Furthermore, a general 
understanding of the reaction engineering aspects of continuous production is important 
for the transfer from batch to continuous processing to become possible. 
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2 The Grignard Reaction 
Even over 100 years after its discovery, the Grignard reaction still serves as an 
important and common method for the formation of carbon-carbon bonds. The popularity 
of Grignard reagents is likely due to their wide application and capability of achieving 
high yields with good selectivity. Of the many different Grignard processes, addition of 
Grignard reagents to carbonyl groups is perhaps the most well-researched. Over the last 
decade, flow methods have been used to investigate the Grignard reaction, demonstrating 
improved outcome of the investigated processes as compared to batch methods. Despite 
the early proposal of the overall mechanism by Victor Grignard back in the early 20th 
century, the details of the reaction mechanism are still being studied today. 
  
41
Chapter 2 
16 
2.1 Introduction 
Grignard reagents are well-known and widely applied organometallic reagents. In 
1899, Philippe Barbier reported a tertiary alcohol achieved from the reaction between 
magnesium, methyl iodide (1) and ketone 3 to give tertiary alcohol 5 upon hydrolysis.92 
Barbier’s student, Victor Grignard, began to investigate the underlying reaction 
mechanisms in 1900 and later proposed the mechanism illustrated in scheme 2.1.93 He 
was honored with the Nobel Prize in 1912 for his exceptional work within 
organomagnesium chemistry and for the discovery of Grignard reagents.94 
Scheme 2.1: The reaction mechanism proposed by Victor Grignard, based on the tertiary alcohol discovered by 
Philippe Barbier.93,94 
 
Grignard proposed that the first step in the mechanism was the formation of Grignard 
reagent 2 from alkyl halide 1, which then adds to the ketone 3 (i.e. the carbonyl functional 
group). Finally, hydrolysis leads to formation of alcohol 5.93 The original reaction, 
discovered by Grignard, is only one of many ways in which Grignard reagents can react. 
Table 2.1 shows a selected overview of the scope of the Grignard reaction. Furthermore, 
Entemann & Johnson have compared the reactivity of different functional groups towards 
Grignard reagents.95 Grignard reagents, as well as the magnesium alkoxides formed, are 
highly sensitive towards water and oxygen. Grignard chemistry is therefore normally 
performed in an inert atmosphere of nitrogen or argon.94 
In recent decades, synthetic methods employing other organometallic reagents such 
as organolithium reactions, palladium-catalyzed cross couplings and other transition 
metal-catalyzed reactions have become more common.50,52,96,97 Despite this, the Grignard 
reaction still serves as a commonly used method, both in the laboratory51,96 and at 
production scale.52,88,98,99 Organometallic reactions account for ca. 13% of the methods 
used for the formation of new carbon-carbon (C-C) bonds in the development of new 
APIs.50,51 
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Table 2.1: Reactants and hydrolyzed products from reaction with a Grignard reagent (RMgX), with R being any 
aryl or alkyl group, X being any halide, M being a metal and n being a number.94,96,100–102 
Reactant Products Comments 
   
   
   
   
   
  
 
  
 
  
 
  
Major product 
  By-product 
 
 
Minor product 
  
 
  
 
  
 
  
 
 
 
 
  
 
  
High temperature 
 
 
Acidic workup 
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2.2 Formation of Grignard Reagents 
Grignard reagents are formed from a reaction between solid magnesium and alkyl or 
aryl halide reagents. The reaction is highly exothermic and the energy released is 
typically in the range of 150 to 350 kJ/mol, which for the most commonly used solvents 
for the Grignard reaction is enough to keep them at their boiling point.79,94,103–106 The 
simplified reaction for the formation of Grignard reagents is shown in scheme 2.2, where 
the magnesium is inserted between the aryl or alkyl group and the halide.94 
Scheme 2.2: Simplified expression for Grignard reagent formation between solid magnesium and an alkyl or aryl 
halide. R is an aryl or alkyl group, X is a halide (Cl, Br, I).94 
 
Since the early proposal of the elementary steps in the reaction studied by Grignard,93 
an ongoing debate has progressed on the underlying mechanism of each of the steps. 
Several reaction mechanisms have been suggested for the formation of Grignard 
reagents94,100,107–109 and still to this day no common mechanism has been agreed upon. 
The most commonly accepted single radical electron transfer (SET) mechanism is 
illustrated in scheme 2.3.94,107–109 
Scheme 2.3: The most commonly accepted reaction mechanism for Grignard reagent formation.108 
 
It is widely accepted94,100,107 that the reaction occurs on the surface of the solid 
magnesium. A fine layer of magnesium oxide is typically present on the surface and 
protects the magnesium from the atmosphere. Due to the passive nature of magnesium 
oxide, it is common to activate the magnesium. Activation can be performed in several 
ways,110 including dry-stirring, ultrasound or addition of iodine or a highly reactive alkyl 
halide (e.g. ethyl bromide). Besides the activation of magnesium, refluxing the 
magnesium together with the solvent helps to overcome the activation energy barrier 
necessary to initiate the reaction.94 Starting the formation of a Grignard reagent is a 
potential risk, since insufficient initiation of the reaction can lead to accumulation of 
unreacted alkyl or aryl halide in the magnesium-solvent dispersion. If the mixture 
suddenly initiates, a huge energy release can result in a spontaneous runaway.94,100,111 
Commonly, Grignard reagent formation is carried out at the boiling point of the solvent, 
where the reflux helps to remove the energy released through constant evaporation and 
condensation.94,103 If the formation is carried out at the boiling point of the solvent, the 
reaction can easily be followed by the temperature,94,100 but other methods have also been 
investigated (e.g. NIR, IR).103,111–114 A number of different magnesium sources 
exist94,100,115 and table 2.2 gives an overview of the most common ones and their 
44
The Grignard Reaction 
19 
advantages and disadvantages. In particular, turnings are commonly used due to their ease 
of use and limited disadvantages.94,100 
Table 2.2: Different magnesium sources for the formation of Grignard reagents.100 
Magnesium Type Advantages Disadvantages 
Turnings Ease of Use Concern about abrasion of glassware and 
glass-lined reaction vessels. 
Powdered More Reactive Finely divided powder gives faster oxidation of 
the surface upon exposure to air. 
Can be pyrophoric. 
Chips 
(from sublimation) 
Higher Purity Lower surface area results in less reactivity than 
powdered turnings. 
Rieke-magnesium More Reactive Requires an extra step in preparation. 
Residual magnesium halide present in reaction. 
Residual potassium may be present. 
Difficult preparation at large scales. 
 
In some cases, alternative methods are used for the generation of Grignard reagents. 
The reason for using alternative routes can be due to non-accessible RX species, 
economic considerations, homocoupling issues and other synthetic difficulties.94 Table 
2.3 provides alternative methods for Grignard reagent generation. 
Table 2.3: Alternative Grignard reagent formation methods.94 
Mechanism Reaction Type 
RnM + nMgX2 → nRMgX + MXn Metal-metal exchange 
RH +R1MgX → RMgX + R1H Acid-base reaction of RH with a Grignard 
reagent 
RMX + Mg → RMgX + M Oxidative-reductive transmetalation 
RMgX + R1X1 → RX1 + R1MgX Metal halide-halide exchange 
 
2.3 Grignard Addition Reactions 
The reaction between carbonyls and Grignard reagents is one of the most well-
studied Grignard processes,94,96,100,116 where ketones in particular have served as the 
carbonyl source. A large number of reaction mechanisms have been suggested over time, 
with the two most prominent being by Meisenheimer & Casper117 and Swain & Boyles118, 
shown in scheme 2.4 and scheme 2.5, respectively. The main difference between these 
two mechanisms, if simplified, is that the Meisenheimer mechanism results in a second 
order elementary reaction and the Swain mechanism in a third order elementary reaction 
due to usage of two Grignard molecules for each coupling. 
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Scheme 2.4: Reaction mechanism suggested by Meisenheimer & Casper for the reaction of Grignard reagents 
with ketones and aldehydes (R1 = H, alkyl or aryl).116,117 
 
Scheme 2.5: Reaction mechanism suggested by Swain & Boyles for the reaction of Grignard reagents with 
ketones and aldehydes (R1 = H, alkyl or aryl).116,118 
 
Esters react very similarly to ketones and aldehydes. The primary product from the 
addition of two equivalents of Grignard reagents to an ester is a tertiary alcohol and a 
by-product primary alcohol, after the hydrolysis has taken place.94,96,100,119 The reaction 
proceeds in two steps, where the second addition is comparable to the one for ketones 
(scheme 2.4 or scheme 2.5). The mechanism for Grignard addition to an ester is 
illustrated in scheme 2.6. In the first step, the Grignard reagent adds to the ester, with 
subsequent collapse of the formed tetrahedral intermediate resulting in the formation of a 
ketone and a magnesium alkoxide. The formation of the ketone allows the second 
addition to take place. The collapse of the tetrahedral intermediate is an equilibrium state, 
which under most conditions is shifted towards the ketone (i.e. the right side).119 
Scheme 2.6: Reaction mechanism for the reaction between Grignard reagents and esters. The second addition 
proceeds as for a ketone (R1 = H, alkyl or aryl). 
 
Special cases have been reported where the primary product of the Grignard addition 
to an ester gives a ketone (mono-addition). Nicaise et al.120,121 documented a stable 
ketone from a Grignard addition to a diester at -78 qC. The hydrolysis of the magnesium 
alkoxide was carried out at -78 qC to give the ketone; however, if the mixture was heated 
to room temperature before hydrolysis the product was an enol (Scheme 2.7). 
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Scheme 2.7: The Grignard addition to a diester to give a ketone upon hydrolysis at -78 qC.120,121 
 
Additions to phthalides have likewise resulted in mono-addition. Smith & Wikman122 
and Hillery & Cohen123 have suggested that the substitution of hydrogen with methyl or 
phenyl on the 3, 4 and 7 positions of the phthalide influences its ability to undergo the 
second addition. A study by Natelson & Pearl124 showed mono-addition to a phthalide but 
has not been confirmed by other researchers.122 
Scheme 2.8: The Grignard addition to a disubstituted phthalide in the 3,3 or 4,7 position, resulting in mono-
addition. R1 and R2 are a hydrogen, methyl or phenyl, R is an alkyl or aryl, X is a halide.122,123 
 
Weinreb ketone synthesis is a possible method if mono-addition to esters is desired 
(i.e. yielding ketones). The method requires transformation of the ester to 
N,O-dimethylhydroxyamide, with a subsequent acidic workup.125,126 
Scheme 2.9: Weinreb ketone synthesis to give a ketone upon acidic workup. R1 and R2 are an alkyl or aryl.125,126 
 
2.4 Hydrolysis 
Grignard reagents are frequently used in organic synthesis due to their capability and 
ease of use for forming new carbon-carbon bonds.50,51 The primary product of importance 
from a Grignard reaction is the alcohol and not the magnesium alkoxide. Hydrolysis of 
the magnesium alkoxide results in the formation of the desired alcohol upon release of 
magnesium salts. A proposed reaction mechanism is illustrated in scheme 2.10. 
Hydrolysis of the magnesium alkoxide is an exothermic reaction, with energy releases of 
150 to 250 kJ/mol.104,127 The magnesium salt is likely to undergo additional reactions with 
the acid and water used for the hydrolysis. 
Scheme 2.10: The hydrolysis of a magnesium alkoxide to yield an alcohol and a magnesium salt.94,100 
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2.4.1 Water and Acid 
Hydrolysis is done by the addition of water to the magnesium alkoxide.94,100 Water is 
sufficient to carry out the hydrolysis, but the reaction is strongly enhanced by the addition 
of any acid that can serve as a catalyst.94,100 The otherwise low solubility of the formed 
magnesium salts is enhanced under acidic conditions. Common acids to use for 
hydrolysis are hydrochloric or sulfuric acid, which due to their strong acidity decompose 
the basic magnesium salts.94 Hydrochloric and sulfuric acid are also commonly used for 
dehydration94,100 and are of limited use if a tertiary alcohol is desired from the addition 
reaction, because this readily eliminates it. Acetic acid is another commonly used acid. 
The less acidic nature of acetic acid makes it a common choice if dehydration is to be 
avoided.94,100 Acetic acid also tends to form complexes with magnesium salts, which 
means that the magnesium salts tend to be soluble even under basic conditions. One 
suggested salt could be magnesium acetate, due to its high solubility in water. Aqueous 
ammonium chloride solution is an alternative to acetic acid when weak acids are 
preferred. 
2.4.2 Magnesium Salts 
The primary product of interest in the Grignard reaction is the alcohol achieved upon 
hydrolysis of the magnesium alkoxide. The by-products of the hydrolysis are magnesium 
salts, which due to their low importance in organic synthesis have received far less 
interest in the literature.128–132 In a classic batch approach, no special precautions need to 
be taken with regard to the magnesium salts. Typically, the salts will either be dissolved 
in the aqueous phase or, in the worst case, precipitate out as solid inorganic salts.94,100 In 
either case, the simplicity of batch setup allows easy handling during recovery of the 
desired product. When considering flow chemistry, magnesium salts are a crucial issue 
that needs to be accounted for. Magnesium salts can be divided into two main categories: 
halide salts and hydroxide salts. Halide salts in general have high solubility133,134 that is 
only slightly affected by temperature changes. Hydroxide salts tend to have very low 
solubility in water, but the addition of diluted acid tends to increase their solubility 
significantly.i Under basic conditions, magnesium hydroxide salts are typically gel-like 
and very sticky.ii,94,100 Table 2.4 provides values for the solubility of different magnesium 
salts in water. 
Table 2.4: Solubility of magnesium salts in water.133,134 
Magnesium Salt Watera (g/100 g water) 
Mg(OH)2 0.00069 
MgO 0.00086b 
MgCl2 56.0 
MgBr2 102.4 
MgI2 146.3 
Mg(CH3COO)2 65.6 
aat 25 qC, bat 30 qC  
                                                 
i Observed in laboratory experiments. 
ii Observed in laboratory experiments. 
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2.5 Special Cases 
The Grignard reaction and the formation of Grignard reagents are a very complex 
matter and the reactions are easily influenced by a variety of parameters. Many of these 
cases have been studied, but despite awareness of their influence on the reaction they still 
tend not to be included when discussing the overall mechanism,94,100 unless the study of 
these is the intention. The Schlenk equilibrium135 and the Wurtz-Grignard coupling136–138 
are two of the most famous of these special cases and they are briefly described below. 
2.5.1 Schlenk Equilibrium 
The reaction mechanism proposed by Grignard enabled more detailed study of the 
chemistry and, due to its versatility, the following decades yielded many new 
discoveries.94,100 Among the discoveries in this period is the Schlenk equilibrium found 
by Wilhelm Schlenk and his son, which describes the stability of Grignard reagents.135 
The simplified view of Grignard reagents as monomeric reactants was challenged by 
several studies. The monomeric Grignard reagent exists in equilibrium with its dimeric or 
higher counterpart, with most being monomeric.94,100,139,140 The general Schlenk 
equilibrium is illustrated in scheme 2.11 and is highly influenced by parameters such as 
the halide and the solvent stabilizing the magnesium. 
Scheme 2.11: The simplified Schlenk equilibrium, where X represents a halide and R represents an aryl or alkyl 
group.135 
 
2.5.2 The Wurtz-Grignard Coupling Reaction 
The Wurtz-Grignard coupling reaction is another observed phenomenon and is 
closely related to the cross coupling reactions.94,136–138,140 The Wurtz-Grignard coupling 
reaction is a metal-halide exchange that mostly takes place during the formation of 
Grignard reagents. The reaction is a homocoupling, where the formed Grignard reagent 
reacts with unreacted alkyl or aryl halide. The principle is illustrated in scheme 2.12. 
Scheme 2.12: The Wurtz-Grignard coupling reaction. R represents an aryl or alkyl group and X a halide.136–138 
 
2.6 Solvents 
Grignard reagents are very sensitive towards moisture and oxygen, where 
protonolysis or oxidation rapidly degrade the product.94,100 Given the air and moisture 
sensitivity of Grignard reagents, aprotic polar solvents or non-polar solvents are typically 
used as storage and reaction media, with only a limited number of these being 
suitable.94,100 Despite the sensitivity of Grignard reagents, the Madsen group141 recently 
demonstrated Grignard alkylation in the presence of a protic solvent (water). With regard 
to non-polar solvents, toluene and heptane are the most commonly used, while toluene is 
still used industrially.iii In the case of non-polar solvents such as toluene, trace amounts of 
                                                 
iii Two full-scale syntheses are still carried out in toluene solvent at H. Lundbeck A/S. 
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ether are typically added to stabilize the Grignard reagents. The stabilizing effect comes 
from the oxygen lone pair in the ethereal solvent that coordinates to magnesium; see 
Figure 2.1. The magnesium preferably stays in a tetrahedral conformation94,100,101,140, 
hence two molecules of ether are needed for each molecule of Grignard reagent. 
 
Figure 2.1: Stabilizing effect of solvent molecules on Grignard reagents.96,101,140 
Ethereal solvents are more commonly used in the synthesis of Grignard 
reagents.94,99,100 From an industrial perspective, diethyl ether (Et2O) has in most cases 
been replaced by less volatile solvents; however, Et2O is still used in laboratory synthesis. 
The low boiling and flash point of Et2O comprise major hazards in full-scale production 
and are the main reasons for the use of other ethers. Tetrahydrofuran (THF) has become 
the industrial standard, as well as the solvent of choice in the laboratory in many 
cases.94,100,103,104 Recent changes in regulatory legislation on THF142 have changed its 
status to being a suspected carcinogen. Because of these concerns about THF, the 
sustainable alternative 2-methyltetrahydrofuran (MeTHF) has steadily gained 
interest.99,105 Some common data on solvents relevant for Grignard chemistry are 
provided in table 2.5. 
Table 2.5: Properties of commonly-used solvents in Grignard chemistry. 
Properties Et2O THF MeTHF Toluene Dimethoxyethane 
(DME) 
Dioxane 
Molecular 
structure    
 
 
 
Boiling point 
(qC) 
34.6 66 80.3 110.6 85 101.1 
Flash point 
(qC) 
-45 -14 -11 4 -2 12 
Density (g/L) 715 889.2 854 867 868.3 1033 
Solubility of 
solvent in 
water 
(%w/w) 
6.9 Miscible 14 0.052 Miscible Miscible 
Solubility of 
water in 
solvent 
(%w/w) 
1.3 Miscible 4 0.033 Miscible Miscible 
Oxygen lone 
pair donor 
1 1 1 0 2 2 
Chelating 
property 
No No No No Yes Yes 
 
50
The Grignard Reaction 
25 
In addition to the commonly-used ethereal solvents (e.g. Et2O, THF, and MeTHF), 
solvents such as 1,4-dioxane and 1,2-dimethoxyethane (DME) find applications within 
Grignard chemistry. These ethers have two oxygen atoms that provide them with 
chelating properties. The use of these more special ethers is often seen in crystallographic 
determination of Grignard reagents.140,143 The chelating effect of these ethers generally 
drives the Schlenk equilibrium towards the right (scheme 2.11). 
2.7 Grignard Chemistry in Flow Setups 
The versatility of Grignard reagents for synthetic purposes, combined with their 
unique behaviors such as being very exothermic and showing good selectivity, are 
perhaps part of the explanation as to why several publications and demonstrations of flow 
setups with Grignard chemistry have been reported. This section presents a selection of 
Grignard reactions that have been studied in flow reactors. 
Some of the first studies on flow chemistry with Grignard reagents were performed 
by Holm.144 Throughout the late 1960s and the 1970s, Holm studied the Grignard reaction 
with the aim of obtaining a better understanding of the mechanism and kinetic behavior of 
the reactions.106,139,144–154 The flow system used in many of the studies consisted of two 
syringe pumps, one containing the Grignard reagent and the other the carbonyl. The two 
reactant streams were forced through a thin glass capillary tube, merging into one 
capillary tube by a T-junction. The reaction time was based on residence times calculated 
from the reactor volume and the flow rate of the streams. Additionally, Holm applied 
thermochemical analysis and IR spectroscopic measurements to his flow system, allowing 
data to be collected in real time. Holm’s studies led to the accumulation of a valuable 
body of knowledge about the Grignard reaction. 
Krummradt et al.68,155,156 demonstrated that microreactor setup significantly 
improved the overall yield of the studied addition of Grignard reagents and 
organometallic reactants to carbonyls; see scheme 2.13. The reaction time was reduced 
from five hours to less than 10 seconds, mostly due to the better heat transfer achieved 
within microreactors as compared to batch reactors. The reaction was highly exothermic, 
releasing up to 300 kJ/mol of energy. This study resulted in the implementation of five 
parallel minireactors for full-scale production. 
Scheme 2.13: General synthetic scheme illustrating the Grignard reactions demonstrated by Krummradt et al. in 
flow setup. R1 and R2 are alkyl or aryl, X is halide.68,155,156 
 
Microreactors’s ability to improve the yield of Grignard reactions was also 
demonstrated by Hessel et al.,157–159 who investigated the desired mono-addition of a 
Grignard reagent to a borate ester to achieve a boronic acid; see scheme 2.14. The 
reaction was sensitive to the addition of several molecules of Grignard reagents to the 
borate ester, but this was suppressed by efficient mixing, which led to improved heat and 
mass transfer conditions. The synthesis was scaled to 10 L/h throughput159 and it was 
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possible in the laboratory-scale experiment to operate at ambient temperatures, avoiding 
the cryogenic temperature conditions necessary for batch synthesis.158 
Scheme 2.14: Synthesis of phenyl boronic acid via the Grignard reaction utilizing a flow setup.157–159 
 
Roberge et al.54,77–79,160,161 have provided a number of small-scale studies and 
implementations of microreactor technologies in full-scale production for the 
pharmaceutical contract manufacturer Lonza. Besides the experimental demonstrations, 
attempts were made to generalize reactions to better estimate the potential benefits 
achievable through continuous processing.22,53 One of the main discoveries was that 
applying multiple injections resulted in a more stable reaction temperature from the 
exothermic reactions; hence large temperature gradients could be avoided, leading to the 
suppression of by-product formation, which is otherwise highly sensitive to 
temperature.78,79 
A conceptual microreactor system (CYTOS) was investigated by Schwalbe et 
al.162,163 One of the syntheses explored was a Grignard addition to a diester, known for 
temperature-sensitive formation of impurities. By using multiple reactors in parallel, the 
heat of the exothermic and fast reactions was distributed and the reaction could be scaled 
to a larger throughput, which furthermore provided a better yield. 
In a study by Riva et al.,164 a large number of addition reactions between Grignard 
reagents and carbonyls were investigated in a flow reactor. Most of the syntheses were 
carried out at room temperature, with an average yield above 90%. The investigations 
were carried out in the commercially available Vapourtec flow reactor, where the reactor 
module was a PTFE tubing. 
Mateos et al.165 studied the formation of ketones by nucleophilic Grignard addition to 
nitrile groups followed by the addition of acid utilizing flow methods; see scheme 2.15. 
The method was very useful for aryl nitriles reacting with phenyl magnesium halide, but 
was less suitable for alkyl nitriles and alkyl magnesium halide. 
Scheme 2.15: The formation of ketones by nucleophilic addition of Grignard reagents to nitriles. R1 and R2 are 
alkyl or aryl, X is halide.165 
 
Recently, the Ley group has studied a number of different Grignard 
reactions.112,166,167 Their work has resulted in a customized tube-in-tube reactor,166 where 
CO2 diffuses over permeable polymer tubing into another tube to react with a Grignard 
reagent. The Ley group also utilized spectroscopic measurements in their experiments, 
where the Mettler Toledo FlowIR was used to determine the concentration of the 
Grignard reagent.112 
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The Jamison group has also investigated Grignard chemistry in flow setups. Their 
studies focused on a number of different Grignard reagents and the products formed from 
reactions with CO2 or O2. Their focus was on finding easier and cheaper ways to generate 
important starting materials for the fine chemical and pharmaceutical industry.168,169 
A novel heterogeneous continuous reactor setup for a Grignard addition to a tricyclic 
ketone was developed by Pedersen et al.88–90 for H. Lundbeck A/S, in the effort to 
modernize an existing batch process method for manufacturing an API intermediate. The 
main challenge was the low solubility of the ketone in THF, which required large 
volumes of solvent if a homogeneous flow reactor was to be used. The solution to this 
quandary was the design of a filter reactor followed by a subsequent multi-injection flow 
reactor in order to assure complete consumption of the ketone. The setup was later 
transferred from the laboratory to full-scale by a slight increase in dimensions; see 
chapter 7.88 
Kupracz & Kirschning170 studied the formation of amitriptyline with flow methods 
(Scheme 2.16). Several organometallic reactions were applied, where the formed tricyclic 
ketone was reacted with an alkyl Grignard reagent to form the desired alcohol upon 
hydrolysis. The alcohol was subsequently dehydrated and precipitated as the desired HCl 
salt. 
Scheme 2.16: The synthesis of amitriptyline by Grignard addition to a ketone.170 
 
Kopach et al.171,172 recently demonstrated Grignard chemistry in flow by the use of 
three coupled continuous stirred tank reactors (CSTRs), an alternative flow method to the 
otherwise commonly-used tubular reactor frequently applied for flow chemistry. 
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2.8 Summary 
Grignard reagents have proven to be highly efficient and important materials for the 
formation of new carbon-carbon bonds. Grignard chemistry has been applied both at 
laboratory scale and within the full-scale fine chemical and pharmaceutical industries. Of 
the many different reactions in which Grignard reagents can participate, addition 
reactions with esters, ketones or aldehydes to form alcohols may be the most widely 
applied. The necessity of ethereal solvents in Grignard chemistry has led to a great 
number of studies on solvent influence on the Grignard reaction. Despite the many 
findings on solvent effects, full-scale applications have tended to use a limited number of 
solvent types. Initially, Et2O was the solvent of choice, but it has now largely been 
replaced by THF. Over the last decade, THF has slowly been replaced by the greener 
alternative MeTHF. Academic society has worked industriously on elucidating the 
underlying chemistry behind the formation of Grignard reagents and their reactions to 
gain a mechanistic and kinetic understanding. The complex nature of Grignard chemistry, 
related to the Schlenk equilibrium and the often undesired Wurtz-Grignard coupling 
reaction, has in reality only produced more questions. As more recent findings within 
Grignard chemistry, reactions in water and the control of mono-addition to esters have 
been reported and promise to expand the utility of the reaction. However, many of these 
special cases are only possible under very specific conditions. During the last decade, 
Grignard chemistry has been explored using flow methods. Flow methods are very useful 
for dealing with fast, exothermic reactions like the Grignard reaction. From an industrial 
point of view, simplicity and efficiency are still the main reasons for the popularity of the 
Grignard reaction today. 
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Chapter 3 
3 Sequential Grignard Addition to an Ester via Flow Chemistry: 
Investigation of Kinetics and Mechanism  
The following chapter has been written in the style of a manuscript format. The 
manuscript is to be submitted to a peer-reviewed scientific journal, expected to be 
Organic Process Research & Development. The authors to be included on the publication 
are: Michael J. Pedersen, Stephen Born, Ulrich Neuenschwander, Tommy Skovby, 
Michael J. Mealy, Søren Kiil, Kim Dam-Johansen and Klavs F. Jensen. 
3.1 Abstract 
The kinetics of sequential addition of two distinct Grignard species onto a lactone is 
studied using flow chemistry. The experimental data are shown to be consistent with a 
kinetic model based on four reaction steps: reduction of ester to magnesium hemiacetal, 
rearrangement to ketone (forward and backward) and reduction of ketone to tertiary 
alcohol upon quenching. The experimentally-derived reaction mechanism is supported by 
ab initio molecular computations and the predicted activation energy is in good agreement 
with the experimental observations. The Grignard reduction follows a substrate-
independent, reductive [2+2] cycloaddition of the Meisenheimer/Casper type. Moreover, 
the rearrangement equilibrium between magnesium hemiacetal and ketone is 
characterized and found to be feasible. Mono-addition of the ester carbonyl group is 
demonstrated for fluorophenylmagnesium bromide at reaction conditions of -40°C with 
several hours of residence time. For the addition of dimethylaminopropylmagnesium 
chloride to phthalide, a full diaddition is observed within seconds at temperatures down to 
-30°C. Working under cryogenic temperature conditions is essential to realizing mono-
addition of the ester with Grignard reagents. 
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3.2 Introduction 
Reactions of Grignard reagents with carbonyls have been intensely studied since the 
discovery of Grignard reactions in the early 20th century.93,94 Ketones have been the topic 
of many, while fewer studies have focused on aldehydes and esters.116 The 
Meisenheimer117 and Swain118 mechanisms (scheme 3.1 and scheme 3.2, respectively) 
remain the most widely accepted mechanisms, despite a simplified representation that 
only considers the reaction between the carbonyl and the Grignard reagent.116,173 A wide 
variety of factors, such as the type of solvent and halide and trace metals in the 
magnesium, have been found to influence the reaction. Underlying equilibria, such as the 
Schlenk equilibrium,116,135 are also known to have a strong influence. The Meisenheimer 
mechanism is a simple bimolecular reaction and is entropically favored compared to the 
Swain mechanism. The Swain mechanism involves the formation of a bimolecular 
complex of the Grignard reagent and the carbonyl substrate, with subsequent reaction of 
an additional Grignard reagent. Moreover, the solvent used (i.e. MeTHF) is highly 
coordinative, which hinders the formation of higher Grignard aggregates.105,174 Therefore, 
our study focused on the Meisenheimer mechanism exclusively. 
Scheme 3.1: The Grignard addition mechanism with ketone carbonyl groups as proposed by Meisenheimer and 
Casper.116,117 
 
Scheme 3.2: The Grignard addition mechanism with ketone carbonyl groups as proposed by Swain and 
Boyles.116,118 
 
Grignard addition with aldehydes, ketones and esters is generally expected to occur 
very quickly, with completion in seconds or minutes.22,94,100,154 Esters are known to react 
up to 100 times slower than aldehydes or ketones,100,154 but factors such as the solvent and 
magnesium used cause deviations from this general trend.94,99,100 Grignard addition to 
either ketones or aldehydes results in the formation of mono-addition products. For esters, 
addition with a Grignard reagent results in a mixture of mono- and diaddition 
products.94,119 The carbonyl oxygen in the ester forms a new ketone carbonyl group via an 
intramolecular rearrangement. The newly formed ketone can undergo a second addition 
that results in the diaddition product. The reaction can be seen as a consecutive 
competitive reaction, where two equivalents of Grignard reagents will result in the 
diaddition tertiary alcohol product upon hydrolysis (scheme 3.3).119 A few studies have 
demonstrated mono-addition of esters as the main product under certain conditions.120,175 
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Scheme 3.3: The reaction mechanism of a Grignard addition of an ester.119 The 4-membered transition state 
where the Grignard addition takes place is characteristic of a [2+2] cycloaddition mechanism. A description of 
the reaction of the ketone is given in scheme 3.1 and scheme 3.2. 
 
Knowledge of the reaction rates of a synthesis, including the main impurity 
formation, is valuable when designing a reactor setup. A detailed understanding of the 
full reaction mechanism can sometimes be useful, but in most cases a good understanding 
of the overall reactions at relevant conditions is sufficient for estimating the rate 
constants, activation energies and pre-exponential factors needed in the design. Kinetic 
information on the synthesis can be used in the dimensioning of reactor setups, as well for 
the determination of the optimal configuration for the given chemistry. Furthermore, the 
knowledge can be used to select the parameters for optimal operation and maximum 
performance of the chosen reactor setup, i.e. high conversion to the desired products 
without the formation of difficult-to-remove impurities.59,60 
Kinetic data may be generated in classic batch experiments with fast mixing of the 
added reactants.173,176 At fixed time intervals, samples from the reaction mixture are 
withdrawn, terminated, and analysed.176. The batch method is highly efficient for slow 
reactions (i.e. reaction times above 30 minutes),22,177 but becomes difficult for fast ones. 
The main limitation of the batch method is the time at which samples can be withdrawn 
and terminated, quenched and analyzed, which provides uncertainty on the actual reaction 
time.178 Alternative methods have been used for generating kinetic data for fast reactions 
(i.e. reaction times less than 5 minutes). Steady state measurements were already being 
used in flow chemistry to some extent in the 1960s to determine the kinetics of Grignard 
addition reactions.144 The advancement of flow chemistry over the last decade and 
progress in the development of in-line analysis have shown growth in these alternative 
methods for obtaining kinetic data.179 The use of microreactor technology combined with 
in-line analysis, either disruptive measurement methods (e.g. HPLC180) or non-disruptive 
methods (e.g. IR181,182, Raman183), is an alternative to batch methods. 
Lately, a number of Grignard reactions and organometallic reactions have been 
demonstrated in flow reactors.22,53,54,68,77–79,88–90,112,155–172,184–190 Pedersen et al.88–90 
transformed a routine batch process into a continuous reactor setup, in which addition of a 
Grignard reagent to a ketone slurry suspension resulted in the formation of a key 
intermediate active pharmaceutical ingredient (API). Kopach et al.171,172 recently 
demonstrated Grignard chemistry in flow by using three coupled continuous stirred tank 
reactors (CSTRs). Roberge et al.54,77–79,160,161 utilized microreactor technology for 
reactions in organometallic chemistry. The Jamison Group168,169 recently demonstrated a 
flow setup for reactions between gasses (CO2 and O2) and Grignard reagents. The Ley 
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Group112,166,167 covered a large number of different setups for Grignard chemistry in flow. 
Riva et al.164 used a flow reactor to demonstrate Grignard addition with a large number of 
carbonyls. 
3.3 Chemistry and Investigational Strategy  
The synthesis of interest is a Grignard addition between phthalide (1), a lactone, and 
4-fluorophenylmagnesium bromide (4-FPhMgBr (2a)) (scheme 3.4). The phthalide 1 is 
chosen as a model compound based on its high solubility and its simple structure, limiting 
the formation of other by-products besides the bis-adduct. The Grignard addition between 
the ester carbonyl group of phthalide 1 and 4-FPhMgBr 2a results in the formation of the 
ketone intermediate (4a) upon rearrangement of the magnesium hemiacetal (3a). The 
carbonyl group in the ketone intermediate 4a can undergo an additional addition with 
4-FPhMgBr 2a, resulting in the formation of an undesired bis-adduct (5). The desired 
product is the mono-addition ketone 4a, which is supposed to react in a second Grignard 
addition reaction with 3-(N,N-dimethylamino) propylmagnesium chloride (DMPC-MgCl 
(2b)) to form the final product 7. 
Scheme 3.4: The generic synthesis route of the Grignard addition studied within the article. Phthalide 1 is used 
as a model compound in the generation of the desired product 7 or 8, depending on the addition order of 2a and 
2b (e.g. 2a followed by 2b gives 7). The main impurities are bis-adduct 5 and 6. 
 
Studies by Smith and Wikman122 and Hillery and Cohen123 suggest that substitution 
of hydrogen with methyl or phenyl at the carbon 3, 4 and 7 positions influences the 
probability of the phthalide undergoing the second addition. Natelson and Pearl124 found 
formation of mono-addition phthalide, but this has not been confirmed by other 
researchers.122 
From a reaction engineering perspective, the synthesis can be considered as a 
competitive-consecutive reaction between phthalide 1 and ketone 4a or 4b towards the 
first Grignard reagent added, 2a or 2b. In order to have reasonable conversion, the 
optimization of the reaction should focus on a 1:1 ratio of reactants and the kinetic 
models must therefore describe the reactivity under these conditions. 
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This contribution explores the kinetics of mono- and diaddition of phthalide 1 with 
Grignard reagents using a flow setup. The aim is to better understand the choice made in 
the routine batch synthesis, by studying the underlying reaction rates and mechanisms of 
the two Grignard reagents required to generate the desired product. The generated data is 
used to verify the potential for an alternative continuous production method, with a small 
scale-up of flow reactors in the laboratory. 
3.4 Experimental Section 
3.4.1 Materials 
The following materials used in this study were commercially available: phthalide (1) 
(Sigma Aldrich), naphthalene (Merck, Sigma Aldrich), 4-FPhMgBr (2b) 1M in MeTHF 
(Alfa Aesar) and anhydrous MeTHF (Sigma Aldrich). A 1M solution of 
3-(N,N-dimethylamino) propylmagnesium chloride (DMPC-MgCl (2b)) was prepared by 
analogy to the method described by Holmes et al.,191 using 1,2-dibromoethane 
(commercially available)94 instead of a crystal of iodine for magnesium activation. The 
concentration of DMPC-MgCl (2b) in MeTHF was determined by a NIR spectroscopy 
calibration curve. The 3-(N,N-dimethylamino) propyl was prepared from a 65% aqueous 
solution (also commercially available as the HCl salt) by liberation of the base in aqueous 
NaOH (28%) and hexane (both commercially available) and purified by vacuum 
distillation (40 qC, 50 mbar). All manipulations of Grignard reagents and solutions were 
performed in oven-dried glassware under a blanket of dry nitrogen using standard cannula 
and syringe techniques. 
3.4.2 Analytical Methods 
For the 4-FPhMgBr 2a only experiment, an Agilent HP GC-MS analyzer (Agilent 
HP 6890 plus GC and Agilent HP 5973 MS) with an Agilent Technologies (190915-413 
HP-5MS) column was used. A 0.1 μL sample was injected, using a split ratio of 100:1. 
The temperature program was such that the start was at 70 qC, followed by a 30 qC/min 
ramp up to 300 qC. Good separation was achieved for the main products and no quenched 
4-FPhMgBr 2a or solvent was detectable with the MS, due to the solvent cut-off of 1.5 
min elution time to protect the filament. The samples were prepared in CH2Cl2 (DCM) 
and it was not possible to distinguish between 3a and 4a. 
For the experiment involving 3-(N,N-dimethylamino) propylmagnesium chloride 
(DMPC-MgCl (2b)), an in-house HPLC method at Lundbeck was used. The method 
provided a good separation of phthalide 1, diaddition product 5, desired products 7 and 8 
(identical upon hydrolysis) and internal standard naphthalene. The mono- and diaddition 
products of phthalide with DMPC-MgCl (2b) were detectable at the beginning of the 
chromatogram, but the method was not suitable for fully separating them. 
3.4.3 Computational Methods 
Kinetic modelling was done in MatLab using the ODE45 solver. Density Functional 
Theory (DFT) geometry optimizations and frequency calculations were made using 
Gaussian09192 using the B3LYP functional.193–195 An all-electron basis set 6-311+G(d,p) 
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was used on all involved elements. For further refining of the relative energies, 
single-point calculations were performed on the 6-311++G(df,pd) level. The energies of 
the stationary points on the potential energy surface (PES), i.e. the molecular ground 
states (GS) and transition states (TS), were corrected for zero-point energy (ZPE). For 
taking solvent effects into account, a robust two-layer approach was chosen: calculations 
were performed with explicit solvent molecules in order to satisfy the valence around the 
magnesium core. Additionally, a polarized-continuum model (PCM) for tetrahydrofuran 
(THF) was used to include solvation energies, both at the geometry optimization and the 
single-point level. For computational feasibility, the explicit solvent molecules were 
chosen to be H2O, since THF is too expensive and attempts at using dimethyl ether failed 
due to the very loose degrees of freedom introduced into the model. 
3.4.4 Initial Screening Experiment on Stabilization 
Two Harvard PHD 2000 pumps, equipped with 8 mL stainless steel high pressure 
Harvard syringes, were used for the 4-FPhMgBr 2a and phthalide 1 solutions. The two 
reactant streams were pre-cooled before being mixed in a Valco stainless steel T-mixer 
(ID 0.02”) followed by 2” of stainless steel tubing (OD 1/16” ID 0.04”) connected to a 20 
mL batch vessel at the target temperature. The reaction proceeded for 1 hour under 
stirring in the batch vessel. The reaction mixture was quenched with 0.5 M HCl at the 
reaction temperature and left to warm up to ambient temperature for sample preparation 
and analysis. 
3.4.5 Kinetic Experiments 
The general flow setup used for the kinetic experiments is illustrated in figure 3.1. 
For the 4-FPhMgBr 2a experiments only, three Harvard PHD 2000 pumps were used, 
equipped with 8 mL stainless steel high pressure Harvard syringes. For the DMPC-MgCl 
2b experiments, two Knauer HPLC Azura P2.1S pumps with stainless steel pistons were 
used for the DMPC-MgCl 2b and phthalide 1 and a Syrris Asia pump with 1.0 mL and 
0.5 mL syringes was used for the TFA in MeOH stream. In both cases, the Grignard 
reagent and phthalide 1 were precooled before being mixed in a Valco stainless steel 
T-mixer ID 0.02”. The reaction progressed in a 2.5 m OD 1/16” ID 0.02” stainless steel 
coil and then terminated in a second T-mixer of PEEK material ID 0.04” at the reaction 
temperature before samples were collected for off-line analysis. 
Temperature Controlled Bath
TFA/
MeOH
Grignard
reagent
Phthalide Sample
 
Figure 3.1: The flow setup used in the kinetic experiments. Phthalide 1 and Grignard reagent (2a or 2b) are 
mixed in a stainless steel T-mixer before entering the SS reactor coil. The reaction is terminated at the second 
T-mixer with TFA in MeOH at the reaction temperature. Samples are collected for off-line analysis. 
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3.4.6 Double Grignard Addition Experiments 
The double Grignard addition experiments were carried out in the reactor setup 
illustrated in figure 3.2. Two Knauer HPLC Azura P2.1S pumps with stainless steel 
pistons were used for DMPC-MgCl 2b and phthalide 1. The two reactants were precooled 
before entering a PEEK T-mixer ID 0.04”, with the reaction proceeding in a 10 mL 
stainless steel coil OD 1/8” and ID 0.08” submerged in the temperature-controlled bath. 
The product stream passed through a 10 μL diamond window IR flow cell from Mettler 
Toledo before 4-FPhMgBr 2a was introduced at room temperature in the second PEEK 
T-mixer. The second reactor coil was a 20’ PTFE OD 1/8” and ID 1/16”; the coil was 
kept at room temperature and samples were collected at the outlet for off-line HPLC 
analysis. 
Temperature
Controlled Bath
FPhMgBrDMPC-MgCl
Phthalide SampleIR
 
Figure 3.2: The up-scaled reactor setup, combined with an in-line IR flow cell for data collection. The first 
reactor coil was a 10 mL SS OD 1/8” and ID 0.08” submerged in a temperature-controlled bath. The second 
reactor coil was made of PTFE tubing 20’ OD 1/8” ID 1/16”. The T-mixer was of PEEK material ID 0.04”. IR 
spectroscopy was used to follow the reaction between the two reactor coils, combined with off-line HPLC 
analysis for the outlet samples. 
The experiments were carried out with reactant streams of the following 
concentrations: phthalide 1 0.25 M, DMPC-MgCl 2b 0.85 M and 4-FPhMgBr 2a 1.0 M. 
Phthalide 1 was used as the limiting reactant, kept at a fixed flow rate of 1.62 mL/min. 
DMPC-MgCl 2b was added in 1.05 or 2.10 equivalents to phthalide 1, corresponding to a 
flow rate of 0.5 mL/min and 1.0 mL/min. The 4-FPhMgBr 2a was added as a 1.12 
equivalent to phthalide 1, corresponding to a flow rate of 0.21 mL/min and 0.17 mL/min. 
A comparison between the reactor setups used in the kinetic experiments and the double 
Grignard addition experiments is found in table 3.1. 
Table 3.1: Comparison of parameters of interest between the reactors used for kinetic experiments and in the 
double Grignard addition experiments. 
 Kinetic Reactor Setup Double Grignard Addition 
Reactor Setup 
 Reaction coil 1st Reactor coil 2nd Reactor coil 
Reactor Volume (mL) 0.5 10 12.07 
Reactor ID (inch) 0.02 0.08 1/16 
T-mixer ID (inch) 0.02 0.04 0.04 
Flow Rate range (mL/min) 0.008-1.020 2.12-2.62 2.33-2.79 
Reaction Temperature (qC) 0 to -40 -10 to -30 Ambient Room 
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3.5 Results and Discussion 
3.5.1 Initial Screening Experiment on Stabilization 
Initially, a few semi-batch experiments were carried out to identify whether the 
magnesium hemiacetal (3a) could be stabilized at low temperature conditions. The 
literature indicates that ester carbonyl groups can be controlled to give the mono-addition 
product if carried out at -78 qC.120,121,175 The experiments were conducted with two 
equivalents of 4-FPhMgBr 2a to the phthalide 1. 
The undesired diaddition product 5 decreases as the temperature is lowered and is 
completely absent at -40 qC (figure 3.3). Full conversion of the phthalide 1 was achieved 
in all experiments, with the exception of -40 qC where minor amounts were still present 
after 1 hour of reaction. Full conversion was achieved at -30 qC with almost no diaddition 
product 5 present. The kinetic experiment should therefore be carried out from -30 qC and 
up, as this seems more suitable for the entire reaction (there is very slow conversion at -
40 qC). From a scaling perspective and a cost perspective, a higher temperature is more 
desirable. 
 
Figure 3.3: The formation of the bis-adduct 5 decreases with temperature 
(-20 qC (―), -30 qC (- - -), -40 qC (∙∙∙)). 
A deep blue color is observed when the reaction progresses at higher temperatures. 
The blue color is also known from the actual batch process, where it is seen near the 
addition point of the 4-FPhMgBr 2a. The color is therefore assumed to be correlated with 
the formation of undesired bis-adduct 5, due to local high concentration and temperature 
at the addition point. The blue coloring can serve as a good indicator, with its absence 
indicating that the desired mono-addition is taking place. This theory is further supported 
by the literature, where a similar color has been observed upon reaction between 
benzophenone and phenylmagnesium halide.173,196 
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3.5.2 Kinetic experiments on 4-FPhMgBr 
The kinetic experiments on 4-FPhMgBr 2a and phthalide 1 were performed in the 
range from 0 qC to -30 qC, with one experiment every 5 qC. The initial stability 
experiment indicated that a low reaction temperature (-40 qC) was necessary to control 
the undesired bis-adduct 5. A 1.0 M 4-FPhMgBr 2a was used in equivalents from 1.1-2.0 
to the 0.25 M phthalide 1 solution with naphthalene as internal standard; both reactants 
were in MeTHF. At temperatures above -15 qC the reaction was completed after 5 
minutes, but up to 1 hour residence time was necessary for the -30 qC experiment with 2 
equivalents of 4-FPhMgBr 2a. The TFA quench stream was a 0.5 M TFA in MeOH with 
a flow rate equal to the combined flow rate of 4-FPhMgBr 2a and phthalide 1. 
The kinetic data was fitted in MatLab with a least squares curve fit by numerical 
solution of the mass balance of the plug flow reactor (PFR) design equations with 
iteration on the rate constants. Several reaction mechanisms were verified for their ability 
to describe the reaction system under investigation before the final model was chosen. 
The first reaction between phthalide 1 and 4-FPhMgBr 2a, illustrated by rate constant k1 
(scheme 3.4), was found to be sufficient to a model of a second order elementary reaction 
(i.e. the Meisenheimer mechanism). The intramolecular rearrangement between 
magnesium alkoxide intermediate 3a and ketone 4a is a more complex matter. 
Intramolecular reactions – with comparable activation energies – are generally 
significantly faster than the reactions that take place between two or more molecules. 
Moreover, esters will normally have a reaction rate up to 100 times slower than ketones 
and aldehydes. Combining these general considerations requires that both a forward, k2, 
and a backward, k-2, reaction take place between intermediate 3a and ketone 4a, 
establishing an equilibrium. If only the forward reaction, k2, existed, a pseudo-first order 
reaction for the formation of bis-adduct 5 would be observed from the data as rate 
constant k3. For the reasons detailed above, the Meisenheimer mechanism was the model 
of choice. The final plug flow reactor (PFR) mass balances are given in equations 3.1-3.5. 
 ௗሾ஼૚ሿௗఛ ൌ െ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ 3.1 
 ௗሾ஼૛ࢇሿௗఛ ൌ െ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ െ ݇ଷሾܥ૝ࢇሿሾܥ૛ࢇሿ 3.2 
 ௗሾ஼૜ࢇሿௗఛ ൌ ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ െ ݇ଶሾܥ૜ࢇሿ ൅ ݇ିଶሾܥ૝ࢇሿ 3.3 
 ௗሾ஼૝ࢇሿௗఛ ൌ െ݇ଷሾܥ૝ࢇሿሾܥ૛ࢇሿ ൅ ݇ଶሾܥ૜ࢇሿ െ ݇ିଶሾܥ૝ࢇሿ 3.4 
 ௗሾ஼૞ሿௗఛ ൌ ݇ଷሾܥ૝ࢇሿሾܥ૛ࢇሿ 3.5 
The activation energy of the reaction between 4-FPhMgBr 2a and phthalide 1 (k1) 
was found to be 52±8 kJ/mol with a pre-exponential factor of 2.53∙109 L/(mol∙s) (figure 
3.1). A strong correlation was found between the equilibrium rate constants (k2 and k-2) 
and the rate constant for diaddition, k3. Therefore, the formation of ketone (4a) was 
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assumed to be in a pseudo-steady state, which reduced the modelling equations to the 
following form: 
 ௗሾ஼૚ሿௗఛ ൌ െ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ 3.6 
 ௗሾ஼૛ࢇሿௗఛ ൌ െ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ െ ݇ୡሾܥ૜ࢇሿሾܥ૛ࢇሿ 3.7 
 ௗሾ஼૜ࢇሿௗఛ ൌ ݇ଵሾܥ૚ሿሾܥ૛ࢇሿ െ ݇ୡሾܥ૜ࢇሿሾܥ૛ࢇሿ 3.8 
 ௗሾ஼૞ሿௗఛ ൌ ݇ୡሾܥ૜ࢇሿሾܥ૛ࢇሿ 3.9 
in which kc =k3k2/k-2. 
For the combined rate constant expression (kc), the activation energy was found to be 
88±9 kJ/mol with a pre-exponential factor of 2.65∙1015 L/(mol∙s). This pre-exponential 
factor is several orders of magnitude higher than expected for a simple bimolecular 
reaction, since for ordinary diffusion-controlled reactions, approximate pre-factors of 
1010±1 L/(mol∙s) are expected.197 However, the pre-factor in the current case represents the 
entropic contribution from not only a single bimolecular reaction (k3) but also from the 
k2/k-2 equilibrium. Since the ring-opened form 4 is entropically highly favored over 3, the 
additional factor of ~105 is reasonable. 
 
Figure 3.4: The Arrhenius plot of the kinetic data of 4-FPhMgBr 2a reacting with phthalide 1. The k1 () is the 
rate constant for the mono-addition reaction and the other terms represent the combined rearrangement 
equilibrium and diaddition reaction kc (S). 
3.5.3 Kinetic experiments on DMPC-MgCl 
In the temperature range 0 to -20 qC, kinetic data for the reaction between 
DMPC-MgCl 2b and phthalide 1 were generated for every 5 qC. As in the 4-FPhMgBr 2a 
kinetic experiments, phthalide 1 had a concentration of 0.25 M in MeTHF with 
naphthalene as internal standard. The concentration of DMPC-MgCl in MeTHF was 
determined to be 0.85 M after the experiments were run, but was assumed to be 1.0 M 
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throughout the experimental run. This deviation in actual concentration was corrected in 
the later data treatment. The 0.85 M concentration of DMPC-MgCl 2b meant that only 
0.9 equivalents of DMPC-MgCl 2b had been added to the phthalide 1, instead of the 
intended 1.1 equivalents. Reaction times of between 0 and 4 minutes were investigated 
(figure 3.5). For all temperatures, approximately 45% conversion of phthalide 1 was 
achieved. The substrate conversion is equal to half the equivalence of the added 
DMPC-MgCl 2b. This suggests that the rearrangement from intermediate 3b to ketone 4b 
is very fast and at the given temperature it was not possible to stabilize intermediate 3b to 
suppress the undesired bis-adduct 6. The very fast reaction of DMPC-MgCl 2b with 
phthalide 1, with a preference for bis-adduct 6, meant that it was not possible to extract 
activation energies under these experimental conditions. 
 
Figure 3.5: Conversion of phthalide 1 as a function of residence time at selected temperatures 
(0 qC (), -10 qC ({) and -20 qC ()). 
3.5.4 Density Functional Theory Characterization 
In order to better understand the molecular basis of this process, a density functional 
theory (DFT) characterization of the potential energy surface was carried out. As 
solvation is crucial in Grignard-type chemistry, a two-level solvation model was used to 
account for the ether solvent: first, magnesium was coordinated with three oxygen 
sigma-donor ligands and second, the whole solvation complex was inserted into a 
polarizable continuum model of THF. This allowed a realistic description of the 
energetics during the reaction, e.g. by estimating activation energies or by verifying the 
feasibility of an equilibrium between intermediate 3 and ketone 4, for reaction with either 
4-FPhMgBr 2a or DMPC-MgCl 2b. The DFT results confirmed that the Grignard 
additions follow the Meisenheimer mechanism. Interestingly, Grignard additions were 
found to have a 4-membered transition state, indicative of a [2+2] cycloaddition (see 
scheme 3.3 and figure 3.6). This is in line with the earlier proposition made by 
Yamazaki,198 who predicted that four-membered transition states govern Grignard 
reactions (although his claims included artificial multimetal aggregates arising from 
incomplete treatment of solvent effects). 
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Figure 3.6: The 4-membered transition state of the mono-addition Grignard intermediate. 
The DFT potential energy predictions (figure 3.7) reflect the reactivity differences 
between esters (1) and ketones (4). Furthermore, even though the transition state for 
rearrangement could not be localized due to the complex geometries involved, an 
equilibrium between the cyclic (3) and open (4) configurations of the mono-addition 
product was found to be energetically feasible. Thus, the rate constants k2 and k-2 could 
be merged into an equilibrium constant Keq, supporting the kinetic model expression used 
above. The DFT characterization showed that the reaction is exothermic by 
approximately 120 kJ/mol, with little difference between the first and second Grignard 
additions. Calculations on modified Grignard reagents showed that neither the halide nor 
the aryl/alkyl of the Grignard reagent causes a large difference in reactivity. Though the 
experiment shows that there is a structure-activity relationship for the Grignard reagent 
with 2a being less reactive than 2b, the differences are too subtle to be quantitated. In any 
case, the 91 kJ/mol activation energy found by DFT for the product k3k2/k-2 (where 70 
kJ/mol are from Grignard addition to ketone 4) is in good agreement with the 
experimentally-determined value of 88±9 kJ/mol. For k1, the agreement is only modest, 
89 kJ/mol by DFT vs. 52±8 kJ/mol by kinetic modelling. However, the k1 experimental 
data appears to be more scattered (figure 3.4) and could be influenced by other factors 
such as steric configuration. General observation shows that esters as such are less 
reactive than ketones, which would require an activation energy value of at least 70 
kJ/mol for the true k1, underpinning the prediction by DFT. 
 
Figure 3.7: DFT characterization of the potential energy surface for reaction of ester (modelled by 2-furanone) 
with two equivalents of Grignard reagent (modelled by MgMeBrL3). The characterization was carried out with 
different Grignard reagents. Very little deviation was found when varying halide and aryl/alkyl groups of the 
Grignard reagent. The numbering of species is according to scheme 3.4. 
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3.5.5 Double Grignard Addition Experiments 
The kinetic experiments formed the basis for the addition of both Grignard reagents 
to achieve the desired diaddition product. The first decision to make was the addition 
order of the two Grignard reagents (2a and 2b). It was only possible to generate kinetics 
for 4-FPhMgBr 2a, as the DMPC-MgCl 2b fully reacts within less than 30 seconds at the 
temperatures studied. To fully suppress the diaddition product 5, a temperature of -40 qC 
or lower was necessary, which would result in very slow reaction times in the range of 
several hours towards the mono-addition reaction of alkoxide 3a. The slow reaction of 
4-FPhMgBr 2a make it an unsuitable choice for first Grignard reagent and DMPC-MgCl 
2b was chosen as the first Grignard reagent despite the uncertain stability at lower 
temperatures. 
The double Grignard addition experiments (figure 3.8) were investigated at three 
temperatures (-10 qC, -20 qC and -30 qC). A conversion of 95-99% was achieved for the 
phthalide 1 at all the settings tried. In the case of 1.05 equivalents of DMPC-MgCl 2b, the 
desired product 8 and undesired diaddition product 5 were detected in the HPLC samples. 
The presence of diaddition product 8 indicates that the DMPC-MgCl 2b reacted to the 
desired alkoxide intermediate 3b. However, it was not possible to suppress the 
rearrangement to ketone 4b even at -30 qC, hence bis-adduct 6 was formed 
simultaneously. Furthermore, the HPLC area of bis-adduct 5 and desired product 8 being 
of similar size for all three temperatures supports the conclusion of missing stabilization 
of alkoxide intermediate 3b. In the case of 2.10 equivalents of DMPC-MgCl 2b, no 
desired product 8 or undesired bis-adduct 5 were observed. As the phthalide 1 was almost 
fully converted, this indicates that bis-adduct 6 was the only product formed. 
 
Figure 3.8: The experimental results from the double Grignard addition experiments. For high equivalents of 
2.1, no desired diaddition product 8 or bis-adduct 5 are generated, indicating that all of the phthalide 1 has 
reacted to bis-adduct 6. In all cases, the phthalide 1 was close to fully converted. Phthalide (1.05 eq.  and 2.10 
eq. ), Product 5 (1.05 eq. { and 2.10 eq. z) and Product 8 (1.05 eq. U and 2.10 eq. S). 
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3.6 Conclusions 
A flow setup has been used in the generation of kinetic data for some selected 
Grignard additions. The chemistry studied was a competitive-consecutive Grignard 
reaction involving two different Grignard reagents reacting with a lactone. The addition 
was studied for temperatures ranging from 0 to -30 qC. For the 4-FPhMgBr Grignard 
reagent, an Arrhenius plot was generated from the kinetic data based on a two-fold 
Meisenheimer mechanism with intramolecular rearrangement in between. DFT analysis 
of the potential energy surface revealed structural and energetic insights into the 
molecular processes involved in Grignard additions and supported the mechanistic 
assumptions made in the kinetic model. At -40 qC, the competitive bis-adduct could be 
suppressed by slowing down the intramolecular rearrangement, simultaneously causing a 
decrease in the reaction rate for mono-addition. The experimental kinetic data was found 
to be in good agreement with a DFT characterization of the potential energy surface 
associated with a two-fold Meisenheimer reaction. For the DMPC-MgCl Grignard 
reagent, the reaction progressed towards undesired diaddition within 30 seconds even at -
20 qC. The very fast reaction time did not allow any kinetic expressions to be derived 
from the data. Addition of DMPC-MgCl to the phthalide followed by addition of 
4-FPhMgBr was tried. Mostly undesired bis-adducts were formed and the slight scale-up 
of reactor dimensions is believed to have caused larger gradients of temperature and 
concentration, giving rise to the undesired formation of bis-adduct. 
Suppressing the formation of bis-adduct from the lactone reacting with Grignard 
reagents is possible under cryogenic reaction conditions, but comes at the cost of reduced 
reactivity towards the desired mono-addition product. In the investigated case, the alkyl 
Grignard reagent turned out to be significantly more reactive than the aryl Grignard 
reagent, which is in good accordance with the literature. The exothermic nature of 
Grignard addition poses a significant challenge if the necessary cryogenic conditions are 
all to be maintained to ensure the desired suppression of the undesired bis-adduct. Use of 
multiple injection reactor technology for the Grignard reagent addition could be a rational 
solution to the heat problem, as this could distribute the energy release, avoiding local hot 
spot gradients of temperature and concentration. 
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Chapter 4 
4 A Solvent-Free Base Liberation of a Tertiary Alkylamino Halide 
by Flow Chemistry 
The following chapter has been written in the style of an article manuscript. The 
manuscript is to be submitted to the peer-reviewed scientific journal Green Chemistry. 
The authors to be included on the publication are: Michael J. Pedersen, Tommy Skovby, 
Michael J. Mealy, Kim Dam-Johansen and Søren Kiil. 
4.1 Abstract 
A flow setup for base liberation of a tertiary amine salt and solvent-free separation of 
the resulting free base has been developed. Production with the flow setup profits from an 
on-demand approach, which is very useful for labile alkylamino halides. The requirement 
for obtaining a dry product has been fulfilled by the simple use of a saturated NaOH 
solution, followed by isolation of the liquid phases with gravimetric separation. The flow 
setup has an E-factor reduction greater than 2 and a distillation step has additionally been 
avoided. The method is an excellent demonstration of how flow chemistry can be used to 
simplify, improve and optimize manufacturing processes. 
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4.2 Introduction 
Isolation and purification of organic compounds by precipitation as salt complexes 
has been used since the infancy of synthetic organic chemistry.199 In pharmaceutical 
tablet production, the final dosage formulation of the active pharmaceutical ingredients 
(APIs) with excipients requires solid APIs, which are often achieved by salt precipitation. 
In other parts of the organic synthesis industry, organic salts are often favored as reactants 
due to their high stability.22,200–203 Synthetic steps, in which organic salts have been 
formed with the intent of purifying an intermediate or for storage considerations, are 
usually followed by a base liberation step to free the organic compound. Commonly, base 
liberation is carried out by mixing the organic salt with an aqueous base (often alkaline) 
and an immiscible organic solvent. Extraction of the organic compound from the aqueous 
phase yields a product-containing organic solvent solution, which is typically dried, 
solvent swapped or distilled to obtain the organic compound in the needed form.199 
The commercially available 3-(N,N-dimethylamino)propyl chloride hydrochloride 
(DMPC-HCl (1)) is a stable starting material frequently used in the synthesis of 
APIs51,170,202,204,205 and may be procured as either the pure solid or an aqueous solution. At 
H. Lundbeck A/S, the syntheses of four different APIs employ the free base (DMPC (2)), 
hence there is a constant demand for this unstable starting material. The reaction is 
illustrated in scheme 4.1 and takes place in aqueous solution. 
Scheme 4.1: The base liberation of DMPC-HCl (1) with NaOH to form DMPC (2). 
 
In spite of the common need for the same starting material in several in-house 
processes, three different batch methods have been employed for the base liberation. The 
necessary reactants and the overall unit operations applied in the existing methods for 
base liberation are shown in table 4.1. 
The three methods listed in table 4.1 all employ sodium hydroxide as a base for the 
neutralization step, require an organic solvent for extraction of 2 and include drying the 
organic phase over an inorganic desiccant. It is of paramount importance that the resulting 
solution or neat 2 has a very low water content (production specification is less than 
0.15% by Karl Fischer titration), since compound 2 is used for preparation of the 
Grignard reagent 3-(N,N-dimethylamino)propylmagnesium chloride (3) (Scheme 4.2). 
Scheme 4.2: The formation of the Grignard reagent 3 from the alkylamino halide 2. 
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Table 4.1: Overview of the current batch methods used in-house for the base liberation of DMPC-HCl (1). 
DMPC Method Reactants Unit Operations Yield (%) 
DMPC Distilled DMPC-HCl 65 wt% 
NaOH 28 wt% 
Hexane 
Water 
Anhydrous Na2SO4 
HCl 30% 
Mixing 
Separation 
Drying 
Filtration 
Distillation 
80-90 
DMPC in Toluene DMPC-HCl 65 wt% 
NaOH 28 wt% 
Toluene 
Water 
K2CO3 
Mixing 
Separation 
Drying 
Filtration 
95-100 
DMPC in MeTHF DMPC-HCl 65 wt% 
NaOH 28 wt% 
MeTHF 
Water 
NaOH Pellets 
Mixing 
Separation 
Drying 
Filtration 
80-85 
 
Organomagnesium halides cannot be formed without scrupulous exclusion of 
moisture and exhibit high reactivity towards hydrolysis140 and different approaches are 
applied in each of the three methods to exclude water. The alkylamino halide 2, obtained 
by the three methods listed in table 4.1, has a limited shelf life due to degradation, e.g. by 
self-condensation or polymerization as depicted in Scheme 4.1 above. The established 
shelf lives of distilled 2 and a solution of 2 in toluene are six and 22 days, respectively. 
The solution of 2 in MeTHF is produced on-demand and not stored. 
The degradation of 2 as illustrated in scheme 4.3 is known as the Menshutkin 
reaction and amines are commonly known to react with alkyl halides to give the highest 
order amines. The Menshutkin reaction is reversible, but gives rise to several other 
products depending on which bond is broken. From a chemical reaction engineering 
perspective, the reaction can be described as a competitive-consecutive reaction. The 
reaction takes place under mild reaction conditions and is the reason for the short life of 
the free base 2. Today, quaternary amines have found great use as phase transfer catalysts 
and in ionic liquid due to their unique behavior.206–214 
Scheme 4.3: Initial degradation pathways of DMPC (2). 
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Since several processes are used internally at Lundbeck to produce 2 and production 
planning can be complicated by the relatively short shelf life of 2, the manufacturing 
approach has been reconsidered. It is obvious that the production set-up would benefit 
from harmonization of the processes; however, the benefit of producing both solutions 
from a scaled-up batch distillation were perceived to be minimal even if the different 
APIs were produced simultaneously. The vacuum distillation method is slow and requires 
a large energy input to obtain at best a modest yield for such a simple operation. Each of 
the established methods requires a tedious drying step, with the requisite filtration to 
remove the drying agent from a malodorous solution containing an alkylating agent – a 
point that weighed heavily on the desire to implement a more HSE-friendly solution. A 
major obstacle to converting to a contained, flow-based method was the necessity of 
refiling some of the API regulatory documentation, since in some instances the 
conversion of 1 to 2 is described as a step that requires adherence to current Good 
Manufacturing Practice (cGMP). 
The fine chemical and pharmaceutical industries are known for their resource-
demanding development and manufacturing. Throughout the last 20 years, the concept of 
Green Chemistry has been used to describe the lack of efficiency and sustainability within 
the chemical industry. The E-factor first described by Roger Sheldon is, due to its 
simplicity, one of the most widely-used metrics in green chemistry; however, other 
methods such as Process Mass Intensity (PMI), Atom Economy (AE), Carbon Efficiency 
(CE) and Effective Mass Yield (EMY) are also prevalent.34,35,49,55,189,215–223 The E-factor 
describes the amount of waste generated per amount of product produced, thus enabling a 
general comparison of efficiency among different chemical industries as shown in table 
4.2. 
Table 4.2: The E-factor related to industry segment.48 
Industry Segment Annual Production (tons) E-factor (kgwaste/kgproduct) 
Oil Refining 106-108 a0.1 
Bulk Chemicals 104-106 <1-5 
Fine Chemicals 102-104 5-50 
Pharmaceuticals 10-103 25-100 
 
The importance of green chemistry in the pharmaceutical industry and how to 
facilitate the adoption of its principles are an ongoing discussion,34 with organizations 
like the recent establishment of the ACS GCI Pharmaceutical Roundtable.31 There are 
many approaches to achieving greener production: classic process optimization, alteration 
of the synthetic route, adoption of sustainable solvent replacements or application of new 
technologies such as flow chemistry.34,35,49,55,189,215–220 This chapter describes the 
harmonization and transformation of the batch manufacturing methods for compound 2 
towards a green flow method. 
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4.3 Chemistry 
The base liberation of 1 is a fast and exothermic acid-base reaction between the 
ammonium salt 1 and NaOH (Scheme 4.1). The free amine 2 decomposes slowly via an 
intra- or intermolecular Menshutkin reaction in which the tertiary amine reacts with the 
alkyl halide moiety to form various quaternary ammonium salts. A mixture of impurities 
is formed from the self-reaction of 2 (Scheme 4.3), leading either to 
1,1-dimethylazetidin-1-ium chloride (4) or a mixture of polymers of varying lengths. The 
decomposition processes are evident from the gradual formation of cloudiness in the neat 
liquid or solutions of 2. In fact, the neat liquid forms a spectacular display of needles after 
a relatively short time if stored improperly. The decomposition occurs under even mild 
conditions, but the rate is accelerated dramatically upon heating. Thus, 2 must be stored 
cold in order to suppress impurity formation, which further complicates the production 
logistics and equipment utilization. The decomposition by-products can potentially 
undergo the reverse Menshutkin reaction; however, this pathway is likely minimized due 
to crystallization of the ammonium salts. 
4.4 Experiments 
4.4.1 NIR Calibration of Water Content in DMPC (2) 
An at-line NIR calibration model was developed to quantify water content in 2 in the 
range from 0 to 5 vol%. A standard solution of 2 containing 5 vol% water was prepared 
from freshly distilled 2. The remaining calibration samples were prepared by standard 
dilution with distilled 2, which after dilution were filtered through a 0.45 μm syringe 
filter directly into a NIR vial and the raw spectra were collected to generate the 
calibration curve. The distilled 2 used to prepare the calibration samples was analyzed for 
residual water content by Karl Fischer titration and a baseline content of 0.059 vol% was 
found. NIR spectra were collected using a MB160 FTNIR Spectrometer equipped with a 
standard vial holder and a DTGS detector (ABB Bomem). A PLS calibration model was 
developed in SIMCA 13.0 (Umetrics AB) using the first derivative of the spectral region 
of 5600-4460 cm-1. A 1-PLS component model was found sufficient, giving a RMSEE of 
0.093 and a RMSECV of 0.098. 
4.4.2 Grignard Reagent: A Qualitative Verification Procedure 
Ca. 1 g of magnesium turnings was added to a 100-mL Erlenmeyer flask with 10 mL 
of anhydrous THF and warmed gently by hand while stirring vigorously with a glass 
spatula to mechanically remove part of the magnesium oxide layer covering the metal 
surface. Sufficient activity of the metal surface was then ensured by addition of ca. 500 
μL of ethyl bromide, whereupon reaction initiation was observed by self-heating to 
vigorous reflux. As soon as the reaction subsided, 1 mL of 2 was added in two separate 
portions and the product was deemed sufficiently dry if a new vigorous reflux was 
observed each time. If water is present, the reaction will not initiate upon addition of 2 
and this will be evident in several ways: (1) a new reflux will not be observed, (2) a milky 
white suspension will be formed instead of a clear metallic solution or (3) a significant 
delay will be observed prior to obtaining a new reflux. 
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4.4.3 Initial Prototype 
The first flow setup was assembled from PTFE tubing (1/8” OD, 1/16” ID) having a 
reactor length of 1 m and mixing the reagents in a PEEK T-mixer (0.04” ID). Reagents 
were dosed at a maximum flow rate of 2.5 mL/min using a two-channel Asia syringe 
pump from Syrris Ltd. The total flow rate of both reactants at all equivalents was 1.5 
mL/min (residence time of 1.32 min). A fraction of 10 mL was collected in a graduated 
cylinder and the volumes of the aqueous and organic phases were recorded. The pH of the 
aqueous phase was determined with pH sticks (pH range 0-14). All reagents used in these 
investigations are bulk commodities. 
4.4.4 Drying and Separation Experiment 
In order to investigate different drying techniques, a portion of 2 was prepared by 
mixing a 2:1 ratio of a 65 wt% aqueous solution of 1 with 28 wt% NaOH (aq.) in a 
separatory funnel. After mixing and allowing the phases to separate, the aqueous phase 
was discarded and the drying agent was mixed with a portion of 2. For the centrifugal 
separation, both a two phase mixture and gravimetrically-separated DMPC (2) were 
tested. For the membrane drying, the experiment was run with similar ratios, but as a flow 
experiment with a similar setup to that used in the first flow experiments. 
In the detailed study of molecular sieves as a drying agent, 10 mL of DMPC (2) were 
transferred to scintillation vials pre-charged with 2 g of pre-dried 0.4 nm molecular sieves 
and stored at 5 qC. 
In the detailed investigation of 50 wt% NaOH solution as a drying agent, volume 
ratios from 1.25-5 of wet DMPC (2) to NaOH 50 wt% were tested. 
4.4.5 Stability Experiments 
A base liberation was carried out in batch using separation funnels and a 2:1 ratio of 
DMPC-HCl (1) 65 wt% to NaOH 28 wt% solution. Afterwards, drying of the wet DMPC 
(2) was achieved using a 2:1 ratio of the solution of 2 and NaOH 50 wt%. Samples were 
transferred to scintillation vials equipped with a screw cap and stored at 5 qC or ambient 
temperature. 
4.4.6 Flow Experiment 
All tubing was of 1/8” OD and 1/16” ID PTFE material and the T-mixers were of 
PEEK material with a 0.04” ID. Tubing length after the T-mixers was 1 m. Each of the 
two decanters was a 100-mL glass hybridization bottle 45GL thread fitted with a 
homemade Teflon lid made durable for the 1/4-28 HPLC fitting connection. The pump 
used for the aqueous solution of 1 (65 wt%) and the NaOH solution (28 wt%) was the 
Asia dual channel syringe pump from Syrris Ltd. fitted with a syringe for a maximum 
flow rate of 2.5 mL/min. The flow rates of solution 1 and the NaOH 28 wt% were 2.5 
mL/min and 1.25 mL/min, respectively. For the wet DMPC (2) stream leaving the first 
decanter, a Knauer HPLC Azura 2.1S pump was used. A similar Knauer pump was used 
for the NaOH 50 wt%. The flow rate was 1.5 mL/min for the wet DMPC (2) and 0.75 
mL/min for NaOH 50 wt%. For the last decanter, an Ismatec Reglo RH00 piston pump 
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was applied for the dry DMPC (2) stream. In both decanters, the aqueous waste phases 
were controlled with gravimetric displacement of the outlet tubing due to lack of pumps. 
The method worked out very efficiently despite its simplicity. The setup was operated at 
ambient conditions. 
4.5 Results and Discussion 
The experimental work was carried out in an iterative sequential implementation 
process, where small batch experiments were used to determine the parameters for the 
flow setup to be verified. 
4.5.1 Analytical Method Assessment and Development 
The routine method for determining the purity of distilled DMPC (2) was not suitable 
for a new solvent-free base liberation method. The distilled method builds on the density 
of DMPC (2), which should be higher than 900 g/L. Neat DMPC (2) has a density of 930 
g/L, while a 65 wt% aqueous solution has a density of 1100 g/L, with the density of water 
being roughly 1000 g/L. The hexane used for extraction in the above distilled method has 
a density of 654 g/L, which is lower than DMCP (2). A mixture of hexane and DMCP (2) 
will have a lower overall density and, as such, density of solution is applicable as a useful 
indicator/measurement of purity in product solutions. When no solvent extractions are 
performed, traces of water will add to the density of the DMPC (2) and no accurate 
measurement is observed using this method. 
A new analytical method was developed for the verification of the base-liberated 
DMPC (2). The method should cover two important factors related to base liberation. It 
should be capable of verifying the DMPC (2) generated with the new solvent-free base 
liberation method. Besides this obvious need, the method should also be able to determine 
the water content, since the intended use of the DMPC (2) was for the generation of 
Grignard reagents, in respect to which obtaining dry DMPC (2) is of crucial importance. 
Furthermore, the method should be fit for online analysis purposes. Given these 
requirements, spectroscopic measurement was the primary choice, with a focus on NIR or 
IR due to their great affinity for detecting O-H bending and stretching, allowing very low 
concentrations of water to be determined. Both methods were found to be suited for the 
purpose and the less costly NIR equipment was chosen. The calibration model for the 
NIR-predicted values versus the Karl Fischer-determined concentration is shown in figure 
4.1. 
75
Chapter 4 
50 
 
Figure 4.1: The NIR calibration curve for water content in DMPC (2), data points for KF vs. NIR (). 
4.5.2 Screening Experiments: Proof of Concept 
The first indications of the possibility of base liberation of 1, without the need for an 
organic solvent extraction, occurred during a study of a Grignard addition employing 3. 
The available starting material for the formation of Grignard reagent 3 was the solid salt 
of 1 and the DMPC in MeTHF method was applied. During one of the many preparations 
of 2, the organic solvent and the aqueous NaOH solution were added in reverse order. 
The result was that the amine separated as an organic layer from the aqueous NaOH 
without the addition of the MeTHF. This finding led to the intense study of the discovered 
phenomenon and ultimately to the investigation of a potential flow setup. 
A setup where an aqueous solution of 1 mixed with an aqueous solution of NaOH 
was desirable, as this would be much simpler to handle in a flow setup than solid 1. One 
major concern was the ability to achieve phase separation of the free base 2 from the 
aqueous phase while having more water present from the aqueous solution of 1, meaning 
this was to be verified before proceeding with a flow setup. A small batch experiment 
quickly determined that separation was possible with the commonly-available production 
solutions and the path towards a flow system with a simple T-mixer and tubing was made 
possible. 
The first flow experiment aimed to shed some light on the importance of 
stoichiometry between NaOH and DMPC-HCl (1), as well as the temperature dependency 
of the base liberation, known to be sensitive to heat. Figure 4.2 summarizes the results of 
these experiments. It was found that the equivalency of NaOH to 1 was very important 
and that the base should be applied at greater than 1 equivalent to achieve the necessary 
base liberation. The pH of the aqueous phase was higher than 10 for all samples, 
increasing to 14 for the higher equivalents of NaOH. The water contents of the selected 
samples were approximately 5 vol%. No temperature dependency was revealed in regard 
to the base liberation, based on the investigated temperatures. However, a slightly slower 
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response in separation of the aqueous phase from the organic phase was observed with 
decreasing temperatures. 
 
Figure 4.2: Condensed results of the base liberation experiment on DMPC-HCl (1) to determine equivalents and 
temperature dependency. Investigated temperatures are 0 qC (U), 10 qC () and 20 qC (). 
For the purpose of visualization of the two phase mixture, an experiment was 
performed with high equivalents where the acid-base indicator phenolphthalein was 
added to the aqueous solution of 1 (pH 1-2). Upon mixing the aqueous solution of 1 with 
the NaOH (28 wt%), the colorless solution of 1 segregates into two phases, where the 
aqueous phase becomes pink (pH>9). Figure 4.3 shows the development of the two phase 
system. 
 
Figure 4.3: The base liberation of DMPC-HCl (1) as flow experiment with phenolphthalein as an acid-base 
indicator for visualization of the process. 
4.5.3 Drying and Separation Consideration 
The high water residual of 5 vol% in the free base 2 after the phase separation called 
for attention, especially due to the later formation of Grignard reagent using the furnished 
DMPC (2). The issue of how to separate the amine organic phase from the aqueous phase 
also needed to be solved for a full operational continuous setup. Mechanical or chemical 
manipulation alone or in combination would be necessary to solve the water issue (there 
should be less than 0.15 vol%). In the previously-mentioned experiment, only gravimetric 
separation for isolation was applied. The current batch methods all use some kind of solid 
drying agent; however, from a flow perspective this is not a desirable solution. The 
alternative is mechanical separation, which in theory looks appealing but might not be 
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sufficient in practice. Table 4.3 provides an overview of the separation and drying 
methods considered and tested. 
Table 4.3: Potential methods for separation and drying of DMPC (2). 
Method Potential, Requirements and Complications Verified 
Membrane 
Separation 
PTFE membrane is capable of separation of organic 
and aqueous solutions from each other. The 
requirement for separation is the hydrophobic PTFE 
membrane. Despite this known capability, they are 
often hard to control and have a narrow window of 
operation if breakthrough aqueous phase or retention 
of the organic phase should be avoided.224,225 
Furthermore, as soon as the PTFE membrane has been 
wetted, water is likely to pass through the membrane 
with very little force. 
Discarded after a 
few trials. 
Gravimetric 
Separation 
(Decanter) 
The gravimetric method is very simple in operation, 
but was already proven not to be applicable for 
suppressing residual water in the organic amine phase. 
However, combination with a suitable drying agent 
could prove to be a useful setup. 
Yes, but not 
useful alone. 
Centrifugal 
Separation 
(Hydrocyclone) 
A high intensity of gravimetric separation by applying 
centripetal force, a commonly used method for 
separation of phases with different density. The 
method may be very sensitive to fluctuations in 
composition and it is unknown whether it is sufficient. 
Yes, but no better 
than gravimetric. 
Was tested as 
batch setup. 
Drying Agents Used commonly in batch processing for the drying of 
solvent to assure elimination of water, A solid drying 
agent can become problematic when applied in a flow 
setup. For instance, fixation (immobilization) of the 
solid reagents in a drying column might be necessary 
and replacement can frequently be required. Often the 
amount of drying agent needed to obtain low water 
content is very high.226,227 
Yes, table 4.4. 
Solid In organic synthesis, a frequently-applied method for 
drying liquid organic solution is by using brine (i.e. 
saturated inorganic salt aqueous solution). The most 
common of these is NaCl solution, due to its rather 
mild and inert nature. 
Yes, table 4.4. 
 
The fact that it was not possible to separate the amine organic phase using any of the 
applied mechanical methods to reach an acceptable level of dryness altered the 
investigation in the direction of employing drying agents. A number of agents were 
evaluated and the conclusions on their capabilities are provided in table 4.4. 
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Table 4.4: Overview of different drying agents and their applicability for flow setup purposes. 
Drying Agent Response Efficiency Capability for Flow 
NaOH Pellets (Coarse Size) Good Within Specification Limited 
Molecular Sieves (0.4 nm) Good Within Specification Possible 
Na2SO4 Anhydrous Slow Within Specification Limited 
MgSO4 Anhydrous Slow Within Specification Limited 
Brine (NaCl sat. aq.) None None High 
NaOH 50 wt% aq. Fast Within Specification High 
 
The molecular sieves were studied a bit more intensively than the other solid drying 
agents, since from a production perspective they prove themselves better suited for a 
drying column than other commercially available solid drying agents.227 Figure 4.4 
provides the dryness obtained by molecular sieves (0.4 nm) in a batch experiment. To 2 g 
of molecular sieves in a scintillation vial with a screw cap, 10 mL of wet amine 2 were 
added and stored at 5 qC during the drying experiment. Despite a rather large number of 
molecular sieves, the response was rather slow and it was not possible to achieve fully dry 
DMPC (2) regardless of there being only 1.6 vol% water to begin with and after 20 hours 
the amount was reduced to 0.35 vol%. Further addition of molecular sieves resulted in 
fully dry DMPC (2); however, given the amount needed, the method is found to be 
insufficient as the sole drying step. 
 
Figure 4.4: Batch drying of wet DMPC (2). A final sample point was taken after 20 hours (0.39 vol%). By adding 
more molecular sieves it was possible to obtain fully dry DMPC (2). NIR measurement () and Karl Fischer 
(KF) titration () were used for analysis. 
Considering flow chemistry, the ability to use a drying agent in a liquid form was 
appealing. The classic saturated NaCl solution was tried with no success and it was 
assumed that the addition of water with the brine could not shift the equilibrium of water 
in the DMPC (2). Knowing the capability of NaOH pellets as a potent drying agent in 
production, the possibility of using a near-saturated NaOH solution (50 wt%) as a liquid 
drying agent was investigated. At the same time, it was also tested whether shifting to the 
NaOH 50 wt% solution could be sufficient for direct base liberation in a one-step flow 
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system. NIR spectra of DMPC (2) from different base liberations (NaOH 28 wt% and 50 
wt%) subsequently treated with NaOH 50 wt% solution are illustrated in figure 4.5, 
where the water peak clearly vanishes upon this treatment. Upon base liberation with 
NaOH 50 wt% a large amount of salt precipitation was observed, hence the idea of using 
NaOH 50 wt% alone was discarded. Several different volume ratios of wet DMPC (2) to 
NaOH 50 wt% were tested, with no significant difference; however, a ratio of 2:1 was 
chosen for later purposes in consideration of a more stable process. 
 
Figure 4.5: The NIR spectra of DMPC (2) treated with NaOH 50 wt% solution for verification of the potential 
for complete drying. DMPC(—), DMPC 1st Ex. NaOH 28 wt% (∙∙∙∙), DMPC 1st Ex. NaOH 50 wt% (- - -), DMPC 
1st Ex. NaOH 28 wt% 2nd Ex. NaOH 50 wt% (- ∙ -), DMPC 1st Ex. NaOH 50 wt% 2nd Ex. NaOH 50 wt% (– –). 
4.5.4 Stability Investigation 
A final issue to be considered before testing a flow setup was the likely degradation 
of the free amine 2 in such a setup. If DMPC (2) is not stable throughout the period 
necessary for collection of a batch size portion, the setup will not be applicable. A 
stability study was established based on samples simulating the fractions of phases likely 
to be found in the setup. One set of samples was kept under ambient conditions, while 
another identical set was stored at 5 qC. After 2 weeks of storage, almost no difference 
could be detected between the samples stored at the two different temperatures. After two 
months, the samples stored under ambient conditions in the laboratory started to show 
signs of degradation. The samples with separated DMPC (2) started to polymerize and, in 
the samples containing NaOH solutions, a reduction in the organic phase (free amine 2) 
was observed. For the samples stored at 5 qC, marginal degradation was observed. The 
stability experiments suggest that a potential full-scale flow setup should not be left 
unused for longer periods; however, the sensitivity towards degradation is greatly reduced 
compared to the free amine from the distilled DMPC method. Nevertheless, a better 
control strategy may be flushing and emptying the setup when production is on hold for 
periods of several weeks. 
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4.5.5 Flow Setup and Demonstration 
The on-demand production of DMPC (2) by use of a flow method is illustrated in 
figure 4.6. 
P1 Dec1
P2
Aq waste
NaOH (50%)
DMPC-HCl 
(65%)
NaOH (28%) T1
C1
P3
C2
T2 Dec2
P5P4 DMPC
Aq waste
 
Figure 4.6: Flow sheet for on-demand production of base-liberated DMPC (2) from DMPC-HCl (1) 65 wt%. 
The setup was operated for several hours with good stability and operation of the 
decanters, which were considered to be the weak part of the setup. Samples of DMPC (2) 
were collected from the setup every 30 minutes for water determination by at-line NIR 
measurement. The first test of the full setup revealed an average residual water content of 
0.5 vol% in the DMPC (2) coming out of the second decanter. In order to achieve better 
results, the mixing of the NaOH (50 wt%) with the wet DMPC (2) from the first decanter 
had to be improved. NaOH (50 wt%) is very viscous and a close examination of the flow 
pattern in the tubing revealed two-phase segregated flow right after the T-mixer. A 
narrowing of the tube was applied at the outlet of reactor coil 2 with a G22 needle, 
causing enough disturbance of the flow to achieve sufficient mixing to obtain dry DMPC 
(2) with approximately 0.10 vol% water on average. 
4.5.6 Control Strategy and Perspective 
For automated operation of the flow setup, simple control strategies could be 
implemented to ensure high quality and dryness of the final DMPC (2). To ensure 
complete base liberation of the DMPC (2) from the DMPC-HCl (1), the pH of the 
aqueous phase from the first decanter after liberation should be higher than 10 and the 
equivalents of NaOH (28 wt%) to DMPC-HCl (1) used should be greater than 1. A 
pH-meter placed at the outlet of the first decanter could be used to ensure the pH 
requirement. A mass balance over the decanter, based on the theoretical release of the 
DMPC (2), combined with an in-line NIR prediction of the water content in the DMPC 
stream should confirm that optimal release is being achieved. Another in-line NIR 
prediction should be used after the second decanter to confirm the dryness of the DMPC 
(2) and ensure that the residual water content is within specification. The yield should be 
confirmed by a mass balance over the inlet and outlet streams. A further level of control 
of the two decanters should be installed to provide information on the separations taking 
place. In relation to optimization of the process, a significant reduction in NaOH (28 
wt%) usage can be achieved if the NaOH (50 wt%) aqueous waste stream is recycled and 
combined with the waste stream of NaOH (28 wt%), as illustrated by the dashed line on 
figure 4.7. The potential reduction of NaOH from this recycling is 18-33%. 
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Figure 4.7: Flow sheet for on-demand production of base-liberated DMPC (2) from DMPC-HCl (1) 65 wt% 
illustrating the necessary control strategies and potential optimization. 
4.5.7 Green Factor Assessment 
The solvent-free flow method was assessed in comparison to the methods currently 
applied. In table 4.5, the calculated E-factor and PMI are provided. Other metrics such as 
the atom efficiency and reaction mass efficiency have not been calculated, as for this 
one-step synthesis they will be identical for the different synthetic strategies. Only DMPC 
Distilled and DMPC in Toluene are compared, since these two methods are located at the 
same production site. 
Table 4.5: Comparison of E-factor and PMI for the different methods of DMPC-HCl (1) base liberation. 
Method E-factor 
(kgwaste/kgproduct) 
PMI 
(kgmass in/kgproduct) 
DMPC in Flow 2.49 3.49 
DMPC in Toluene 2.53 3.53 
DMPC Distilled 4.73 5.73 
 
In particular, the DMPC Distilled synthesis will become a more sustainable process if 
the new flow method is implemented. Besides the values used in calculating the E-factor 
and PMI, the removal of distillation, minimizing the equipment setup, higher yield and 
reduction in reactant consumption are just a few of the benefits that contribute to the 
greenness of this transformation. For the DMCP in Toluene, only minor benefits are 
obtained by using a flow setup based on a simple comparison of the E-factor and PMI 
achieved. Nevertheless, the better control of DMPC (2) concentration in toluene and 
standardization of base liberation methods justify the consideration of changing this 
process as well. 
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4.6 Conclusions 
An organic solvent-free flow method for base liberation of DMPC-HCl (1) has been 
developed as an alternative to the routine batch processes currently applied. DMPC (2) is 
a frequently-used reactant in the production of pharmaceuticals. However, its tertiary 
amine and alkyl chloride functional groups are capable of reacting with each other 
following the Menshutkin reaction to form quaternary ammonium salts and polymers. 
Menshutkin reactions are reversible, but the reverse reaction may lead to multiple 
possible products, since the reversion can occur with any of the four substituents bound to 
the nitrogen in the quaternary configuration. The degradation is easily detected, as long 
threads of milky white polymers start to develop in the otherwise clear and transparent 
DMPC (2), and for neat DMPC (2) the degradation is relatively fast. The flow method 
developed is capable of delivering on-demand amounts of DMPC (2) with limited waste 
generation. By changing the batch method to the developed flow method, great 
simplification can be achieved. Other obvious benefits include the reduction in utilities 
and energy usage as well as lead time. Due to the removal of the need for extraction 
solvent and the lowering of energy consumption, such transformation to a flow process is 
an illustrative example of green thinking in the pharmaceutical industry. Furthermore, it is 
very likely that this setup can be transferred to other base liberation syntheses, especially 
when tertiary amines are involved. 
83
84
Chapter 5 
59 
 
 
 
 
 
Chapter 5 
5 Safe Production of Grignard Reagents in a Continuous Reactor 
The following chapter has been written in the style of a manuscript format for 
potential later publication. 
5.1 Abstract 
A flow method for production of Grignard reagents has been developed. The method 
involves a heterogeneous reactor setup capable of handling solid magnesium in a 
well-mixed reactor with an in-line filter. The setup has been demonstrated for production 
of 3-(N,N-dimethylamino)propylmagnesium chloride in 2-methyltetrahydrofuran from 
3-(N,N-dimethylamino)propyl chloride in the laboratory. This laboratory-scale reactor 
setup is capable of producing liters of high quality Grignard reagent per day. Quality is 
ensured by an in-line NIR measurement that is also used to determine the concentration. 
Four additional Grignard reagents have been demonstrated in the laboratory reactor, 
including one with alkyl halide as a gas (MeCl). A full-scale version of the reactor has 
been implemented at H. Lundbeck A/S and is used in routine production of three key 
Grignard reagents. 
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5.2 Introduction 
Flow chemistry has steadily gained ground within the pharmaceutical and fine 
chemical industry over the last decade.31,36,38,39,42,88,228 Several arguments have been made 
for the justification of flow reactors and it is often a combination of these arguments that 
gives their advantages. The large surface-to-volume ratios and small active reactor 
volumes in particular are positively emphasized when dealing with hazardous chemistry 
with either highly exothermic reactions or toxic materials.32,57,77,161,229 The large surface-
to-volume ratio is ideal for better heat transfer and, when combined with a reduction in 
active volume, it minimizes the risk of accidents in case of a runaway. On a laboratory 
scale, these two issues may not be important, but upon scaling of the chemistry the 
advantages of the small flow reactor compared to a larger batch reactor become 
visible.54,189 
Grignard reagents are commonly-used reactants in the pharmaceutical and fine 
chemical industry because of their wide range of applications, especially for the 
formation of carbon-carbon bonds.50,51,230 Grignard reagents fit well into the 
above-mentioned categories of chemistry, where flow processes can improve safety and 
hazard issues.79,103,111,127,163 Many alkyl/aryl halides are considered carcinogenic, while 
from a safety perspective concealed and small active reactor volumes reduce the risk to 
the operators that are handling them.231–233 Grignard reagents are commonly formed in 
ethereal solvents, typically diethyl ether (Et2O), tetrahydrofuran (THF) or 
2-methyltetrahydrofuran (MeTHF), which all have low flash and boiling points.94 THF 
has become the industrial standard over Et2O due to its higher boiling temperature and 
flash point. THF is likely to be replaced by MeTHF, as THF is a possible carcinogen and, 
additionally, MeTHF is generated from renewable resources, unlike THF.94,99,100,105,109,174 
The last reactant specie is solid magnesium, which under most conditions is stable but 
reacts fiercely with water and acid. The formation of Grignard reagents is highly 
exothermic, with a typical energy release of 150-350 kJ/mol.79,94,103,104,106 Grignard 
formation releases large amounts of energy and is enough to keep the commonly-used 
solvents at reflux. Grignard reagents react vigorously with water, with a large exothermic 
energy release comparable to the energy release during formation.94,127 
Grignard reagent formation is commonly carried out in a batch process at solvent 
reflux.94,100 All solvents and reactants must be dry and covered by inert atmosphere (e. g. 
nitrogen and argon) to avoid reaction of the formed Grignard reagent with water and 
oxygen. The reactor is loaded with magnesium, which is subsequently covered by solvent 
and heated to the solvent’s boiling point. To initiate the reaction and remove the 
protective oxide layer from the magnesium,94,234 highly reactive alkyl halide (e.g. 
dibromoethane) is commonly used in small amounts. To ensure that initiation takes place, 
the addition to the magnesium-solvent slurry is carried out at a temperature below the 
boiling point and upon addition a sudden temperature increase should be observed. The 
same procedure is applied for the alkyl or aryl halide that is to give the desired Grignard 
reagents, where addition of a small portion to a non-boiling reaction mixture should cause 
a temperature increase. After assuring good reactivity of the magnesium, a stable addition 
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of the alkyl or aryl halide is used throughout the rest of the addition. The reason for these 
many precautions is to avoid having large amounts of unreacted alkyl or aryl halide that 
suddenly start to react, with a huge energy release causing runaway of the reaction.94,100 
The above-mentioned risk factors involved in the production of Grignard reagents 
could be reduced or completely removed if Grignard reagents were to be produced by 
continuous processes instead of batch methods. A few examples of continuous formation 
of Grignard reagents do exist.112,163,169,185,187,230,235 The common laboratory flow method is 
a halide exchange, which for full-scale production is less efficient, especially from an 
economic perspective, due to the generation of waste caused by the halide 
exchange.112,163,169,185,187 This chapter demonstrates a new and safe production method for 
Grignard reagents by a flow method. The aim is to develop a continuous reactor setup 
with a small active reactor volume and the ability to handle solid magnesium, with the 
goal of reducing risk while producing Grignard reagents of consistent yield and high 
quality. 
5.3 Chemistry 
The Grignard reagent formation focused on in this article is the coupling between 
magnesium and the alkyl halide 3-(N,N-dimethylamino)propyl chloride (DMPC (1)) to 
form 3-(N,N-dimethylamino)propylmagnesium chloride (DMPC-MgCl (2)). This routine 
batch production currently uses one of three different solvent mixtures (toluene/THF, 
THF and MeTHF), depending on the subsequent usage. The solvent chosen for the 
continuous reactor is MeTHF, as utilization in the subsequent synthesis steps would most 
likely benefit from this solvent. The reaction is fast and is highly exothermic after the 
activation energy is first overcome. Scheme 4.2 illustrates the reaction taking place in 
order to form the desired DMPC-MgCl (2). 
Scheme 5.1: The formation of the Grignard reagent 3-(N,N-dimethylamino)propylmagnesium chloride (2) from 
the alkyl halide 3-(N,N-dimethylamino)propyl chloride (1). 
 
Minor amounts of impurities are commonly formed during the Grignard formation of 
DMPC-MgCl 2; the three most common and their formations are described below. One is 
the quench product (N,N-dimethylpropan-1-amine (3)) of DMPC-MgCl 2 that is present 
due to trace amounts of water in the solvents and reactants or moisture in the headspace 
atmosphere of the reactors. (This impurity is only present in trace amounts as strict 
requirements exist for the dryness of solvents, reactants and nitrogen). The second is the 
Schlenk equilibrium impurity (4) of DMPC-MgCl 2. The Schlenk equilibrium is 
empirically known to be well distributed towards the DMPC-MgCl 2 side for the three 
solvent mixtures used in routine batch production. Impurity 4 is only present in the 
Grignard reagent and will in later synthetic steps either react or be present as product 3 
due to hydrolysis. The third impurity is the homocoupling product (5), occurring when 
DMPC-MgCl (2) reacts with itself, and is also empirically known to be insignificant. The 
structures of the four impurities are illustrated in scheme 5.2. 
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Scheme 5.2: The three common impurities in the production of DMPC-MgCl 2. From left to right: the quenched 
product (3), the Schlenk equilibrium product (4) and the homocoupling (5). 
 
5.4 Experiments 
5.4.1 Reactor Setup 
The current continuous reactor setup (Figure 5.1) consists of a well-mixed laboratory 
reactor with an in-line filter to retain the solid magnesium. The reactor has no 
cooling/heating jacket and the reaction is performed at the reflux temperature of the 
reaction mixture. Cooling is done by condensing the refluxing solvent and by heat loss to 
the surroundings through the reactor wall. The active volume of the reactor is 
approximately 450 mL and the volume level is controlled by simple overflow using 
gravity. Two Ismatec Regloo RH00 stainless steel piston pumps are used for the alkyl 
halide and the solvent and the two streams are premixed in a T-mixer upon entering. Two 
pumps provide flexibility to the concentration of DMPC (1) in the solvent, by changing 
the ratio on the two pumps. All tubing is of PTFE material and of 1/8” OD 1/16” ID 
dimension, with an exception around the NIR flow cell where a slight increase was 
needed to fit the 1/2” stainless steel NIR flow cell (Cross Flow Cell from Brimrose 
Corp.). All fittings are Swagelok stainless steel. 
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Figure 5.1: The flow sheet of the continuous Grignard reagents reactor setup. 
5.4.2 NIR Model Development 
To evaluate the quality and concentration in real time, an analytical method was 
developed. NIR spectroscopy was decided on, since previous in-house experience using 
NIR spectroscopy for Grignard reagents had been implemented with success. Neither 
DMPC-MgCl (2) nor DMPC (1) are commercially available in MeTHF, since both have 
limited shelf life. In particular, DMPC (1) has a very low shelf life, with degradation by 
polymerization within days. Because of the lack of commercial availability, all calibration 
samples for the model development were produced. 
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Initially, NIR spectra were acquired on the three main components in order to 
identify unique spectral peaks. It was possible to distinguish between the MeTHF solvent 
and the DMPC-MgCl (2), but spectral differences between DMCP (1) and DMPC-MgCl 
(2) are less distinct. The raw NIR spectra in the range of 6400-4400 wavenumbers are 
shown in figure 5.2. 
 
Figure 5.2: The raw NIR spectra of MeTHF (—), DMPC (1) (∙∙∙∙) and DMPC-MgCl (2) (---). A distinct difference 
between MeTHF and the DMPC-MgCl is seen, but less deviation between DMPC-MgCl (2) and DMPC (1) can 
be found. 
A standard batch procedure was used to make six batches of DMPC-MgCl (2) in 
MeTHF for the purpose of developing a NIR prediction model for DMPC-MgCl (2) 
concentration in MeTHF containing unreacted DMPC (1). The DMPC-MgCl 
concentration of each batch was determined with a standard titration of a tricyclic ketone 
and an in-house HPLC method was used for analysis, not discussed in further detail. A 
total of 59 calibration samples were made from the four batches by diluting with different 
amounts of MeTHF and addition of trace amounts of DMPC (1). In this way, selectivity 
and robustness are built into the calibration model as the DMPC (1) and DMPC-MgCl (2) 
are varied independently. The 59 reference samples are shown in figure 5.3 as the 
DMPC-MgCl (2) concentration plotted against the DMPC (1) concentration. The 
correlation between samples is very low, giving rise to the development of a robust 
model. 
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Figure 5.3: Molar DMPC-MgCl versus molar DMPC of the 59 reference samples used for the NIR prediction 
model to determine concentration of DMPC-MgCl (2). 
NIR spectra of all 59 samples were acquired using a Bomem FTPA2000 FT-NIR 
(ABB Bomem) using a ½” NIR Flow Cell (Cross Flow Cell from Brimrose Corp.) as 
cuvette. The flow cell was connected to the spectrometer using 500 μm optical fibers. 
Raw spectra were acquired in the range of 15792-4500 cm-1 with a resolution of 16 cm-1 
and with 64 subscans in each spectrum. Background spectra were acquired on air. The 
DMPC-MgCl (2) concentration model was created from data by reducing the spectral 
region of interest to 5454-5292 cm-1, centering and taking the first derivative. A partial 
least squares (PLS) model with five principal components was chosen and the model was 
cross-validated by the leave-7-out principle. The final PLS model has a cross-validated 
prediction error of 0.065 M, which is a reasonable error within the 0-1.65M operational 
window. 
An attempt was made to build a PLS model for the potential unreacted DMPC (1), 
but it was not possible to develop a valid model. Despite the inability to develop a PLS 
model for prediction of the unreacted DMPC (1), the reaction progress is stoichiometric, 
hence from a safety perspective the added DMPC (1) should equal the formed 
DMPC-MgCl (2). It is still valuable to keep all samples in the calibration as this will 
secure selectivity and robustness in the presence of unreacted DMPC. Figure 5.4 shows 
the NIR PLS model’s ability to predict the concentrations of the DMPC-MgCl (2) 
reference samples, using the first derivative spectra of the region 5454-5292 cm-1. 
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Figure 5.4: A predicted versus measured plot of the final PLS model for DMPC-MgCl (2) determination in 
MeTHF. 
5.4.3 Operational Procedure 
5.4.3.1 Start-up 
The start-up of a continuous reactor is associated with operation under non-steady 
state conditions. The reactor is initially flushed with nitrogen to ensure an inert 
atmosphere before addition of the solid magnesium and subsequently with MeTHF to 
cover the magnesium turnings. The reactor does not have any active heating since the 
exothermic reaction is sufficient to maintain reflux under continuous operation. However, 
during start-up, active heating of the magnesium-MeTHF slurry is necessary and is done 
with a heat gun pointed towards the reactor wall (stainless steel reactor) under stirring of 
the mixture until reflux is achieved. The protective oxide layer on the magnesium is 
removed to ensure good reactivity of the magnesium and is done by the commonly-used 
method of highly reactive alkyl halide (e.g. dibromoethane).94,234 Before addition of the 
dibromoethane, the temperature has to decrease below the reflux point to ensure that the 
reaction can be visually followed by the temperature increase and re-establishing of the 
boiling of the MeTHF (e.g. bubbling on the surface of the mixture) upon reaction with 
magnesium. This procedure is only necessary the first time the reactor is started and 
afterwards the magnesium turnings left in the reactor are active enough to start upon 
addition of DMPC (1). The choice of no heating unit or having a jacket reactor is merely 
a matter of keeping the cost of the full-scale reactor down by saving on an otherwise 
costly heating module. The reaction between DMPC (1) and magnesium is observed as 
foam on top of the liquid surface and other small bubble formations on the magnesium 
surface, more easily observed when the stirring is stopped. To ensure no accumulation of 
unreacted DMPC (1) during start-up, the feed pumps are turned on and off a couple of 
times, letting the mixture stop boiling indicating that all DMPC (1) has been consumed. 
Addition of new DMPC (1) should make the mixture start boiling again and a switch to 
continuous operation is made. 
R² = 0.97 
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5.4.3.2 Continuous Operation and Short Shutdown Periods 
Operating the reactor continuously requires constant surveillance of the magnesium 
turning level in the reactor. The feeding of DMPC (1) and MeTHF is carried out by the 
two pumps and feeding is adjusted to fit a vigorous boiling, but without heavy bumping. 
The easiest way to fit the flow rates is by an iterative adjusting cycle: 
1. Stop pumps 
2. Allow boiling in the reactor to settle (approximately 5 minutes for correct flow 
rate) 
3. Adjust flow rate (increase for boiling less than 5 minutes, decrease for boiling 
longer than 5 minutes) 
4. Start pumps with new flow settings and run for 5 minutes before returning to step 
1. 
Solid magnesium is fed manually through one of the reactor necks. In the laboratory 
this is easier than building a solid handling device, but this solution is implemented at full 
scale. The concentration of the product is measured with the NIR flow cell shortly after 
the overflow from the reactor. The flow cell is mounted in a way that ensures the flow is 
upwards, thereby avoiding air-bubble issues. The product is collected in nitrogen-flushed 
and covered bottles. When shutting down the setup for short periods of time, such as 
overnight, the pump is stopped and everything is left to cool as the reaction stops and the 
boiling gradually fades. The setup is left standing till the next morning, when feeding of 
DMPC (1) should quickly bring the reactor back to boiling conditions. The NIR 
measurements are used to ensure that the concentration of DMPC-MgCl increases as 
expected during addition of DMPC to the reactor. Hereby, accumulation issues can be 
avoided and we thereby have a safer production setup. 
5.4.3.3 Long Shutdown Periods 
The reactor can be shut down for long periods of time (e.g. months) without the need 
for cleaning and dismantling. Shutting down the reactor only requires the active reactor 
volume to be flushed with pure MeTHF, needing approximately 5 residence times to 
clean out most DMPC-MgCl (2). NIR measurement during this cleaning process could be 
used to ensure a low concentration of DMPC-MgCl (2) in the reactor. It is ensured that 
the magnesium turnings are well covered with MeTHF and a small overpressure of 
nitrogen is kept to ensure inert atmospheric conditions. This shutdown procedure is more 
a matter of safety, as DMPC-MgCl (2) is significantly more reactive than magnesium 
turnings covered with MeTHF in case of any accident. 
5.5 Results and Discussions 
The choice of operating at reflux temperature was based on a safety assumption, 
where most energy is consumed while evaporating and condensing the refluxing solvent. 
The setup was operated for several days, collecting DMPC-MgCl (2). This laboratory 
production included both start-up and short shutdown periods, as well as proof of concept 
for the long shutdown period. Figure 5.5 shows the operation of the setup for a 140-
minute period and the trend curve shown is the NIR prediction of DMPC-MgCl (2) 
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concentration over time. Run-out of DMPC (1) caused a decrease in concentration at 
around 20 minutes. Replacing the bottle of DMPC (1) and increasing the ratio of DMPC 
to MeTHF started a new period of production. The combined flow rate of the DMPC and 
the MeTHF to the reactor was between 10-30 mL/min, with a ratio of DMPC/MeTHF of 
0.15-0.30. At these ratios, the concentration of DMPC-MgCl achieved was 1-2 M and the 
concentration stability, as seen over a period of time, was within the acceptable 
performance range of the laboratory equipment. The laboratory reactor is capable of 
producing more than 10,000 L of Grignard reagent per year if fully utilized (30 mL/min). 
 
Figure 5.5: The concentration of DMPC-MgCl (2) (—) predicted by the NIR PLS model during operation. 
DMPC-MgCl (2) formation has not been implemented in a full-scale reactor at this 
time. Currently four other Grignard reagents have been demonstrated in the laboratory 
flow reactor along with a subsequent successful full-scale implementation of three of 
these. One of these Grignard reagents is an alkyl halide that is a gas under ambient 
conditions and the original reactor was redesigned to meet this challenge by pressurizing 
the pipe in which the ethereal solvent and alkyl halide were pre-mixed before entering the 
reactor, resulting in a mixing of two liquids instead of a gas and a liquid. 
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5.6 Conclusions 
A successful transformation of batch production of 3-(N,N-dimethylamino) 
propylmagnesium chloride (DMPC-MgCl (2)) into a continuous reactor setup has been 
demonstrated at laboratory scale. The continuous reactor setup differs from most flow 
setups used to make Grignard reagents, as it is able to handle solid magnesium instead of 
using the magnesium halide exchange procedure more common for laboratory flow setup. 
This direct Grignard reagent formation generates less waste compared to the halide 
exchange method. Furthermore, the later synthetic step will have easier purification and 
recovery, since no impurities can arise from reactions with the magnesium-carrying 
reagent that are present if the magnesium halide exchange method is used. The setup has 
proved itself highly flexible towards different Grignard reagents, with demonstration of 
five different alkyl and aryl halides as reactants. The setup of three of them has been 
successfully implemented for full-scale routine production. The laboratory reactor itself is 
capable of producing more than 10,000 L of Grignard reagent per year if operated at full 
utilization. The setup also improves the safety of making Grignard reagents, as the active 
volume is insignificant compared to routine full-scale batch production. Especially during 
start-up, the addition of alkyl or aryl halide may start the reaction properly and the risk of 
accumulation of halide reactant that could suddenly initiate has been reduced significantly 
and is almost non-existent. The implementation of NIR measurement to follow the 
reaction provides a fast method for quality assurance but also improves safety, as 
unreacted DMPC (1) can be spotted due to correlation with the DMPC-MgCl (2) 
concentration. The full-scale setup is a completely closed system, whereas the laboratory 
reactor setup is designed with freedom for fast operation but is small enough to be safely 
operated within a fume hood. The full-scale continuous reactor setup is a safer method in 
comparison to the old batch method and has reduced the risk of exposure to carcinogenic 
reactants and products. 
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Chapter 6 
6 Redesign of a Grignard-Based API Batch Synthesis to Flow 
Chemistry 
The following chapter has been written in the style of an article manuscript. The 
manuscript is to be submitted to the peer-reviewed scientific journal Organic Process 
Research & Development. The authors to be included on the publication are: Michael J. 
Pedersen, Tommy Skovby, Michael J. Mealy, Kim Dam-Johansen and Søren Kiil. 
6.1 Abstract 
A current Grignard-based melitracen HCl batch synthesis process has been 
redesigned to fit a continuous reactor system. The Grignard addition is carried out at 
room temperature, with subsequent one-step hydrolysis and dehydration of the 
magnesium alkoxide intermediate. The melitracen is isolated by simple gravimetric phase 
separation and is crystallized with 2 M HCl in diethyl ether to melitracen HCl. All steps 
in the laboratory setup are connected and the setup is capable of producing a significant 
amount of the commercially-needed melitracen HCl. The flow setup has reduced area 
footprint, energy consumption, synthesis steps and raw material usage compared to the 
batch process. 
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6.2 Introduction 
The efficiency of the pharmaceutical industry has been a widely discussed topic 
throughout the past decade. The debate has been broad, ranging from early target drug 
development to the actual production and distribution of pharmaceuticals.12,19,31,43,236,237 
Expiring patents and empty pipelines have forced pharmaceutical companies to look for 
alternative methods to remain competitive against generic manufacturers.21,238,239 
Furthermore, the industry has one of the highest solvent-to-carbon ratios, which in 
combination with the fact that most of these solvents have high environmental impacts 
has given the industry a somewhat damaged reputation.48 In addition, the authorities have 
steadily increased the tightening of legislative requirements for pharmaceutical 
manufacturing, in both development and production.31,237 
With respect to the production of active pharmaceutical ingredients (APIs), the focus 
has especially been on batch methods and their insufficiency, especially their mass and 
heat transfer properties.54,77 As early as the 1970s, Popov44 suggested continuous 
manufacturing as a method for improving the efficiency of pharmaceutical production. 
However, it was not until the last decade that progress was seen. The establishment of the 
pharmaceutical round table and the increased interest from academia and industry have 
been driving the transformation forwards.31,39–41,43,88 The authorities have since 2002 
acknowledged new production methods and strategies within manufacturing. Process 
analytical technology (PAT) approaches and Quality-by-Design (QbD) concepts have 
been important factors in the acceptance of continuous manufacturing by the 
authorities.21,240,241 
Earlier publications concerning the new paradigm of pharmaceutical manufacturing 
often focused on single synthesis steps and unit operations, often with the use of 
microreactor technology.33,37 Later trends have changed the focus towards multiple 
synthesis steps, pharmacy-on-demand and end-to-end manufacturing.39–41,242 As the trend 
has moved from single step to end-to-end manufacturing,39 the previous out-scaling 
concept33 of microreactors has also been replaced by mini-scale flow systems.39,88–90,167 
The scale-up of a continuous setup needed to meet full-scale requirements is often minor; 
hence the benefits such as mass and heat transfer are almost comparable to microreactor 
technology.54 
Reactions having multiple phases still pose a significant challenge within flow 
chemistry.22,32,243 Flow reactors are known for being poor at handling solid material due 
to clogging issues, with some exceptions such as packed bed reactors with fixed catalytic 
material. The pharmaceutical industry is notorious for their usage of solid compounds, 
either as reactants, intermediates or APIs.22,243 Low solubility is often a huge obstacle for 
applying the chemistry to a flow setup, unless alternative methods are applied.22,236 In 
cases of high solubility, the simple use of a plug flow reactor (PFR) can be applied, often 
with great success and larger throughput.167,244 The challenging part then becomes the 
purification of the product from impurities and unreacted reactants, as well as the final 
isolation of the product. Many old batch processes utilize the benefits of precipitation as a 
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purification step, hence altering an old batch process to fit a flow setup requires new ways 
to overcome these challenges.88,236,243 
6.3 Chemistry 
As illustrated in scheme 6.1, four synthetic steps are involved in the manufacturing of 
melitracen HCl (6). The four steps are a classic Grignard addition to a ketone, a 
hydrolysis of a magnesium alkoxide, a dehydration of an alcohol and a salt precipitation 
to isolate the API. The Grignard addition is between 10,10-dimethylanthrone 
(10,10-DMA (1)) and 3-(N,N-dimethylamino)propylmagnesium chloride (DMPC-MgCl 
(2)), resulting in formation of the magnesium alkoxide 3. The magnesium alkoxide 3 is 
then hydrolyzed to the alcohol 4 and dehydrated to form product 5. The last step is a 
crystallization of the API as a salt, where HCl is added to obtain the melitracen HCl (6). 
Scheme 6.1: Syntheses of magnesium alkoxide 3, alcohol 4 and dehydrated product 5 in the manufacturing 
process of melitracen HCl 6, from ketone 1 and Grignard reagent 2. 
 
6.4 Current Batch Synthesis 
The current batch synthesis involves individual synthetic steps, as illustrated in figure 
6.1. DMPC-MgCl 2 is made in-house before it is used, due to its limited storage shelf life, 
in a toluene-THF solvent mixture. THF is present in trace amounts in order to stabilize 
the magnesium in the Grignard reagents.94 A solution of 10,10-DMA 1 is prepared in 
toluene and is slowly transferred to the DMPC-MgCl 2, maintaining a temperature of 
50qC. DMPC-MgCl 2 is used in an equivalence of 1.6 compared to 10,10-DMA 1. The 
formed magnesium alkoxide 3 is hydrolyzed with water and acetic acid (80%). The 
aqueous phase is discarded and concentrated hydrochloric acid (37%) is used to dehydrate 
alcohol 4 to form dehydrated product 5. Toluene is replaced with ethanol by a solvent 
swap. Crystallization of the dehydrated product 5 from the ethanol phase is done with 
HCl gas to obtain the final melitracen HCl (6), which is subsequently isolated by 
filtration. 
97
Chapter 6 
72 
Grignard 
Addition
Dehydration
Hydrolysis
Phase 
Separation
Phase 
Separation
Solvent Swap
Crystallization
Grignard 
Addition
Hydrolysis/
Dehydration
Phase 
Separation
Crystallization
Batch Method Flow Method
 
Figure 6.1: The operational steps involved in the current batch method and the simplification achieved by the 
flow setup. 
6.5 Investigational Strategy 
The API manufacturing strategy at H. Lundbeck A/S is focused on continuous 
production. Melitracen HCl synthesis currently occupies significant production facilities 
and is produced by routine batch synthesis procedures. The process shows potential for 
being redesigned to fit a continuous reactor setup, with potential for significant 
simplification of the operation and the synthetic route. This article describes the 
laboratory work for redesigning the process to fit a continuous reactor setup for the 
Grignard addition to the final melitracen HCl crystallization. 
6.6 Screening Experiments 
The routine batch synthesis for production of melitracen HCl 6 was considered 
suitable for redesign into a flow process, as most of the synthetic steps are categorized as 
fast reactions.22 The current batch methods could possibly be transferred directly into a 
flow setup, providing the common benefits achieved when changing from batch to 
continuous processing. However, additional savings could potentially be achieved with 
the flow setup if simplifications of aspects such as the solvent choice and synthetic steps 
were possible. Classic batch screening experiments were conducted to assist in the 
decision on and design of a flow setup and, based on these experiments, the flow setup 
decided on was to be experimentally verified afterwards. 
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6.6.1 Solubility of Reactants and Products in Solvents 
The first consideration in the process for redesigning melitracen HCl 6 synthesis is 
the solubility of reactants, intermediates and products. Solubility is one of the key 
parameters when designing a reactor setup and an instructive discussion may be found in 
Pedersen et al.88 The primary focus was on the Grignard addition step, where reactants 
10,10-DMA 1, DMPC-MgCl 2 and magnesium alkoxide product 3 are of interest. 
DMPC-MgCl 2 already has a high solubility and was not tested further. 10,10-DMA 1 is 
a solid starting material and needs to be dissolved before it can react with DMPC-MgCl 2. 
The solubility of 10,10-DMA 1 should therefore be tested in potential solvents and at 
different temperatures. Magnesium alkoxide 3 is not easily isolated, as the magnesium 
halide part easily reacts with water and moisture. Instead of determining the exact 
solubility of magnesium alkoxide 3, a qualitative first estimate of its capability to stay in 
solution could be sufficient. The requirement is, of course, that the concentration of 
magnesium alkoxide 3 in the reaction mixture is representative of the concentrations of 
the 10,10-DMA 1 and DMPC-MgCl 2 intended for the synthesis. The later synthetic steps 
should be tested accordingly for solubility where necessary, since low solubility in these 
steps could require a lower concentration of 10,10-DMA 1 and DMP-MgCl 2 to have a 
fully operational flow setup from start to end of the synthesis. 
The solubility experiments on 10,10-DMA 1 focused on three solvents to be verified: 
toluene, tetrahydrofuran (THF) and 2-methyltetrahydrofuran (MeTHF), all of which are 
suitable candidates for later full-scale production. The solubility temperature was tested 
up to 20qC, which is to be considered the high limit due to ambient temperatures if no 
heat tracing should be applied to pumps and pipes. Figure 6.2 shows the solubility of 
10,10-DMA 1 in the three solvents, where THF shows a significantly higher solubility 
than toluene or MeTHF. 
 
Figure 6.2: The solubility of 10,10-DMA 1 in toluene (), THF () and MeTHF (U). The 10,10-DMA 1 has high 
solubility even at low temperatures in the tested solvents. THF has the highest solubility, approximately 100 g/L 
more 10,10-DMA 1 compared to MeTHF and toluene. 
The significantly higher solubility of 10,10-DMA 1 in THF makes it an obvious 
choice. If toluene were to be continued with, trace amounts of ether would still be needed 
to stabilize the magnesium in DMPC-MgCl 2. 
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The concentration of 10,10-DMA 1 in THF was set to the lower side of 20qC (1.8 
mol/L, 400 g/L) to minimize the risk of precipitation while operating a flow setup. The 
DMPC-MgCl 2 was available at approximately 1.5 M concentration in THF from the 
production and it was decided to proceed with this concentration. A couple of quick 
qualitative batch experiments were carried out to verify whether the magnesium alkoxide 
3 could remain soluble in the reaction mixture, as it was not possible to isolate the 
unstable magnesium alkoxide 3 for a solubility study. These experiments came out 
positive for the desired concentrations of 10,10-DMA 1 and DMPC-MgCl 2 and no 
further testing of the solubility of magnesium alkoxide 3 was found necessary. 
6.6.2 Phase Separation: Organic Phase and Aqueous Waste 
A batch experiment, representing the expected concentration for the flow setup, was 
used to verify the potential for phase separation of THF from the aqueous phase. A 
requirement for success was that the magnesium alkoxide 3 was mostly distributed in the 
THF phase. The DMPC-MgCl 2 was slowly added in excess amounts with a dripping 
funnel to a round-bottom flask of the 10,10-DMA 1 solution. The mixture was afterwards 
hydrolyzed with water and acetic acid (80%). The addition of the acid caused the pH of 
the mixture to become slightly acidic (pH a6) and an one-phase mixture was achieved. 
The pH was adjusted with aqueous ammonium (25%) and at pH 8 a two-phase mixture 
appeared. Alcohol 4 was distributed at 63% in the organic phase and 37% in the aqueous, 
according to HPLC assay. Adjusting the pH in the aqueous phase to 10 with additional 
aqueous ammonium (25%) resulted in an additional organic phase, with less than 1% 
alcohol 4 left in the aqueous phase. At pH ≥ 10 the tertiary amine is completely 
deprotonated, which is assumed to force the alcohol 4 out of the aqueous phase and into 
the organic phase. In acidic conditions the tertiary amine is fully protonated, causing the 
alcohol 4 to be soluble in both the aqueous and organic phase. 
Alcohol 4 in the organic phase was then dehydrated with hydrochloric acid (37%), 
followed by adjustment of the pH to 10 with aqueous ammonia (25%). Adjusting the pH 
to 10 allowed a phase separation with more than 99% of the product in the organic phase 
and with a a99% purity of the dehydrated product 5. During the hydrolysis and 
dehydration, a minor precipitation of solid material was formed that easily dissolved as 
the reaction progressed and should therefore not be a major concern for a flow setup. 
Fortunately, it was found that a well-defined separation of alcohol 4 in THF could be 
achieved from the aqueous phase by judicious selection of pH. Due to the tertiary amine 
in alcohol 4, at acidic pH the amine is protonated, causing it to be soluble in water and 
form a single phase. At pH higher than 10, the amine is deprotonated, becomes almost 
insoluble in water and separates cleanly. Had this not been possible, one could consider 
changing the synthesis solvent to MeTHF, which is not miscible with water, and thus 
simplify the workup of the product 4 or 5 from the aqueous phase. 
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6.6.3 One-Step Hydrolysis and Dehydration 
The ability to phase separate both the alcohol 4 and the dehydrated product 5 in THF 
enabled a simplification of the targeted flow method. Ideally, hydrolysis and dehydration 
should be possible in one step, hence saving a phase separation and combining two 
synthetic steps into one. Screening for a potential acid for the one-step hydrolysis and 
dehydration was done, focusing on acetic acid and hydrochloric acid, either separately or 
in combination. Table 6.1 shows the results of the product formation based on the 
different acid systems. 
Table 6.1: Screening of different acids for direct hydrolysis and dehydration of the magnesium alkoxide 3 to the 
dehydrated product 5. 
Acidic Solution Product (%) Phase Separation (%) 
HCl 37% (aq.) Dehydrated 5 (100%) >99 
AcOH 80% (aq.) Alcohol 4 (100%) >99 
HCl 37% (aq.)/AcOH 80% (aq.) (1:1) Dehydrated 5 (90%) 
Alcohol 4 (10%) 
>99 
 
As seen in table 6.1, only hydrochloric acid was able to hydrolyze and dehydrate the 
magnesium alkoxide mixture in one step. The experiment with hydrochloric acid resulted 
in significant heat development and an immediate precipitation of solids that potentially 
could be critical, even though it dissolved within a few minutes. An additional set of 
screening experiments was done to verify the potential of a lower concentration of 
hydrochloric acid. These experiments were carried out to verify whether the immediate 
precipitation of solid could be avoided and whether the energy released from the 
hydrolysis and dehydration could be distributed, as both steps are exothermic. Equal 
volumes of hydrochloric acid with different concentrations (1, 3, 6, 9 and 12 M) were 
used. For the concentrations lower than 6 M, it was not possible to achieve full 
dehydration at ambient temperature. For the concentrations equal to 6 M and higher, full 
dehydration was obtained, but all concentrations resulted in precipitation of a white solid 
that dissolved after few minutes of standing. From a production and environmental 
perspective, the more concentrated hydrochloric acid is the optimal choice; less aqueous 
waste is generated if the acid used is stoichiometric. Given the fact that precipitation 
could not be avoided and the production perspective, it was decided to proceed with 12 M 
hydrochloric acid. 
6.6.4 Precipitation of Melitracen HCl from THF 
The dehydrated product 5 was crystallized as the final HCl salt in the THF in a batch 
experiment, in order to remove a solvent swap to ethanol. The crystallization was carried 
out with 2 M HCl in Et2O, as this was considered more suited for a later flow process and 
more easily implemented in the laboratory setup. An equivalence of 1.1 HCl was used 
and the requirement was an achievement of pH<2. The mixture was kept stirred during 
the crystallization and carried out at ambient temperature. After 10 minutes, fine white 
solids started to form, followed by a massive precipitation of melitracen HCl 6. The 
melitracen HCl 6 was filtered with a Büchner funnel and washed with THF. The isolated 
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yield was 80% and within the specifications for the in-house analysis methods used in the 
routine production (CHN, TGA, UV-vis, HPLC, melting point). Figure 6.3 is a 
microscope picture of the isolated melitracen HCl 6. For full-scale production, the HCl 
gas would still be more desirable for the crystallization and the 2 M HCl in Et2O merely 
serves as a proof of concept for the laboratory flow setup.  
 
Figure 6.3: Microscope picture of the isolated melitracen HCl 6 from the THF solution. 
6.7 Flow Experiments, Results and Discussion 
6.7.1 Flow Process 
The initial batch screening experiments all indicated that the chemistry should be run 
in PFRs. This decision is based on several parameters from the screening experiments. In 
particular, the high solubility of the reactants and products makes the synthesis ideal for 
PFRs. Additionally, all of the synthesis steps are categorized as fast (full conversion 
within minutes) and hence small reactor volumes can be used. The final setup is 
illustrated in figure 6.4 as a flow sheet. All tubing was 1/8” OD and 1/16” ID and made 
from PTFE; the T-mixer was of PEEK material ID 0.04”. All synthetic steps were 
performed at ambient temperature, with no active cooling or heating. Every step, except 
for the addition of acetic acid and the decanter phase separation, is exothermic. The 
decanter was a 100 mL glass bottle, fitted for the purpose with an in-house-made PTFE 
lid. After the Grignard addition (T1,C1) of DMPC-MgCl 2 to 10,10-DMA 1, a flow IR 10 
μL head from Mettler Toledo was applied for in-line monitoring of the conversion and 
reaction. After the acetic acid addition (T3,C3), a 100 psi back pressure regulator (BPR) 
was applied to avoid boiling of the THF due to the hydrolysis and dehydration taking 
place at the HCl addition (T2,C2). The choice of placing the BPR is due to precipitation 
of solid material right after the HCl addition that is fully dissolved throughout the acetic 
acid coil. The HCl precipitation was done by collection of the two streams in a flask. A 
number of different pumps were used, all of them being positive displacement pumps for 
dosing purposes. Knauer Azura P 2.1S HPLC pumps with 10 mL stainless steel pump 
heads (P1 and P2) were used for the 10,10-DMA (1) and DMPC-MgCl (2); a Syrris Asia 
pump (dual pump) equipped with 0.5 and 1.0 mL glass syringes was used for both 
hydrochloric acid (P3) and acetic acid (P4). A Merck-Hitachi HPLC pump with a 10 mL 
stainless steel pumphead was used for the aqueous ammonium (P5) and Ismatec Reglo 
RH00 piston pumps were used for the decanter outlet (P6) and the 2 M HCl in Et2O (P7). 
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The flow rate was determined in accordance with the maximum capacity of each pump 
and the limitation was the pump used for the acetic acid. 
P1
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P4P3
P6P7
Aq waste
HCl 2M in Et2O
10,10-DMA
DMPC-MgCl
HCl (aq) AcOH (aq)
Melitracen 
HCl
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Figure 6.4: Flow sheet of the flow reactor setup for the redesign of the melitracen HCl synthesis. 
6.7.2 Stepwise Verification of Flow Reactor Parts 
A stepwise implementation and verification of each step was done to minimize the 
risk of operational problems, while operating the entire setup as illustrated in figure 6.4. 
The major risks were considered to be clogging issues and separation performance. 
The Grignard addition of DMPC-MgCl 2 to 10,10-DMA 1 was the first part to be 
verified and an equivalence of 1.1 DMPC-MgCl 2 was used to ensure full conversion of 
10,10-DMA 1. Only a few minutes of residence time were needed for the reaction to 
achieve full conversion of the 10,10-DMA 1. The reaction was easily followed visually, 
as the magnesium alkoxide 3 becomes dark red/orange. The product stream was collected 
in a flask, where it turned to a more orange-like appearance over time. 
Implementation of the HCl stream for hydrolysis and dehydration caused boiling of 
the THF solvent, but full conversion was achieved within minutes. Implementing the 
acetic acid stream resulted in some alteration of the setup to account for the boiling of the 
THF, as full conversion was not achieved. A back pressure regulator (BPR) of 100 psi 
was added to prevent the boiling of the THF (65 °C at STP). The BPR provided a stable 
flow that ensured a steady residence time in the HCl coil (C2), resulting in the desired full 
conversion of the magnesium alkoxide 3 to the dehydrated product 5. Adding the aqueous 
ammonium stream to the setup caused precipitation of ammonium chloride salt. The 
precipitate was easily dissolved by addition of water. Due to lack of pumps, it was 
decided to dilute the acetic acid to 40% from the original 80% and to double the flow rate. 
From a production perspective, an additional pump with water would be better suited as 
80% acetic acid is the standard concentration in production. The BPR was originally 
implemented right after the HCl coil, but the white solid precipitate later caused clogging 
of the BPR, so it was moved to be after the acetic acid stream where a full liquid 
homogeneous phase was present. The choice of not moving it to be after the aqueous 
ammonium coil was due to a small risk of having precipitation upon the addition thereof, 
as this was observed in a previous run. At the end of the acetic acid addition during all 
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adjustments, a full one-phase homogeneous stream was constantly present and it was 
considered more stable to add the BPR at this point in case of any fluctuation. 
Having the entire setup running, the decanter was tested for the setup. A previous 
flow setup had proved the decanter’s capability for separating organic and aqueous phases 
from each other, so that a single experiment was enough to demonstrate the decanter for 
this separation. The last stream to be implemented was the 2 M HCl (Et2O) stream for 
crystallization. At first, mixing of the two streams was attempted in a T-mixer (2.5 mm 
ID), but the low pressure pumps used (Ismatec pumps) could not deliver a high enough 
pressure to avoid clogging. The clogging was caused by evaporation of the solvents due 
to the low boiling points of both THF and Et2O and the crystallization of melitracen HCl 
(6) happening in the T-mixer. As an alternative, the two streams (P6 and P7) were 
pumped individually into the collecting bottle. No optimization was done to control the 
crystallization, as this was not the scope of the project, and for a full-scale setup HCl gas 
would be a preferred choice. Figure 6.5 shows the fractions collected from the setup. 
 
Figure 6.5: The collected fractions of product streams from the setup during continuous operation. To the left is 
the aqueous waste from the decanter, at the center is the organic phase containing dehydrated product 5 and to 
the right is the crystalline melitracen HCl 6 API and the mother liquid. 
6.7.3 Operation of Full Flow Setup 
The final flow setup, as illustrated in figure 6.4, was operated for 300 minutes under 
steady state conditions. The experiment was terminated at the point of complete 
utilization of the 2 M HCl (Et2O). For the first 30 minutes the setup was not in steady 
state due to a bursting of tubing and fittings around the IR flow cell, but a steady state 
was achieved shortly after replacement of the broken fittings. The flow rate of the system 
is given in table 6.2 and table 6.3 provides the residence times in the important parts of 
the reactor. 
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Table 6.2: The reactor configurations and residence times, along with important observations, for the melitracen 
HCl 6 synthesis as operated with the flow setup (Figure 6.4). 
Reactor 
Part 
Flow 
Rate 
(mL/min) 
Reactor 
Volume (mL) 
Residence 
Time (s) 
Observation 
Coil 1 4.5 4.95 66 Deep red color from reaction. 
Temperature higher than ambient, 
lower than the boiling point of 
THF. 
Coil 2 5.5 1.98 21.6 Temperature is above the boiling 
point of THF, 100 psi suppress 
boiling. 
Stream becomes transparent with a 
white solid that disappears into an 
one-phase system. 
pH < 2 
Coil 3 8.0 0.99 7.4 One-phase system. 
pH < 2 
Coil 4 9.9 1.98 6.0 Two-phase system. 
pH > 10 
Decanter 
(Org/Aq) 
9.9 
(4.5/5.4) 
100 606.1 Two-phase system. 
pH > 10 
 
Table 6.3: The flow rates and concentrations of the different reactants used in the flow setup. 
Reactants Flow Rate 
(mL/min) 
Concentration 
(M) 
Equivalents 
10,10-DMA 1 2.0 1.8 1.0 
DMPC-MgCl 2 2.5 1.5 1.05 
HCl (aq.) 1.0 12 (37%) 3.33 
AcOH (aq.) 2.50 7 (40%) 4.86 
NH3 (aq.) 1.9 13.4 (25%) 7.07 
HCl (Et2O) 2.25 2 1.25 
 
An IR flow cell was placed after coil 1 and was used to follow and ensure that full 
conversion of 10,10-DMA 1 was achieved. Figure 6.6 shows the carbonyl peak of the 
10,10-DMA 1 as it progressed throughout the experiment. The trend line absorbance 
intensity of the peak is based on area to zero baseline for the IR region of 1610-1580 cm-1 
and is given in arbitrary units. The off-line HPLC data in table 6.4 confirms full 
conversion of 10,10-DMA 1. The replacement of the tubing caused an exposure of the 
magnesium alkoxide 3 to the surrounding atmosphere (i.e. moisture in the air), resulting 
in the deposit of magnesium salts on the IR diamond window. Despite an attempt to clean 
the window, some deposit was still present, causing the small offset from the zero 
baseline, which explains why zero is not achieved. 
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Figure 6.6: The IR data on the flow setup run, following the peak of the carbonyl functional group of 10,10-DMA 
(1) and the reference samples for off-line HPLC analysis given in table 6.4. Steady state conditions were achieved 
after 30 minutes; the initial 30 minutes of unstable flow were related to bursting and replacing of tubing and 
fittings. 
A portion of the melitracen HCl (6) was collected by filtration in a Büchner funnel, 
washed with THF and dried in a vacuum oven at 50 °C for 24 hours. The product was 
subjected to complete release analysis for the API and all product attributes were found to 
be within specification. 
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Table 6.4: The HPLC samples, where samples were collected from the aqueous waste stream of the decanter, the 
crystallized melitracen HCl (6) and the mother liquid, and a few from the organic phase of the decanter. 
Sample 
No. 
Compound Crystallized 
Product 
(Area%) 
Mother 
Liquid 
(Area%) 
Decanter 
Aqueous 
(Area%) 
Decanter 
Organic 
(Area%) 
1 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
97.65 
nd 
2.1 
0.2 
62.0 
38.0 
nd 
nd 
No sample 
2 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
97.8 
nd 
2.0 
0.2 
37.8 
62.1 
nd 
nd 
No sample 
3 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
96.3 
nd 
3.5 
0.2 
20.5 
79.5 
nd 
nd 
No sample 
4 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
99.0 
nd 
0.8 
0.2 
nd 
100 
nd 
nd 
No sample 
5 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
99.9 
0.1 
nd 
nd 
99.1 
nd 
0.7 
0.2 
nd 
100 
nd 
nd 
No sample 
6 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
99.3 
nd 
0.5 
0.2 
nd 
100 
nd 
nd 
100 
nd 
nd 
nd 
7 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
39.8 
60.2 
nd 
nd 
39.3 
60.7 
nd 
nd 
99.8 
0.2 
nd 
nd 
8 Melitracen (5 or 6) 
Alcohol (4) 
10,10-DMA (1) 
Other Impurities 
100 
nd 
nd 
nd 
56.4 
43.6 
nd 
nd 
26.2 
73.8 
nd 
nd 
100 
nd 
nd 
nd 
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6.8 Conclusions 
A full redesign of a current batch synthesis to a full flow setup has been possible, 
from the starting material to the final salt crystallization of the active pharmaceutical 
ingredient, melitracen HCl. The flow process was significantly simplified compared to 
the batch process, with removal of a phase separation and usage of tetrahydrofuran (THF) 
only as a solvent compared to the previous toluene-THF solvent mixture. All synthetic 
steps were carried out at ambient temperature, whereas routine batch production requires 
active heating (up to 50qC) and cooling in several steps. The crystallization of the 
melitracen HCl was proved possible in THF with 2 M HCl in diethyl ether (Et2O) and 
eliminated a solvent swap to ethanol. The crystallization was not optimized and would 
most likely be done with HCl gas, with an expected additional gain in yield from the 
lower volume of solvent. The isolated yield in the given study was approximately 85%. 
The phase separation achieved with the decanter was higher than 99% product in the 
organic phase, with a HPLC purity of greater than 99%. The isolated melitracen HCl was 
analyzed in accordance with the in-house release methods required for current batch 
production and all measurements were in accordance with requirements. A production of 
60 g/h of isolated melitracen HCl can be achieved with the flow setup. Furthermore, the 
setup demonstrated great robustness towards fluctuations in reactant streams. The 
one-step hydrolysis and dehydration could potentially be applicable for other Grignard 
additions, as could the subsequent decanter phase separation. 
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7 Full-Scale Continuous Mini-Reactor Setup for Heterogeneous 
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7.1 Abstract 
A reactor setup consisting of two reactors in series has been implemented for a full-
scale, heterogeneous Grignard alkylation. Solutions pass from a small filter reactor into a 
static mixer reactor with multiple side entries, thus combining continuous stirred tank 
reactor (CSTR) and plug flow reactor (PFR) technologies. Through the use of the reactor 
train in combination with in-line NIR analysis, on scale a 35% reduction in solvent 
volume was achieved and the formation of a key impurity was suppressed. The mini-
reactor solution achieved many of the economic advantages attributed to microreactor 
technology, while avoiding the difficulties associated with handling of solids in 
microreactors. 
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7.2 Introduction 
The origin of continuous processing within the pharmaceutical industry can be traced 
back to Popov,44 who asserted the relative inefficiency in many cases of batch processes 
compared to flow methods. Batch and semi-batch reactors provide great flexibility 
towards different chemistries and are workable for heterogeneous reactions. The 
flexibility of batch methods requires a number of compromises, such as variation in 
product quality and large reactor volume, causing poor heat and mass transfer.19,22 In 
2005, the American Chemical Society (ACS) Green Chemistry Institute (GCI) 
Roundtable was founded as a cooperation between the ACS, GCI and several 
pharmaceutical companies with the aim of identifying areas that could contribute to 
sustainable development and process optimization. Among 10 engineering items the 
group highlighted for improvement of sustainable processing, continuous processing was 
identified as the most significant contributor.31 
Due to stringent regulatory requirements, the pharmaceutical industry had not, apart 
from a few exceptions,245–247 considered continuous processing as a real option until the 
early 2000s.240 The shift in regulatory strategy, first embodied in the FDA’s PAT 
Guidance in 2002, has occurred concurrently with an increased interest in microreactor 
technology for organic syntheses and an improvement in process analytical 
technologies.21,32,36–38,241 The academic world, especially, has embraced microreactor 
technology for organic syntheses, but little industrial implementation of microreactors for 
production purposes has been seen.33,36,54,79,160,248 Most of the advantages observed with 
microreactor technology, as compared to those of batch methods, are not due to the 
microstructure of the reactor channel but are merely related to flow chemistry.54 From a 
production perspective, only the heat transfer superiority stands out significantly in 
comparison to meso- or mini-flow reactors.54 Several articles discuss kilo-scale setups or 
pilot plant configurations, but only a limited number are found where implemented setups 
are used in routine manufacturing.43,249–253 The overall smaller reactor volumes of flow 
reactors in comparison to batch and semi-batch reactors provide improved safety for 
processes involving hazardous and explosive reactants, products and/or solvent.31 
Additionally, one of the main barriers to implementation of flow methods is solid material 
and microreactors are notoriously poor at handling solids.243 In many pharmaceutical 
processes, at least one solid component is present and often one of the reactants or the 
product is in solid form.22 Roberge et al. have estimated that, from a kinetic perspective, 
50% of the reactions employed in the pharmaceutical and fine chemical industries could 
benefit from microreactor technology; however, only 16% could benefit due to the 
presence of solid components.22 Other overall benefits of mini-reactors are easier 
cleaning, lower capital investment and infrastructure cost, reduced labor requirements, 
lower energy consumption and footprint reduction. Due to the limitations of 
microreactors, meso- or mini-flow reactors are poised to become the industrial 
standard.19,31 
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In reaction engineering, processing of reactants is divided into two categories: 
homogeneous and heterogeneous.59 A survey of the flow chemistry literature reveals that 
the majority of continuous processes are homogeneous, liquid-phase reactions.32,36 Most 
heterogeneous flow reactions reported in the literature are typically gas-liquid or solid-
catalyzed reactions of liquid or gas.36 Continuous crystallization has been extensively 
investigated in, for example, oscillatory flow reactors (OFRs) and this type of reactor also 
has potential for slurry reactions.86,87 Despite the fact that solid material (reactants or 
product) is present in most pharmaceutical and fine chemical syntheses, this is rarely 
illustrated in the literature, where solubility issues are typically solved by extensive 
dilution.36 From a manufacturing and process intensification perspective, dilution is rarely 
the desired approach.57 In general, homogeneous reactions can often be the most suitable 
conditions for flow chemistry and, at the same time, are the easiest to implement. In spite 
of this, the advantages presented by heterogeneous reaction conditions employing other 
reactor types cannot be overlooked. Heterogeneous reactors operate on two different 
principles: retention or residence time. The retention subgroup operates by holding back 
any solid material; hence the solubility of the product should at least be higher than the 
reactant of lowest solubility. Such reactor types are very robust towards fluctuations in 
reactant streams.90 The residence time subgroup uses a more complex method, where 
dissolution and reaction rate must be considered more carefully to properly dimension the 
reactor correctly to ensure full conversion. The beneficial part of such setups (e.g. OFR) 
is the potential to operate at charges far greater than those that allow complete dissolution 
of the reactants and product, making the approach interesting for processes where the 
product solubility is also limited but sensitivity towards fluctuations in process 
parameters is an evident drawback of the method. 
Both homogeneous and heterogeneous reactor configurations have been considered 
for the full-scale reactor configuration discussed in this article. A homogeneous approach 
was abandoned, due to the poor solubility of 2-chlorothioxanthen-9-one (1) in most 
solvents; for instance, 35 volumes of tetrahydrofuran (THF) are needed to completely 
dissolve 1 at the reaction temperature. The excessive solvent consumption could 
potentially be handled by recycling; however, this would increase both infrastructure cost 
and energy consumption. The limited solubility of 1 in all practicable solvents, including 
THF, provided the motivation for a novel heterogeneous reactor design. While there are 
many potential heterogeneous reactor configurations, the continuous filter reactor setup 
presented in a previous work90 was deemed suitable and robust. The reactor setup thus 
consists of two continuous-flow reactors connected in series: a filter reactor and a side-
entry reactor, as illustrated in Figure 7.1. Conceptually, the reactor train can be 
envisioned as a continuous stirred tank reactor (CSTR) with a filter in the outlet 
connected to a plug flow reactor (PFR) with multiple feed points. 
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Figure 7.1: Schematic representation of the full-scale reactor setup, representing only the main components of 
interest. Allylmagnesium chloride (AllylMgCl) is fed to the filter reactor by pump P1 and solid ketone 1 is fed by 
a screw feeder. A product stream containing alkoxide intermediate 2 and dissolved ketone 1 is withdrawn from 
the filter reactor by pump P2. P2 feeds the product stream into the side-entry reactor, where the remaining 
dissolved ketone 1 is processed with allylmagnesium chloride fed by pump P3. An in-line NIR measurement is 
conducted at the outlet of the reactor setup to ensure that full conversion of ketone 1 is achieved. 
7.3 Chemistry 
One of the synthetic steps in the production of the antipsychotic API 4, 
zuclopenthixol hydrochloride (Clopixol), is a classic Grignard alkylation of a ketone. As 
illustrated in Scheme 7.1, a solution of allylmagnesium chloride in THF is added to 
ketone 1 to produce the magnesium alkoxide intermediate 2, which is subsequently 
hydrolyzed with dilute acid to form compound 3. The reaction proceeds cleanly; however, 
an unknown impurity is formed near the equivalence point. The structure of this impurity 
has not been elucidated. The legacy semi-batch process involved suspension of 1 in THF, 
addition of allylmagnesium chloride in THF, hydrolysis and isolation of alcohol 3. The 
alkylation and hydrolysis are rapid, highly exothermic reactions that require some safety 
precautions. For several reasons, organometallic reactions can benefit from the 
advantages of continuous manufacturing and this has been demonstrated by a variety of 
groups.22,57,68,159,164 
Scheme 7.1: Synthesis of alcohol 3 and intermediate 2 in the manufacturing process of zuclopenthixol 
hydrochloride (Clopixol) 4. 
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7.4 Reactor Constraints 
The full-scale continuous reactor setup has been a customized in-house project in 
cooperation with DTU Chemical Engineering and was designed, built and implemented at 
H. Lundbeck’s API production facility in Lumsås, Denmark. Preliminary laboratory 
work, including proof of concept, on the synthesis of zuclopenthixol hydrochloride 
(Clopixol) was conducted at DTU.89,90,225 As part of our overall continuous manufacturing 
strategy, the reactors were designed to meet several criteria. Each reactor module should 
be delivered as complete as possible from the workshop to facilitate a “plug-and-play” 
approach, minimizing production downtime. Modules should be compact enough to pass 
freely through existing entrances and corridors in the factories. The equipment should 
also be highly flexible in daily operations; shutdown should be possible without affecting 
steady state conditions. 
This final constraint was the most troublesome, since it would significantly impact 
the overall utility of the continuous facility. A long ramp-up to steady state would be 
time-consuming and generate waste during start-up and shutdown procedures. An 
additional concern was the stability of the alkoxide 2, which was initially to be collected 
in a tank for subsequent batch processing to alcohol 3. Fortunately, the alkoxide 2 proved 
to be quite stable and thus the collection period could be prolonged, improving the 
efficiency of the final batch processing. 
7.5 Solid and Liquid Handling 
In the interest of intensifying the process as much as possible, it was necessary to 
ensure that ketone 1 was always in excess in the filter reactor. This reduced the required 
precision of the solid feeder and, as such, a double volumetric screw-feeder with 
self-cleaning ability was chosen and operated with small batch feeding sequences. As 
observed in the laboratory,90 the solid has a tendency to form bridges; however, in this 
case scale-up was beneficial as it facilitated the installation of anti-bridge-forming 
components. The solid feeder can be operated for a complete shift before refilling of the 
hopper is necessary. In this case, “automation” has a price, as the hopper is one of the 
largest components of the setup, as can be seen in Figure 7.2. 
The choice for liquid handling was the diaphragm pump that is one of the most 
widely applied pumps for production, in accordance with Good Manufacturing Practice 
(cGMP) for API manufacturing. Three pumps were needed, all with different 
specifications regarding precision. The least sensitive pump is the allylmagnesium 
chloride solution feeding pump, P1 to the filter reactor and the most sensitive pumps are 
the feeding pumps, P3 to the side-entry reactor and P2 from the filter reactor, which must 
provide stable flows. The different sensitivities and robustness of the pumps are a result 
of both the chosen process control strategy and the design of reactor setup compared to 
conversion degree. 
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Figure 7.2: Full-scale continuous reactor setup for production of alkoxide ion 2 at H. Lundbeck’s production 
facility in Lumsås. The entire reactor setup is comparable in size to a normal-sized batch vessel in area footprint 
occupation, but in addition to the filter reactor (1) and the side-entry reactor (2) it includes pumps (3), cooling 
regulation (4), solid feeding (5) and other ancillary unit operations. 
7.6 Filter Reactor 
The filter reactor is included in the subcategory of heterogeneous retention reactors 
described in the Introduction. The reactant of lowest solubility, ketone 1, must be 
dissolved in THF in order to react with allylmagnesium chloride. Combining dissolution 
and reaction of ketone 1 in the same reactor places two operations into a single piece of 
equipment, thereby reducing the physical size and capital cost of the reactor 
configuration. The novelty of the filter reactor is the potential for operating heterogeneous 
syntheses continuously with higher flexibility and robustness. 
The concentration of alkoxide 2 leaving the filter reactor is correlated to the 
concentration of allylmagnesium chloride with adjustment for the volume expansion 
caused by the dissolved ketone 1, which is empirically found to be approximately 
15-20%.90 The dissolution rate of ketone 1 was found to be slower than the alkylation 
reaction rate between the solubilized ketone 1 and allylmagnesium chloride. Therefore, 
the flow rate of allylmagnesium chloride to the filter reactor must be adjusted to ensure 
that the reaction mixture is at the saturation point of ketone 1. The dissolution of 1 is 
positively influenced by the total surface area of solid particles present in the filter 
reactor; however, excessively high solid loading may cause viscosity problems. 
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The total consumption of 1 in the reactor setup is the sum of the ketone 1 reacted in 
the filter reactor and the 1 leaving with the product stream to be reacted in the side-entry 
reactor. This amount is used to calculate the conversion of ketone 1 in the filter reactor. 
The choice of conversion in the filter reactor was based on the formation of “impurity A” 
and the desired solvent reduction. Impurity A is increasingly formed at near-equivalent 
addition of allylmagnesium chloride to ketone 1. A conversion of 85-90% in the filter 
reactor portion of the reactors was found to be optimal in suppressing the formation of 
impurity A while still achieving the reduction in solvent consumption. 
The filter reactor ended up being a classic vessel design, but an optimized 
asymmetrical design was considered, as this facilitates a smaller volume-to-surface area 
with a large top area for installation of probes, sensors, etc. 
The potential for filter clogging required that the filter should be easily accessible for 
replacement, preferably without disturbing the steady state condition within the reactor. 
In addition, the available filter area should be as large as possible. Having the filter 
normally positioned at the bottom of the reactor fulfilled only the filter area requirement 
and to replace the filter, the reactor would have to be emptied (thus disrupting the steady 
state). Using a filter cartridge submerged from the top of the reactor (see Figure 7.1) 
fulfilled both requirements, since replacement of the filter could be done with a full 
reactor and the cylindrical geometry of the cartridge provided a comparatively large filter 
area. 
7.7 Side-Entry Reactor 
The necessity of the side-entry reactor is a consequence of how a CSTR functions, 
where the composition of the product stream is equivalent to the composition within the 
reactor. A higher conversion of ketone 1 could be achieved in the filter reactor, but an 
increased formation of impurity A is provoked if operated at near-equivalent addition of 
allylmagnesium chloride. The side-entry reactor has the purpose of reacting all 
unconverted ketone 1 that leaves the filter reactor in its outlet stream. The 
allylmagnesium chloride solution fed into the side-entry reactor is split into three 
injection points along the reactor length to spread the heat of reaction and suppress 
impurity formation. Modelling of side-entry reactors has indicated that only marginal 
improvement is observed if more than three injection points are employed.75,79 
The flow in the side-entry reactor is not sufficient to satisfy a turbulent flow regime. 
Considering the mixing sensitivity of Grignard alkylation in general, improving the 
mixing was needed, in particular as the side-entry reactor has the task of converting the 
last of the ketone 1 with a minimum of impurity formation. The mixing was improved 
with static mixers positioned after each T-mixer in the reactor. To further improve the 
mixing, each feed point was narrowed before the injection into the reactor to increase the 
linear flow rate of the allylmagnesium chloride upon mixing with the reaction mixture in 
the T-mixer. All the improvements were based on empirical experience and no 
optimization was attempted. 
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7.8 Process Regulation 
The mass flow is probably the most important part of the process regulation control 
and is based on a fixed concentration of allylmagnesium chloride. After careful 
consideration of the two reactors and their contributions to the transformation of ketone 1 
to alkoxide intermediate 2, it was concluded that the flow rate of the product pump (P2) 
for flow out of the filter reactor should be fixed. If the flow from P2 were to be a variable 
parameter, each change would result in an adjustment of both allylmagnesium chloride 
pumps (P1 and P3) and the entire regulation process would be more complicated. 
Introducing a fixed flow rate for P2 had two major benefits. Liquid level control in the 
filter reactor was simplified as considerations of volume expansion, caused by the 
dissolved ketone 1, did not need to be accounted for. Additionally, a fixed flow into the 
side-entry reactor facilitates simpler regulation of the conversion of the remaining ketone 
1 entering the side-entry reactor. The fixed flow of P2 and the temperature dependency of 
ketone 1 in THF90 led to a simple feed forward process control loop, based on 
temperature measurement within the filter reactor under the assumption of CSTR-like 
behavior. 
A major concern for continuous operations is the start-up and shutdown phase of a 
continuous run, which presents a challenge for handling product streams not meeting the 
product specification. In this application, the equipment is dedicated to intermediate 2 
production; therefore, start-up and shutdown cycles occur infrequently. In addition, the 
lowest operational volume in the filter reactor is a5 L, which is simply discarded in the 
event of a complete shutdown. During start-up, a semi-batch-like approach is used to 
achieve a concentration in the filter reactor approaching the steady state condition. This 
technique requires fewer residence times for the filter reactor to reach steady state. Even 
though the concentration during start-up has not achieved the steady state level, the 
quality of the product stream is equal to that of the steady state, only more dilute. This 
strategy enables routine production to operate with only an infrequent waste of 5 L on the 
rare occasion of a complete shutdown of the facility. 
7.9 In-line NIR Control 
An optical cross-flow cell connected to a near-infrared (NIR) spectrometer was 
installed after the side-entry reactor for in-line process control at a fixed temperature. A 
NIR measurement is a non-destructive measuring method in complete agreement with the 
ICH Q7 PAT description.26 The NIR installation is used to measure concentrations of 
ketone 1 and alkoxide intermediate 2, indicating whether the process is proceeding in 
accordance with expected temperature regulation. At present, the NIR is not implemented 
as an automatic feedback regulator, but there is the potential for such. Earlier laboratory 
experiments have been conducted wherein the NIR measurement was verified for process 
regulation in a feedback control loop.89 In the factory, the NIR is used to monitor the 
process to give operators the opportunity to take action on any malfunction or offset 
during the synthesis. NIR monitoring during a test of the side-entry reactor’s 
effectiveness can be seen in Figure 7.3. The solid line is the alkoxide intermediate 2 
concentration and the dashed line is the ketone 1 concentration. The NIR calibration is 
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performed on the basis of samplings from the actual processes, which are analyzed by 
offline HPLC. Quantitative NIR calibrations were developed for ketone 1 and alkoxide 
intermediate 2, using standard partial least squares (PLS) regression. As illustrated in 
Figure 7.3, ketone 1 concentration was initially high due to zero feed of allylmagnesium 
chloride to the side-entry reactor. The small fluctuation in the concentration of ketone 1 is 
merely a result of the overall process regulation, monitoring and the pumps. Feeding of 
allylmagnesium chloride to the side-entry reactor to achieve full conversion of ketone 1 
resulted in an immediate decrease in the response from the NIR on ketone 1, indicating 
the effectiveness of the side-entry reactor. The initial testing phase clearly illustrated the 
relevance of retaining NIR monitoring in the full-scale setup. 
 
Figure 7.3: In-line NIR monitoring of the process for the full-scale continuous reactor setup. Solid line is the 
alkoxide intermediate 2 concentration; dashed line is the ketone 1 concentration. 
7.10 Implementation 
Several minor adjustments were made to the reactor setup during the implementation 
phase and some of the most important changes are shown in Table 7.1. The first test run 
showed difficulties for the product pump (P2) in delivering the target flow rate. The issue 
was related to clogging of the filter cartridge, initially attributed to an excess amount of 
solid ketone 1. A switch to a filter cartridge of slightly greater pore size enabled the 
desired P2 flow rate to be achieved. While the larger pore size reduced the filter reactor’s 
capability to retain solid material, it also caused problems in the NIR measurement due to 
turbidity too high for valid transmittance spectra measurements. It was expected that 
ketone 1 was the origin of the problems; in fact, however, alkoxide intermediate 2 had 
precipitated in the filter reactor, since only minor amounts of ketone 1 were detected. 
Alkoxide intermediate 2 becomes a sticky and highly viscous mass when it precipitates 
and helps explain the difficulties with the flow rate and NIR measurements. The 
temperature was increased to 30 °C, the upper limit from the previous semi-batch method, 
to circumvent the precipitation and clogging issue. A higher temperature solved the 
problem and resulted in a less viscous reaction mixture but required a larger fraction of 
ketone 1 to be processed in the side-entry reactor, a move that increased solvent 
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consumption. A somewhat lower concentration of the allylmagnesium chloride than 
anticipated also introduced greater solvent consumption. Nonetheless, these adjustments, 
albeit minor, have great impact on the operation of the design and illustrate the 
importance of a flexible design space if a fully functional full-scale reactor configuration 
is to be achieved. 
Table 7.1: Design parameters derived from the laboratory experiments and the actual implemented parameters 
used to achieve a fully functional reactor setup.a 
Parameter Design 
parameter 
Actual 
parameter 
Temperature (qC) 15 30 
Concentration of allylmagnesium chloride (M) 1.4 1.0-1.1 
Pore size filter (μm) 45 500 
Flow rate capacity (L/h) 18.8 25 
Conversion of ketone 1 in the filter reactor (%) 85 75 
aChanging the temperature has a strong influence on other parameters (flow rate and 
solubility). 
 
Table 7.2: Verification data for the test runs of continuous manufactured alkoxide intermediate 2; as shown, all 
requirements are met. 
Product Analytical 
Method 
Specification 
(expected) 
Test 
1 
Test 
2 
Test 
3 
Product yield 3 + 5a,b HPLC NLT 95% by area 99.5 99.5 99.4 
Alcohol 3 HPLC (g/mL) Confirm NIR 
+/- 3% 
244.4 
±2% 
252.6 
±2% 
267.7 
±2% 
Alkoxide intermediate 2 NIR (g/mL) Confirm NIR 
+/- 3% 
218.6 224.1 244.5 
Ketone 1 HPLC NMT 5% by area nd nd nd 
Ketone 1 HPLC (g/mL) Confirm NIR 
+/- 3% 
na na na 
Impurity A HPLC NMT 5% by area 0.2 0.3 0.5 
Other impurities HPLC NMT 1% by area 0.3 0.2 0.1 
a  
bIn refs 90 and 89, the applied HPLC method had a mobile phase with pH 9; however, the 
validated analytical HPLC method contains mobile phase with pH 4.8, therefore the 
reaction shown in footnote a is expected. 
 
As part of the implementation, the continuous reactor setup functionality was verified 
by a number of test runs. Table 7.2 shows that the continuous reactor setup is capable of 
producing product of high purity based on the isolated alcohol 3, with an insignificant 
amount of impurities. It was intended that the NIR measurement should be used to 
estimate the accumulated alkoxide intermediate 2 for the subsequent processing. 
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Unfortunately, the deviations between the HPLC and the NIR predictions were too large 
for this purpose and therefore the subsequent processing of the alkoxide intermediate 2 is 
based on the mass balance of ketone 1 processed in the reactor setup. In any case, a 
method for determination of alkoxide intermediate 2 had not previously been available for 
the semi-batch production. 
The total yield of product 3 meets the process specification of not less than (NLT) 
95% yield with a purity of NLT 99.5%, where sample preparation has caused a small 
amount of the product (3) to dehydrate to a later-stage product (5). The impurity amount 
is within the not more than (NMT) acceptable range, if the dehydrated product caused by 
the sample preparation is accounted for. 
An overall improvement was obtained in a number of key success areas for the 
implementation of the continuous reactor setup. In addition to the improved conversion of 
ketone 1 to alkoxide intermediate 2, several other factors have influenced the decision to 
implement a continuous reactor setup. The reduction in solvent consumption from 5.8 to 
3.8 L/kg ketone 1 as well as elimination of a solvent swap in a later process stage have 
been motivating economic factors. The reactor volume was reduced from m3-scale to 
liter-scale and a complete continuous setup, including everything such as pumps, cooling 
loops, etc. at approximately the same size as those of the old batch vessel, alone resulted 
in a significant reduction in the footprint of the production area. The small reactor volume 
has led to better temperature control of the reactor with fewer eddies, causing a reduction 
in energy consumption. The energy and solvent consumption are further reduced due to 
less frequent cleaning, since the reactor configuration is dedicated equipment, unlike the 
semi-batch equipment. Benefits such as reduced labor consumption, release of old batch 
equipment and reduction in the production footprint are more difficult to quantify, but are 
significant contributors to the overall business case. Table 7.3 summarizes some of the 
parameters of interest between the legacy semi-batch process, continuous laboratory-scale 
feasibility studies and the new continuous full-scale process. 
Table 7.3: Comparison of the old batch processes against the laboratory continuous reactor setup and the 
continuous full-scale reactor setup.a 
Parameter Full-scale 
(Semi-batch) 
Laboratory 
(Continuous) 
Full-scale 
(Continuous) 
Active Volume 1600 L 250 mL 8 L 
Total Size 
(Area Footprint) 
a10 m2 Fume hood 2 m2 1.45 m2 (1.1 m ∙ 1.3 m) 
Production time (h) 4 900 <50 
Yield (%) >95% >96%a 95-99% 
Purity >95% >99% 96.5-99.8% 
Solvent consumption 5.8 L/kgCTX 2.3 L/kgCTX 3.8 L/kgCTX 
Cleaning Each campaign 
(batch) 
Dedicated Dedicated 
aThe isolated yield is based on the HPLC assay from ref 89. 
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7.11 Conclusions 
A novel full-scale reactor setup for continuous processing of 
2-chloro-thioxanthen-9-one (1) with allylmagnesium chloride into the magnesium 
alkoxide intermediate 2 has been designed and implemented successfully in full-scale 
production. The new continuous reactor setup has replaced the previous semi-batch 
process that, in many aspects, could be considered as a typical pharmaceutical 
manufacturing process. The low solubility of ketone 1 in THF motivated the design of a 
heterogeneous reactor setup capable of handling solid material to avoid the difficulty and 
expense associated with processing large volumes of solvent. The reactor setup consists 
of two reactors in series, where the first reactor retains solid reactant, making this reactor 
robust and flexible towards fluctuations in the processing of solid ketone 1. The second 
reactor has the primary function of ensuring full conversion of the unreacted ketone 1 
from the first reactor. A significant reduction in reactor volume was achieved relative to 
the previous semi-batch process in downsizing from cubic meter scale to liter scale. In 
fact, laboratory studies suggested that an even smaller reactor at milliliter scale could 
have been sufficient. The regulation of the reactor setup was based on simple 
measurement of process parameters, combined with the latest methods in process 
analytical technology to ensure product quality. 
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Chapter 8 
8 A Reactor Design Methodology for Grignard Reactions in the 
Pharmaceutical Industry 
The following chapter has been written in the style of an article manuscript with the 
intention of later publication. 
8.1 Abstract 
In this work, a general method aimed at an easy decision-making process when 
choosing a reactor design for Grignard addition reactions is proposed. The methodology 
focuses on the transition from a laboratory setup to full-scale production. This includes a 
preliminary economic assessment to evaluate the benefits or downsides that can be 
expected from the chosen reactor design. Three different case studies have been used as 
the basis for the development of the methodology, all with differences in solubility of 
reactants and products, as well as impurity formation. A few factors have been found 
critical in the decision making for the reactor setup for Grignard addition reaction, with 
the most important ones given below. The solubility of reactants, products and impurities 
are the most crucial parameters when deciding on a reactor configuration. Basic 
understanding of the chemistry is essential, including how temperature influences the 
reaction. Formation of unwanted products can be reduced by taking secondary reactions 
leading to impurities into account when designing the process. Manipulating the impurity 
formation by analyzing the temperature dependency of the reactions has been found to be 
a most useful approach. To evaluate the potential of and make a fast decision on a reactor 
setup, simple screening experiments and pragmatic approaches in the laboratory can often 
be sufficient. Hours of development and resources can be saved if these simple and 
pragmatic approaches are used during the decision process. 
  
121
Chapter 8 
96 
8.2 Introduction 
Throughout the last decade, the pharmaceutical industry (i.e. research-based 
companies) has experienced increasing pressure from generic manufacturers and 
authorities and has struggled to remain competitive with the frequently changing 
requirements and cheap production of generics, facing challenges such as strict 
regulations, enhanced environmental requirements, patent expirations, generic 
competitors and difficulties in new drug discovery, to mention a few. The debate on how 
pharmaceutical companies can remain competitive and overcome the challenges they are 
facing have been many and the general opinion of industry, academia and the authorities 
is pointing towards higher efficiency.5,6,8–12,18,19,21,31,237,254–257 The view on efficiency in 
the pharmaceutical industry is no different from other chemical industries. Efficiency is a 
broad term and, in the early stages of any drug development, it is often associated with 
fast development of the potential drug candidate.6–8,12,256,258 Later in the lifecycle of a 
pharmaceutical product, efficiency concerns the ability to achieve high yields and purities 
by simple production methods.15,19,34,38,57,58,256,259–261 Bridging the gap between early 
development and eventual manufacturing is associated with great costs of both time and 
resources, such that the ability to make fast decisions is crucial for avoiding later redesign 
of synthetic routes or post-optimization of existing processes.5,18,19,21,237,256,262,263 
The pharmaceutical industry is known for protection of intellectual properties by 
patents or secrecy policies. A patent only provides protection for a limited time of 20 
years from the first application5,10,11,19 and is combined with high expenses for the 
development of new pharmaceutical products.7–10,12 If a product can be brought to market 
and full-scale production faster, a longer period under patent protection to regain the 
investment can be achieved. Another way to ensure better profits is by optimizing the 
process, a strategy that applies to both old and new pharmaceutical products.38,57,58,88,264 
However, the pharmaceutical industry lacks the ease of readjusting a process after the 
full-scale synthesis route has been filed, as strict regulations prevent large changes in 
process conditions compared to the originally-filed process.19,20  
Refining production methods and rationalizing the decision-making process for 
reactor setup configurations have received increasing interest over the last few decades.264 
The urge to formulate standardized descriptions of process implementation, optimization 
and intensification has resulted in great amounts of written material.56,265–279 Most of this 
material covers a broad pallet of general methods to be followed and applied. The 
procedures are often complex and with multiple steps using advanced investigation 
methods. Following these methods will require time-consuming studies before a decision 
can be made. The pharmaceutical and fine chemical industry again separate from the 
remaining chemical industry, as the complexity of the synthesis routes is often high and 
non-standard operations are needed if a successful process is to be implemented. Hence, 
following such standard procedures is not beneficial.34,38,274,275,280 
A selection of methodologies is now presented, with a short description of the focus 
of each. Cervera Padrell et al.273,281 applied a process system engineering (PSE) assisted 
design methodology to a full synthetic route of an active pharmaceutical ingredient (API). 
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Moseley et al. 282,283 have demonstrated a method for synthetic route selections by the use 
of Kepner-Tregoe decision analysis. Papavasileiou et al.269 demonstrated the efficiency of 
computer-aided process simulation for the optimization of a pharmaceutical production 
schedule. The Jensen group32 made a review focusing on decision making in general for 
continuous processing. Roberge et al.22,54,78,79 provided detailed documentation on the 
process implementation made in the effort to transition from batch to continuous 
production.  
Flow chemistry started to become of interest to the fine chemical and pharmaceutical 
industry in the early 21st century,31–34,36,37,55,158 with later proposals of general 
methodologies for deciding on the chemistry that could potentially benefit from flow 
chemistry.22,57 Flow chemistry is believed by many to be one of the best ways to stay 
competitive, as large benefits can potentially be achieved compared to batch 
processes.31,33,88 However, few full-scale implementations are currently known.88,171 
These general methods still lack the ability to allow for fast decision making on 
potential reactor setup configuration from early development. Additionally, they are 
unable to easily evaluate whether any benefits could be achieved if an old process were 
modified. This work provides a methodology specifically aimed at Grignard reaction-
based chemistry (particularly addition reaction with carbonyls). The goal is to provide a 
generic work that describes the procedures and processes that lead to the final decision. 
As Grignard chemistry is already believed to benefit highly from flow processes,22,57 the 
discussions throughout the article often focus on the decision between batch and 
continuous setups, as these are considered to be counterparts. At best, the method could 
be generalized to cover other reaction types. 
8.3 Categorization of Reactor Concepts 
A common categorization and conceptual description of reactor concepts is necessary 
in order to discuss potential reactor configurations. Three main categories are used 
throughout this work: batch reactors (batch and semi-batch), homogeneous flow reactors 
and heterogeneous flow reactors. The definition of homogeneous and heterogeneous flow 
reactors is based on the (solid) physical state of reactants, intermediates and products 
observed during operation. Most continuous reactors can, in spite of their complex 
appearance, be modelled based on different configurations of PFRs and CSTRs in terms 
of reaction engineering aspects. 
8.3.1 Batch Reactor Concept 
The batch reactor has for generations been the workhorse of pharmaceutical 
production due to its characteristics as a multipurpose setup with great flexibility. The 
biggest disadvantages are the poor mass and heat transfer and the biggest advantage is the 
multipurpose usage. The batch reactor is not described in more detail here as it is already 
covered in the literature.59,60 
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8.3.2 Homogeneous Flow Reactor Concept 
Homogeneous flow reactors are theoretically much simpler than the heterogeneous 
flow reactor, as everything stays in solution, from reactants to products. The 
concentrations of reactants, intermediates and product should be high (if possible neat) 
for a successful implementation related to throughput and yield. If high concentrations are 
possible, the focus can be changed towards chemistry and reaction engineering aspects 
such as impurity formation, heat and mass transfer. Two operational principles can be 
applied for dissolving the reactant for usage in the homogeneous flow reactor. One is the 
making of a predefined batch solution, a method commonly applied in the laboratory due 
to its simplicity. For full-scale implementation, this requires a storage facility. The 
benefits of this method are an always well-defined concentration and limited equipment 
needs (often available). The main drawback is the predefined amount of reactant available 
due to the batch approach. Hence, there is a risk of running out during production. The 
other method is based on a heterogeneous flow module, where the solution is made on 
demand in a separation reactor with an excess of solids (for an elaborated discussion, see 
Pedersen et al.88). Its benefits are the lack of limitations on the dissolved reactant and 
smaller equipment. Its main drawbacks are the need for control strategies to determine the 
concentration (solubility rate and assurance of concentration) and a more equipment-
heavy setup (on-line process control). Figure 8.1 illustrates the two homogeneous flow 
reactor concepts. 
Dissolving
Storage
Separation
Liquid 
Reaction
Batch
Continuous
Solid 
Reactants
Solvents
Dissolved
Dissolved
Solid/Liquid Recycling
Full 
Conversion
Solvent Recycling
Liquid Reactants
 
Figure 8.1: A principal visualization of the homogeneous flow concepts. 
8.3.3 Heterogeneous Flow Reactor Concept 
The heterogeneous flow reactor concept is complex and the solubility of reactants, 
intermediates and products have to be taken into consideration. The solubility of 
intermediates and products gives rise to two different concepts. 
The first heterogeneous reactor concept is a development of the homogeneous flow 
reactor with separation, where the reaction is allowed to progress in the dissolving unit. It 
requires that the intermediates and the products have higher solubility than that of the 
reactants. The setup is more complex compared to the homogeneous flow reactor, with 
separation of the solids from the outlet. The most easily-applicable modules for 
separation are a CSTR (mixing sensitive chemistry can cause problems) or alternatively a 
vertically-oriented oscillatory flow reactor (OFR)86 (more difficult to control) with 
reactants entering the vessel from the bottom, allowing the particles to settle on the 
bottom by gravitational force. An additional reactor is necessary to react dissolved 
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reactants as they leave the first reactor. Major benefits can be achieved for low-solubility 
reactants with high-solubility intermediates or products. 
The alternative to the above-mentioned heterogeneous concept has no retention of 
solid material, hence after a certain residence time in the reactor all the solid reactants 
will have been dissolved and the remaining part of the reactor can be considered as a 
liquid-liquid reaction. Since there is no retention of solid material, the intermediates and 
products formed throughout the reaction can be easily handled if they precipitate. The 
obvious benefits are the ability to handle reactions with poor solubility of reactants, 
intermediates and products. The drawback is the risk of fluctuation in conversion 
throughout the reactor that will require an extensive control strategy to ensure consistency 
of conversion (solubility rate and reaction rate). Figure 8.2 illustrates the two 
heterogeneous flow reactor concepts. 
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Figure 8.2: A principal visualization of the heterogeneous flow concepts. 
8.4 Initial considerations 
Operating under the assumption that a process is developed to generate profit, some 
general considerations on the stages of an API are important. APIs go through several 
stages before reaching a final product that can be released on the market. This includes 
everything from early development, scale-up and implementation to the final commercial 
manufacturing, but also covers the “off-patent” production and final termination of the 
product from the market. It is early in this lifecycle of the API that decisions on Good 
Manufacturing Practice (GMP) or non-GMP synthesis steps are made. After the final 
synthesis has been filed with the authorities, only small deviations from the original route 
are allowed. This comprises a potential problem in the process of keeping late production 
of APIs as a profitable business, as it is often the cost of refiling an optimized process that 
prevents further optimization of the original route. For non-GMP steps it is significantly 
simpler, as no refiling is required and it can be compared to change to a new supplier of 
starting material, where quality verification of the final API often will be sufficient. 
In close relation to the GMP and non-GMP considerations, the question of whether 
the synthesis is new or old should also be raised. An old process will typically have 
undergone multiple optimization processes and thus perform well overall. In addition, 
large amounts of process knowledge exists, hence committing to an alternative process 
might limit the benefits over the already existing process. The decision on how to design 
a reactor setup for a newly-developed synthetic route benefits from not having to take 
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already existing and authority-regulated processes into account. Comparing an old 
process with a newly developed one, it should be relatively easier to use a continuous 
process for a new synthetic route. However, in practice this will require close 
collaboration between the Research & Development and the Implementation & 
Manufacturing departments of a company. Traditionally, the development of APIs has 
been based on batch chemistry, a procedure that is still widely dominant in the 
pharmaceutical industry.1 As a natural consequence, the subsequent scale-up taking place 
throughout the phase I-III trials tends to follow the same principles. The GMP process 
steps defined during the phase trial periods, as discussed above, are primarily based on 
batch procedures, hence making later implementation of continuous production difficult. 
More processes would most likely have been made continuous if no consideration had to 
be made in relation to GMP steps. Refiling a blockbuster is often a considerable 
investment, due to the required documentation for the authorities 
Developing a continuous process is often more costly than batch chemistry 
development, since more process knowledge is required to design the reactor setup and 
more complex process control is often required.19,22,56 Early development of continuous 
methods can, however, be profitable, due to the potential long-run benefits from lower 
production costs. Table 8.1 suggests the likeliness of profit from a continuous setup for 
different lifecycle stages of a synthetic route for an API. 
Table 8.1: Early business case considerations for flow reactor profit. 
Profit Regulatory Consideration Lifecycle 
Likely Non-GMP Old or New 
Potential GMP New 
Unlikely GMP Old 
 
Especially for an old GMP regulated step, the decision to transform a process from 
batch to continuous often ends up being a case-specific decision. In the end, the final 
decision will rely on the willingness and the ability of the company to take risks and to 
believe in future profits from the process and the product. For a new synthesis, similar 
considerations are at the root of the final decision. Hesitation in making such changes in 
company structure is obvious, because the outcome of the effort is unknown compared to 
the well-known methods used today. The company culture as seen today also needs to be 
broken down and replaced by a much more flexible and stronger collaboration between 
the development, implementation and manufacturing departments, if success is to be 
expected.19,25 
The decision to go for a new synthetic route or a continuous reactor configuration is 
not always purely related to chemical and physical limitations. Considering the current 
lifecycle stage of the API and the placement in relation to GMP steps can help in 
addressing the likeliness of profitable success for a potential flow method without the 
need to perform a full business case analysis. 
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8.5 Chemistry 
A general understanding of the chemistry will provide useful information that can 
assist in making the decision upon choosing the most suitable reactor configuration. 
Many of these findings are not required to be carried out in a specific order or studied in 
depth, but the information they provide is useful for making the decision to proceed with 
batch or continuous processing. For Grignard chemistry, reactions typically take place in 
the liquid phase and if solid or gas phase reactants are present these will therefore not take 
part in the reaction unless dissolved. In some cases the process can benefit from such 
properties, e.g. by protecting the product by precipitation. A deeper analysis of solvents 
and solubility is given in sections 8.9 and 8.10, respectively. By simple evaluation of the 
chemistry, useful information can be revealed that will be helpful in evaluating and 
developing the final setup without the need for resource-intensive laboratory experiments. 
Furthermore, it also indicates whether special care or more thorough investigations of the 
reaction behavior should be carried out. A generic synthetic route for a Grignard addition 
reaction followed by hydrolysis is illustrated in scheme 8.1. 
Scheme 8.1: A generic representation of a Grignard addition reaction followed by a hydrolysis to yield an 
alcohol. R1, R2 and R3 are an alkyl or aryl, X is a halide. 
 
8.6 Grignard Addition Reactions 
A general classification of the chemistry is often done based on reaction type and 
order. First, the desired reaction needs to be specified and for a typical Grignard addition 
reaction a second order elementary reaction is often sufficient for describing the 
chemistry in relation to reaction engineering aspects. If the carbonyl source is an ester, the 
common outcome is a diaddition product, hence the reaction becomes a competitive 
consecutive reaction with both steps being second order elementary reactions.  
The next step should be determination of potential impurity formations and their 
relation to reactants, intermediates and product. For Grignard reactions, many of the 
impurities are related to multiple functional groups on the reactants and the Grignard 
reagents themselves. These functional groups may react with the Grignard reagents, 
causing the unwanted reactions leading to impurities. Contamination by secondary 
reactions between functional groups on the reactants and the Grignard reagents are, 
however, often not cause for concern as the carbonyl group will usually be the most 
reactive of all the functional groups present, reducing the relative influence of undesired 
reactions. In the ester case, if only the mono-addition product is desired, the diaddition 
taking place is considered a source of impurity. In general, the amount of impurity formed 
is often correlated to the temperature, as many of the less reactive functional groups 
become more active at elevated temperatures.94,95 The reactivity can be manipulated by 
temperature regulation, following a standard Arrhenius relationship. However, the 
reaction conditions should preferably be kept close to ambient if possible, which will 
reduce the input of energy necessary to maintain the reaction at a fixed temperature. For 
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Grignard reactions in general, no heating is normally necessary for the reaction to take 
place (exothermic (150 to 250 kJ/mol)); on the contrary, cooling of the reaction may be 
necessary.77,104,127 The general considerations are summarized in table 8.2. 
Table 8.2: Considerations for Grignard chemistry. 
Functional 
Group 
Chemical Behavior Reactor Consideration Additional 
Remarks 
Carbonyl 
(Aldehyde or 
Ketone) 
Mono-addition 
product. 
Wide temperature 
range applicable. 
Kinetics of little 
concern. 
Exothermic. 
No special considerations. 
Depends on the physical 
states of the reactant and 
product; see solubility 
consideration. 
A PFR can be 
sufficient if the 
solubility of 
reactants and 
products is high. 
Carbonyl 
(Ester) 
Mono- and Diaddition 
products (Mono<Di). 
Temperature should be 
low. 
Kinetics might be 
important 
(kester<<kketone); see 
kinetics section. 
Exothermic. 
Mixing and heat transfer 
are important. 
Multiple Grignard 
injections could prove 
useful. 
A heterogeneous product 
reactor is likely to be 
beneficial (kprecipitation 
competes with kreaction). 
Depends on the physical 
states of the reactant and 
product; see solubility 
consideration. 
 
Special cases 
where substitutes 
influence the 
ester to give 
mono-
addition.120,121,175 
Carbonyl and 
Others94 
Mono-addition product 
and other cross-reacted 
impurities 
(Mono>>Other). 
Temperature should be 
low. 
Kinetics might be 
important 
(kcarbonyl>>kother); see 
kinetics section. 
Exothermic. 
Mixing and heat transfer 
are important. 
Multiple Grignard 
injections could prove 
useful. 
A heterogeneous product 
reactor is likely to be 
beneficial. 
Depends on the physical 
states of the reactant and 
product; see solubility 
consideration. 
 
 
Besides the reaction rate order and impurity formation, it is of general interest to 
understand the requirements for cooling or heating. Due to the exothermic release of 
energy from a Grignard reaction combined with solvents with low boiling and flash 
points (see solvent section), most Grignard syntheses are cooled to minimize the risk of a 
runaway during a batch process from a safety perspective. Formation of temperature 
gradients within the reactor setup due to poor heat transfer can be critical for a process 
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and, combined with poor mass transfer, can give rise to impurity formation. As a common 
approach to distribute heat release and achieve better temperature control, a stepwise 
dosing concept can be applied. In a batch process, this is known as semi-batch or 
fed-batch operation. The continuous analogue is a setup with multiple inlets. This concept 
is also used if one of the reactants should be kept low in concentration to avoid impurity 
formation, e.g. due to hot spots.75,76,78,79 
8.7 Hydrolysis, Dehydration and Chemical Reactions 
The desired product from a Grignard addition is the alcohol formed upon the 
hydrolysis of the (unstable) magnesium alkoxide with diluted acid. The alcohol is also 
commonly dehydrated. The focus is often on the Grignard addition; however, the 
hydrolysis and potential dehydration are fairly simple reactions and should therefore be 
considered as part of the potential reactor system. Both steps are exothermic reactions 
with slightly lower reaction enthalpies than the Grignard addition reaction. If the 
dehydrated product is the desired product, it might be worthwhile to investigate whether a 
strong acid (e.g. HCl (aq.) or H2SO4 (aq.)) can handle both the hydrolysis and the 
dehydration in one step.94 Most likely some acetic acid would still be needed to dissolve 
the magnesium halide salts formed from the hydrolysis, as acetic acid tends to form 
highly water-soluble complexes with magnesium.i The influence of pH on the solution 
should be investigated, as this might need to be adjusted for separation of the aqueous 
phase from the organic phase. Alternatively, a different solvent could be considered at 
this point. 
8.8 Kinetic Investigation 
Reaction kinetics can be of great importance in order to choose the most suitable 
design and dimensions for a setup. Precise studies can be carried out in order to 
characterize reaction kinetics, helping to identify optimal reaction parameters and 
conditions and thereby a better dimensioning of the reactor setup. Accurate determination 
of rate constants often requires that the individual steps of desired and undesired reactions 
can be well isolated. Often, the focus in kinetic investigation is on the reaction rates, as 
these determine the operational parameters and dimensioning of the reactor setup.59,60 
However, it is important to keep in mind that these reactions only constitute a small share 
of the kinetics necessary to determine how a synthesis will progress in a reactor. In a 
situation with more complex chemical systems (e.g. combined solid dissolution and 
reaction, combined reaction and precipitation) a more pragmatic approach could be 
necessary, but with a less precise result. Design of Experiments (DoE) can be a strong 
tool for extracting combined information on optimal performance when isolation of steps 
cannot easily be done. Generating kinetic information is often time consuming and, 
combined with often non-ideal reactor performance, an effort should be made towards it 
being “need to have” instead of “nice to have”. Rough estimates and more pragmatic 
methods can sometimes serve much better for fast decision making than precisely 
determined parameters. As reactors often perform non-ideally, precisely determined rate 
constants can result in a too-narrow design and a rough estimate would potentially be 
                                                 
i Observed in laboratory experiments. 
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better for understanding the performances and be achieved much more quickly in the 
laboratory. In general, kinetic investigation is of less importance for Grignard reactions as 
the chemistry is fast under ambient reaction conditions. As already discussed in the 
chemistry evaluation, only a few impurities are formed; hence, unless the desire is the 
mono-addition product of an ester carbonyl or high temperatures with other functional 
groups, the need for kinetic investigation is limited (Grignard additions are fast 
reactions22). Table 8.3 summarizes below the need for kinetic investigation of Grignard 
chemistry. 
Table 8.3: Reaction order considerations and the need for kinetic investigation.a 
Reaction Type Functional Groups Kinetic Investigation Level 
A+B o C Ketone or Aldehyde Limited to a pragmatic approach. 
A+B o C 
C+B o D 
Ester Carbonyl A detailed understanding might be 
beneficial. 
A+B o C+D Carbonyl and Others Less crucial than for ester carbonyl, 
but rough temperature influence is 
useful. 
aAll reaction orders are simplified and a more detailed understanding of kinetics 
and reaction orders is found in the literature94,100,116,154 
 
8.9 Solvent Considerations 
From a broad perspective, a solvent should be chosen based on its applicability for 
the chemistry and secondly, aspects such as availability, safety (Atmosphères Explosibles 
(ATEX)), health and environmental impact (sustainability and pollution) should be 
considered. When working with Grignard chemistry the range of useful solvents is 
limited, at least from an industrial perspective. The commonly accepted tetrahedral 
configuration of the magnesium requires two solvent molecules to stabilize it, molecules 
that should have lone pair donation properties.94 The choice of preference is therefore an 
ethereal solvent such as diethyl ether (Et2O), tetrahydrofuran (THF) or 
2-methyltetrahydrofuran (MeTHF) as the industrial standard. Et2O has generally been 
replaced by THF due to safety and MeTHF is currently replacing THF for health and 
environmental reasons. More exotic ethereal solvents such as 1,4-dioxane or 
1,2-dimethoxyethane (DME) could in special cases be tested, but should in general be 
avoided as they often shift the Schlenk equilibrium (Scheme 8.2)135,139,140,143 towards the 
right, resulting in precipitation of the Grignard reagent complex due to the solvents’ 
chelating properties.140,143 The category of non-donation lone pair solvents includes 
toluene and hexane, but these should only be used if ethereal solvent is not an option, as 
trace amounts of ethereal solvent would still be needed.94 
Scheme 8.2: The simplified Schlenk equilibrium, where X represents the halide and R represents the aryl or 
alkyl functional parts.135 
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Two solvents stand out for initial screening, THF and MeTHF. Generally, THF 
exhibits higher solubility of carbonyl reactants compared to MeTHF, the trend being the 
opposite for Grignard reagents. Another favored property of MeTHF compared to THF is 
its very low miscibility with water, where THF is fully miscible in most conditions.174,284 
A few comparisons of common solvent properties for THF and MeTHF are provided in 
table 8.4. 
Table 8.4: General solvent properties of preferred solvents for Grignard chemistry.174,284 
Properties THF MeTHF 
Molecular formula C4H8O C5H10O 
Molecular weight (g/mol) 72.11 86.13 
Molecular structure 
  
Boiling point (qC) 66 80.3 
Flash point (qC) -14 -11 
Density (g/L) 889.2 854 
Solubility in water (%w/w) Miscible 14 
Water in solvent (%w/w) Miscible 4 
Oxygen lone pair donor 1 1 
Chelating No No 
 
8.10 Solubility Considerations 
The solubility of reactants, products and impurities (side products or salts) are 
perhaps the most important part of the decision on a potential flow setup, in contrast to 
the batch reactor, which can easily handle solids. It should be emphasized that catalysts 
are not included in this discussion and that solids only refer to materials either formed or 
consumed during the reaction. A review of 86 reactions at Lonza22,53 indicated that about 
50% of these would not be easily transferred to flow chemistry due to solids. This 
investigation is backed up by the fact that only a few demonstrations of flow chemistry 
with solid material have been published.88,236,243 Some commercially available flow 
reactors for handling solid material exist, including conceptual reactors such as the 
Oscillatory Flow Reactor (OFR),83,86,87 the Coflore Agitated Cell Reactor (ACR)236 and 
the filter reactor.88–90 
The solubility of solids is an important factor for choosing the right reactor 
configuration. Despite the fact that many reactants are solids and that most intermediates 
and products are isolated as solids (mostly due to purification, lifetime and storage 
concerns), most organic synthesis reactions take place in a liquid phase. It is therefore of 
utmost importance to find a suitable solvent when working with solid reactants. 
Solubility is highly influenced by solvent choice and in many situations is also 
affected by temperature. The solubility should be determined at the expected operation 
temperature, which will preferably be near to ambient if the chemistry allows it. The 
preference for ambient conditions should also be seen with respect to sustainability and 
131
Chapter 8 
106 
eco-friendly viewpoints. If a higher temperature is necessary for the chemistry to 
progress, a higher concentration could in principle be used as an alternative. This would 
most likely be a cause for better cooling of the reactor setup, due to the exothermic nature 
of Grignard reactions. In contrary to reactions that require high temperatures, these are 
reactions where cryogenic reaction conditions become necessary. To avoid precipitation 
in a cryogenically-operated reactor, the solubility should be accounted for at the known 
operation temperature, despite higher concentrations being possible if the solutions are 
stored in ambient conditions.285–287 
Co-solvent effects are another factor commonly known to have a strong influence on 
solubility, but are not discussed further since they are preferably avoided, if possible, due 
to the obvious complexity they add to a system.286 Additionally, changes in pressure can 
cause similar effects on solubility as temperature, but in general the influence is lesser 
due to the incompressibility of liquids.287 
To keep the experimental cost to a reasonable level, a limited number of solvents 
should be picked (see solvent section) and tested for the saturated solubility of the 
compound within a reasonable temperature span (10 to 30 qC). Knowledge of the 
saturated solubility is very useful in the later design phase for continuous reactors to set 
the boundaries for temperature and mass loading. The choice of analytical method 
depends on the compound, but in most cases dry matter determination is sufficient. In a 
more long-term approach, spectroscopic measurement with equipment applicable for later 
control strategies (see PAT and QbD section) could be used. A requirement for this 
approach would be the development of calibration curves for each compound, a large 
undertaking that could be profitable if the outcome of the investigation is positive. 
Regardless of whether a spectroscopic method is chosen, it is recommended that spectra 
of the samples are taken for potential later development purposes, as the labor cost of this 
is insignificant. Some intermediates and products (as well as impurities) may be unstable 
or not easily isolated. If it is not possible to isolate the compound for solubility 
determination, a different and more pragmatic approach should be applied. The pragmatic 
solubility method is based on the preferred concentration of reactants in the solvent of 
choice and a batch synthesis is carried out under the desired reaction conditions. This 
simple approach provides a useful visual determination of the intermediates’ or products’ 
behavior in the solvent (e.g. precipitation, dissolution, solid, solution) but without any 
exact values. Table 8.5 gives an overview of flow reactors likely to be suitable for 
different solubility concentrations of reactants and product; separation reactors only work 
in cases with higher solubility of product than of reactants. 
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Table 8.5: Flow reactor choice related to solubility of reactants and products.a 
Solubility Reactant 
(Sol. > 1.0 M) 
Reactant 
(1.0M > Sol. > 0.1M) 
Reactant 
(Sol. < 0.1 M) 
Product 
(Sol. > 1.0 M) 
Homogeneous 
Flow Reactor 
Heterogeneous 
Separation Reactor 
Heterogeneous 
Separation 
Reactor 
Product 
(1.0M > Sol. > 
0.1M) 
Heterogeneous 
Residence Time 
Reactor 
Heterogeneous 
Separation Reactor or 
Heterogeneous 
Residence Time 
Reactor 
Heterogeneous 
Separation 
Reactor 
Product 
(Sol. < 0.1 M) 
Heterogeneous 
Residence Time 
Reactor 
Heterogeneous 
Residence Time 
Reactor 
Heterogeneous 
Separation 
Reactor or 
Heterogeneous 
Residence Time 
Reactor 
aHeterogeneous separation reactors only work if the product has higher solubility than the 
reactants. 
 
8.11 Process Analytical Technology (PAT) and Quality-by-Design 
(QbD) 
In modern process development, different control and regulation strategies are used 
in order to meet the required specification of the final product and ensure steady and 
robust production of high quality products. This relates to the concepts of process 
analytical technology (PAT) and Quality-by-Design (QbD)1,28–30,241,276,277,279,288 and this 
section provides an overview of how to gradually implement these throughout the 
development of a process in the early stages. Later on, full methods should be integrated 
into the setup. In a flow process, the ability to control the process is a central part, as the 
outcome of small fluctuations could have significant consequences for the performance. 
In comparison, a batch reactor may be more flexible towards fluctuations. A good control 
strategy is the backbone of a continuous reactor setup but is often completely neglected in 
the development process of the setup in the laboratory, as the goal is to explore the 
potential of the setup. A great amount of useful data can be collected throughout the early 
stages of investigation that can later benefit the control strategy’s development. In 
particular, utilization of spectroscopic measurement methods and the raw data generated 
with these can be good indicators of the likeliness of the developed process being easily 
controlled or not. At minimum, screening of reactants, solvents and preferably the 
product should be carried out. Executing a quick spectroscopic screening will provide fast 
and cheap knowledge on which methods can be useful and whether there are any 
characteristic spectral fingerprints that distinguish one compound from the others. 
Besides the spectroscopic techniques, general considerations on potential control strategy 
with simpler equipment such as pH measurement, conductivity and mass balance can all 
be useful. 
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8.12 The Scale-Up versus Scale-Out Discussion 
As flow chemistry demonstrations became more common, a discussion of the 
potential industrial application of these newly applied methods for running organic 
synthesis began as well.32–34,37,38,258 Many of the early approaches focused on 
microreactor technology, which is why full-scale production was considered to be 
achieved through out-scaling instead of up-scaling, thus maintaining the high mass and 
heat transfer of the microreactors.19,33 The out-scaling concept has gradually been 
replaced by up-scaling approaches. In theory, out-scaling works very well, as it provides 
flexibility in relation to the demand for the amount to be produced. In addition, the 
transition from developing the process in the laboratory to full-scale production can be 
achieved without the normal pilot plant step. Operating multiple microreactor units to 
meet a certain production need is not as appealing in real life, as each reactor module 
must be fitted with all necessary measuring equipment, supply units, etc., which will be 
rather expensive. Alternatively, the streams can be split into each reactor, requiring fewer 
supply units but resulting in a setup that is significantly harder to regulate and control. 
Additionally, microreactors’ poor ability to handle solid material only sets them further 
back compared with larger reactor dimensions. The major benefits that are normally 
claimed to come from microreactors are benefits more or less achieved in relation to the 
continuous processing rather than to their dimensions.54 A small increase in the 
dimensions of a flow reactor provides a small difference in performance in mass and heat 
flow, hence the classic problem known from batch scale-up is not found to the same 
extent when working with flow reactors. In addition, the benefits of the slightly bigger 
dimension that also allows for the handling of solids (to a certain extent) make mini- and 
meso-scale reactors a better fit for production purposes. 
8.13 Case Studies 
Three case studies constitute the backbone of this methodology development. All 
three case studies deal with chemistry already in production and have therefore already 
been highly challenged in the initial consideration (Table 8.1). Additionally, all involved 
synthesis steps dealing with Grignard chemistry are GMP related. However, it should be 
emphasized that, besides the potential transformation to a flow chemistry setup and 
improved production, these case studies have also served as a learning process leading to 
this methodology. A can serve as a useful tool for later decision making related to 
Grignard chemistry. Table 8.6 gives an overview of important parameters for the three 
case studies and a more detailed discussion on each is given in the following sections. 
  
134
A Reactor Design Methodology for Grignard Reactions in the Pharmaceutical Industry 
109 
Table 8.6: A selection of interesting parameters in the evaluation of retrofitting three Grignard addition 
reactions. 
Reaction Case Study 1 
Allylcarbinol 
Case Study 2 
Escitalopram 
Case Study 3 
Melitracen HCl 
Carbonyl Solubility ≤0.5 ≤0.1 ≥1 
Alkoxide Solubility ≥1 ≤0.1a 
Highb 
≥1 
Operation Temp. 15-25 qC Sub-zero Ambient 
Impurity Formation High near 
equivalence addition 
of Grignard reagent 
High Limited 
Flow Reactor Heterogeneous 
Separation Reactor 
Heterogeneous 
Residence Time 
Reactor 
Homogeneous Flow 
Reactor (PFR) 
Additional Steps Potential direct 
hydrolysis and 
dehydration 
Intended hydrolysis One-step hydrolysis 
and dehydration, 
phase separation and 
salt precipitation 
Solvent THF MeTHF THF 
Kinetic 
Investigation 
No Yes No 
aIntermediate first addition 
bFinal alkoxide product 
 
8.13.1 Case Study 1: Alyllcarbinol 
Case study 1 (Scheme 8.3) involved an old process where the carbonyl is a ketone 
substrate (1) with one additional functional group (Cl). The overall reaction is highly 
dominated by the carbonyl reacting with the Grignard reagent, but a competitive reaction 
is known to exist (the impurity has not been determined). 
Scheme 8.3: Synthesis of alcohol 3 and intermediate 2 in the manufacturing process for zuclopenthixol 
hydrochloride (Clopixol) 4. 
 
This is also supported by knowledge from production, where impurity formation is 
especially observed near equivalent addition of Grignard reagent to the ketone substrate 
and at elevated temperatures. Due to the existing knowledge on how the reaction 
progresses and the fact that the formation of impurities is found to be low, no kinetic 
investigation was necessary. The solvent choice was heavily based on the GMP-filed part 
and only THF was considered. The reaction in the current batch was operated on the 
lower side of ambient temperature, hence the solubility of the (solid) ketone substrates 
was investigated for a temperature range of -10 to 60 qC. Solubility of the product (2) was 
found to be significantly higher than that of the reactants and a lower temperature (0 to 20 
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qC) was chosen to suppress any formation of impurities based on knowledge from the 
batch reaction. On this basis, a heterogeneous separation reactor followed by a subsequent 
multi-injection reactor for full conversion in the outlet was chosen as the first reactor 
setup. Simultaneously with the laboratory work on the reactor, work on the control 
strategy based on NIR measurement was carried out. The later steps of the process 
involve hydrolysis with subsequent dehydration. Both steps were demonstrated in the 
laboratory as segmented experiments from the Grignard addition reactor setup but not 
implemented at full scale. The setup was demonstrated to be useful in the laboratory and 
was later scaled up with great success. Some slight modification between the laboratory 
and the full-scale setup was made to meet functionality requirements. Table 8.6 
summarizes the details of the investigation. In Pedersen et al.,88–90 a more detailed 
discussion on the case study can be found. 
8.13.2 Case Study 2: Escitalopram 
Case study 2 (Scheme 8.4) involved an existing batch process having a lactone 5 with 
an additional functional group (CN). The desired outcome of the process was a diaddition 
to the lactone 5 by two different Grignard reagents (6 and 11). The lactone 5 reacts as a 
competitive consecutive reaction resulting in the formation of impurities, as only mono-
addition for each Grignard reagent addition is desired to obtain the final product 10 upon 
workup. 
Scheme 8.4: The Grignard addition to cyanophthalide (5) with two Grignard reagents (4-fluorophenyl 
magnesium bromide (6) and (3-(dimethylamino)propyl)magnesium chloride (11)), to yield product 10 upon 
hydrolysis and workup. Bisadduct impurities like product 9 are commonly seen due to competitive reactions. 
 
Additionally, the cyano-group adds more complexity to the reaction as this group 
will compete directly with the lactone for the Grignard reagent. From production, the 
reaction was known to be sensitive to temperature and thus if the formation of impurities 
is to be minimized the temperature should be kept low. The two Grignard reagents also 
behave differently in terms of reactivity, hence the less reactive of these was added first 
(Grignard reagent 2). Both THF and MeTHF were considered for the reaction and both 
are used in the routine batch production. The (solid) lactone has low solubility in both 
solvents and the same is true for the product of the first Grignard reagent addition. It was 
decided to progress with MeTHF due to its non-miscibility with water for later phase 
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separation. A heterogeneous residence time reactor (OFR) was chosen due to the low 
solubility of both reactants and product. Prediction models for the reactants’ and 
products’ subsequent conversion and concentration throughout the reactor were 
developed early in the process due to the high complexity of the chemistry. 
Simultaneously, kinetic investigation was carried out on a phthalide model compound, 
which was chosen in order to study only the addition reaction to the lactone, as this part 
contributes to the major impurity formation. The kinetic investigation verified the 
addition order at the given reaction temperature to be the best suited. The investigation 
also indicated that the diaddition impurity product could be suppressed with cryogenic 
reaction conditions. The investigation of the reaction in the OFR caused a series of 
difficulties related to the precipitation product from the first addition reaction. The 
magnesium alkoxide intermediate turned out to be highly viscous and stuck to the wall of 
the reactor, significantly reducing mass and heat transfer capability. Without good heat 
and mass transfer, the chance of suppressing impurity formation is limited. The project 
was terminated in the end due to the high complexity of the chemistry and unforeseen 
challenges. The knowledge ultimately obtained from the process is summarized in table 
8.6. 
8.13.3 Case Study 3: Melitracen HCl 
Case study 3 only involved a ketone (12) functional group and therefore its chemical 
analysis should be rather straightforward. The synthetic route is illustrated in scheme 8.5. 
Scheme 8.5: Syntheses of alkoxide product 13, alcohol 14 and diene 15 in the manufacturing process for 
melitracen HCl 16, from ketone 12 and Grignard reagent 11. 
 
The routine batch production was carried out in a solvent mixture of toluene and 
THF, but pure solvents (toluene, THF and MeTHF) were investigated for solubility of the 
solid ketone substrate, as later reactions and workup are expected to be easier with pure 
solvent. All investigated solvents showed high dissolution of the ketone (12); THF had a 
significantly higher concentration and was chosen for that reason. The product (13) also 
had high solubility and a tubular flow reactor was chosen. The temperature was lowered 
from approximately 55 qC to ambient temperature. No kinetic investigation was needed 
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and the addition reaction step was relatively easily implemented in the laboratory. The 
synthesis also includes hydrolysis and dehydration of the formed alcohol (14), which was 
optimized to a one-step synthesis with concentrated HCl. Upon pH adjusting, it was 
possible to make a phase separation with a simple gravity decanter and an additional 
precipitation to the final API, the latter of which was not optimized. The API was within 
production specification and improvement of the process compared to routine production 
was achieved. Due to the smaller market share of the API, no further action was taken in 
order to implement the new flow method. The scale-up is considered reasonably simple, 
due to the simplicity of the laboratory setup and the operational conditions applied. 
Furthermore, only a minor scale-up is necessary to fulfil the demand of the market. 
8.14 Discussion and the Wider Perspective 
This methodology has focused on the Grignard addition reactions and provides a 
step-by-step approach to fit Grignard reactions to suitable reactor configurations at an 
early stage. If methodologies and decision making for batch versus flow chemistry are 
really to make a difference, multiple synthesis steps need to be taken into account. For 
Grignard addition reactions, this involves hydrolysis that could be followed by a 
dehydration and separation of the organic and aqueous phases. Other methodologies 
should be developed for different chemistries and a common method of integrating these 
with each other will be necessary. The general methodological approach developed in this 
article is illustrated in figure 8.3 and it is believed that it can be fitted to suit other 
chemistries. The ideal vision for future production should be “plug and play” modules, 
where fast screening of chemistry results in a fast transfer to full-scale production. 
1) Overall Specification 
of Synthesis
2) Specification of 
synthesis main 
component
3) Specification of 
Physcial and Chemical 
properties
Main step
4) Manufacturing 
method and reactor 
configuration
Substep
1
1) New synthesis 
or redesign
2) GMP or
Non-GMP
3) Reaction type
Substep
2
1) Reactants
2) Products 
(desired)
3) Impurities
(by-products)
4) Solvent
5) Utilities
Substep
3
1) Solubility
2) Reaction 
temperatures
3) Reaction time
Substep
4
1) Dimensioning of 
reactor
4) Later process 
steps to be 
considered
 
Figure 8.3: The decision tree for reactor design in the case of Grignard chemistry in pharmaceutical production. 
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8.15 Conclusions 
A general methodology has been developed with the purpose of simplifying decision 
making for reactor design for Grignard reactions. The methodology focuses on the 
necessary laboratory experiments to perform in order to estimate the potential for a 
continuous reactor setup. With the increasing interest in continuous pharmaceutical 
manufacturing, this method aims to assist in making the decision between flow and batch 
processes. From an industrial perspective, the decision is always based on economic 
benefit or on health and safety issues. An old process or synthetic route is not always 
easily changed in the pharmaceutical industry without significant expenses due to 
regulatory restrictions. The restrictions often change a profitable optimization into a 
non-profitable one, this being one of the issues making the pharmaceutical industry very 
different from most of the other chemical industries. Solubility turned out to be the most 
important factor to have knowledge of when decisions are to be made on reactor 
configuration, as this will often be the most challenging parameter for reactor setup, 
especially for flow reactors. Fast screening experiments or a full solubility study can 
provide the data needed for decision making. A good understanding of the chemistry, 
especially temperature’s influence on the reaction rate and impurity formation, is of 
significant importance. The biggest flexibility in manipulation can be achieved with flow 
setups, but as the chemistry becomes more complex the simplicity of the batch reactor 
may in some situations still prove to be the best choice. 
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Conclusions 
Continuous pharmaceutical production has steadily grown during the last decade, a 
transformation that many stakeholders believe will make a major contribution to making 
the pharmaceutical industry more efficient and sustainable. The present trend of 
end-to-end production and pharmaceuticals on demand is in direct contrast to the earliest 
flow chemistry demonstrations of single synthetic steps and unit operations. Grignard 
chemistry has, since its discovery more than one hundred years ago, been a very 
important reaction type for the formation of new carbon-carbon bonds. The work 
documented throughout this project has aimed at providing valuable information about 
Grignard chemistry in flow reactors, with the purpose of developing a methodology for 
evaluating the potential of Grignard chemistry for various flow setups. The methodology 
is built on three very different Grignard addition reactions (e.g. solubility, functional 
groups) used for the synthesis of three APIs (melitracen HCl, zuclopenthixol and 
escitalopram). The main finding is the importance of reactant and product solubility, 
which largely dictate which types of reactor technology are likely to be suitable for 
production. Additionally, the strict regulation of the pharmaceutical industry by 
authorities can change an otherwise profitable continuous method into a non-profitable 
one, if refiling of documents becomes necessary. Some of the important findings for the 
syntheses investigated are summarized below. 
Understanding reaction mechanisms is of great value when decisions on reactor 
design and optimization of yield and purity are to be made. A flow setup and method for 
generation of reaction data (kinetics) for Grignard addition reactions was developed and 
the addition of two different Grignard reagents to a lactone was studied. The investigation 
indicates that the addition reaction follows the Meisenheimer mechanism and involves 
equilibrium between the two configurations of the mono-addition product. The 
equilibrium was found to be very sensitive towards temperature and for one of the 
Grignard reagents it was possible to shift the equilibrium towards monoalkylated product. 
A scale-up of a continuous reactor setup for Grignard reagent addition to a ketone 
with low solubility was investigated. The scale-up demonstrates the relative ease with 
which a continuous process can be transferred from a laboratory setup to full-scale 
production, where the small changes in dimensions in particular minimized the 
physicochemical deviations caused by mass and heat transfer. The continuous reactor 
setup also proved quite adept at handling solid reactants, which is typically one of the 
most difficult operations. 
Melitracen HCl was used as a case study for the demonstration of continuous 
production of an active pharmaceutical ingredient. Three segmented setups were 
developed to facilitate the production of melitracen HCl. While outside the scope of this 
work, the three setups could readily be coupled to provide full end-to-end production of 
melitracen HCl, if desired. The three setups each demonstrate some of the advantages that 
can be achieved with flow processes, such as improved safety, simplification of 
processing and reduced production cost, to mention a few. 
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The production of 3-(N,N-dimethylamino)propylchloride (DMPC) is performed 
through a base liberation of a HCl salt that originates as either an aqueous solution or a 
solid. The routine batch process for preparing DMPC requires the use of organic solvent 
for the extraction and a subsequent vacuum distillation. The flow process simplified the 
preparation by eliminating the organic solvent-assisted extraction and distillation. In a 
flow reactor setup, the base liberation of DMPC-HCl was demonstrated by use of 28 wt% 
NaOH (aq.), followed by a decanter separation of the DMPC from the aqueous phase. 
The free base from the separation was subsequently mixed with 50 wt% NaOH (aq.) for 
drying, before a second decanter was used for final separation of the essentially dry 
DMPC from the aqueous phase. This flow setup is an illustrative demonstration of how a 
continuous process can improve sustainability and greenness in the pharmaceutical 
industry by reducing solvent and energy consumption. 
Continuous processes have been praised for safer production when dealing with 
hazardous reactions. Closed reactor systems, smaller active volumes and more efficient 
heat transfer compared to batch reactors are some of the benefits mentioned when dealing 
with toxic and exothermic reactions. Grignard reagents are notorious for the risks 
associated with their production because of the often toxic alkyl/aryl halide, the highly 
exothermic reactions, low boiling solvents and very reactive organometallics that are 
formed. A continuous reactor system capable of handling solid magnesium was used for 
the production of DMPC-MgCl in MeTHF. The flow setup significantly reduces the 
active volume necessary for production as compared to normal batch methods and 
minimizes risk in case of runaway reactions. The closed handling of reactants and 
products and the assurance of concentration and quality by in-line near-infrared 
spectroscopic measurements have likewise reduced hazard risks when handling toxic 
compounds. An industrial version of the laboratory reactor setup has been implemented in 
full-scale production for formation of other Grignard reagents, ensuring consistent quality 
and safe production. 
The batch production of melitracen HCl, an active pharmaceutical ingredient for 
antidepressant treatment, was redesigned to a continuous process. The solvent was 
simplified from a mixture of toluene and THF to use only THF. In addition, due to the 
high solubility of the ketone, the Grignard addition was suited for a plug flow reactor and 
furthermore the reaction temperature was able to be lowered from 50°C to ambient. The 
hydrolysis and dehydration were merged into a single synthetic step, causing a reduction 
in the number of unit operations by removal of a phase separation. Judicious adjustment 
of the pH generated a two phase system, resulting in near quantitative extraction of the 
melitracen raw base into the organic phase. A decanter was used for the subsequent 
separation. A non-optimized precipitation of the melitracen HCl in THF was carried out 
by use of a 2 M HCl solution in Et2O, which resulted in an overall isolated yield of 80%. 
The melitracen HCl was analyzed in accordance with current release procedures for the 
routine batch production, wherein the product was found to be in full compliance with all 
specifications, with the exception of the particle size distribution, which was marginally 
larger than specification. The laboratory setup is capable of producing a significant 
amount of the current annual production and profits from a significant simplification over 
the routine production method. 
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Future Perspective 
The major changes that have occurred within the pharmaceutical industry during the 
last decade have opened doors for new and interesting opportunities. The industry, the 
authorities and academia have all contributed to the overall discussion on how the 
pharmaceutical industry can change to become more efficient and sustainable in a highly 
competitive business regime. In particular, flow processing has received much positive 
interest and is believed to have a major influence on the changes taking place. The earliest 
demonstrations focused very much on establishing proof of concept by conducting a 
single synthetic step and unit operation with the aim of improved performance. As the 
new technologies have become familiar in academia and to the pharmaceutical industry, 
the trend has been towards complete synthesis of pharmaceuticals comprised of multiple 
unit operations. Recent efforts have also resulted in some full-scale implementations 
reported in the literature, highlighting that pharmaceutical companies believe in the new 
paradigm of continuous production methods. 
The concept of continuous manufacturing has gained a foothold, but major areas are 
still unexplored. Much work lies ahead before continuous manufacturing in the 
pharmaceutical industry can rival the more traditional batch production. A better 
understanding of the possibilities of continuous processing still needs to be established. 
R&D departments tend to reapply reaction types when developing new syntheses for 
pharmaceuticals; hence standardized “plug-and-play” reactor modules would ease the 
transfer between R&D and production. R&D chemists and chemical engineers can utilize 
each other’s competencies in the effort to develop standardized reactor concepts, ensuring 
long-term success from the collaboration. Besides the development of modular concepts, 
it is just as important to understand the limitations of the available technologies in order 
to make appropriate decisions on which processing approach is preferred. Methodologies 
are essential for rapid selection of processes suitable for development in flow, but they 
must be simple if they are to gain acceptance and be implemented in industry. It is 
paramount that these areas receive proper attention in order to accelerate the momentum 
of the modernization of the pharmaceutical industry and facilitate the transition to flow 
manufacturing. 
143
144
References 
119 
References 
(1)  am Ende, D. J. Chemical Engineering in the Pharmaceutical Industry: R&D to 
Manufacturing; Wiley & Sons, Inc.: Hoboken, New Jersey, 2010. 
(2)  Rowland, M.; Noe, C. R.; Smith, D. A.; Tucker, G. T.; Crommelin, D. J. A.; Peck, 
C. C.; Rocci, Jr., M. L.; Besancon, L.; Shah, V. P. J. Pharm. Sci. 2012, 101, 4075–
4099. 
(3)  H. Lundbeck A/S. 2011, 1–9. 
(4)  H. Lundbeck A/S. H. Lundbeck A/S http://www.lundbeck.com/global (accessed 
Jul 31, 2014). 
(5)  Federsel, H.-J. Acc. Chem. Res. 2009, 42, 671–680. 
(6)  Baxendale, I. R.; Hayward, J. J.; Ley, S. V.; Tranmer, G. K. ChemMedChem 2007, 
2, 768–788. 
(7)  Munos, B. Nat. Rev. Drug Discov. 2009, 8, 959–968. 
(8)  Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; 
Lindborg, S. R.; Schacht, A. L. Nat. Rev. Drug Discov. 2010, 9, 203–214. 
(9)  Pammolli, F.; Magazzini, L.; Riccaboni, M. Nat. Rev. Drug Discov. 2011, 10, 428–
438. 
(10)  Abou-Gharbia, M.; Childers, W. E. J. Med. Chem. 2013, 56, 5659–5672. 
(11)  Abou-Gharbia, M.; Childers, W. E. J. Med. Chem. 2014, 57, 5525–5553. 
(12)  Suresh, P.; Basu, P. K. J. Pharm. Innov. 2008, 3, 175–187. 
(13)  Vogel, R. J. Clin. Ther. 2002, 24, 1204–1222. 
(14)  Danzon, P. M.; Towse, A. Int. J. Health Care Finance Econ. 2003, 3, 183–205. 
(15)  Zhang, T. Y. Chem. Rev. 2006, 106, 2583–2595. 
(16)  Webber, P. M. Nat. Rev. Drug Discov. 2003, 2, 823–830. 
(17)  Mullard, A. Nat. Rev. Drug Discov. 2014, 13, 85–89. 
(18)  Federsel, H.-J. Expert Opin. Drug Discov. 2010, 5, 813–818. 
(19)  Plumb, K. Chem. Eng. Res. Des. 2005, 83, 730–738. 
(20)  Dunn, P. J. Green Chem. 2013, 15, 3099–3104. 
(21)  Behr, A.; Brehme, V. A.; Ewers, C. L. J.; Grön, H.; Kimmel, T.; Küppers, S.; 
Symietz, I. Eng. Life Sci. 2004, 4, 15–24. 
(22)  Roberge, D. M.; Ducry, L.; Bieler, N.; Cretton, P.; Zimmermann, B. Chem. Eng. 
Technol. 2005, 28, 318–323. 
(23)  Kneller, R. Nat. Rev. Drug Discov. 2010, 9, 867–882. 
(24)  DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. J. Health Econ. 2003, 22, 151–
185. 
(25)  Welch, C. J.; Hawkins, J. M.; Tom, J. Org. Process Res. Dev. 2014, 18, 481–487. 
(26)  International Conference on Harmonisation (ICH). Good Manufacturing Practice 
Guide for Active Pharmaceutical Ingredients Q7; ICH Guideline; Q7; 2000. 
(27)  Nally, J. D. Good Manufacturing Practices for Pharmaceuticals; 6th ed.; Informa 
Healthcare USA, Inc.: New York, New York, 2007. 
(28)  Dünnebier, G.; Tups, H. Chemie Ing. Tech. 2007, 79, 2019–2028. 
(29)  Pomerantsev, A. L.; Rodionova, O. Y. J. Chemom. 2012, 26, 299–310. 
(30)  Schmidt-Bader, T. Chemie Ing. Tech. 2010, 82, 415–428. 
(31)  Jiménez-González, C.; Poechlauer, P.; Broxterman, Q. B.; Yang, B.-S.; am Ende, 
D. J.; Baird, J.; Bertsch, C.; Hannah, R. E.; Dell’Orco, P.; Noorman, H.; Yee, S.; 
Reintjens, R.; Wells, A.; Massonneau, V.; Manley, J. Org. Process Res. Dev. 2011, 
15, 900–911. 
(32)  Hartman, R. L.; McMullen, J. P.; Jensen, K. F. Angew. Chemie Int. Ed. 2011, 50, 
7502–7519. 
145
References 
120 
(33)  Wild, G. P.; Wiles, C.; Watts, P. Lett. Org. Chem. 2006, 3, 419–425. 
(34)  Hessel, V.; Kralisch, D.; Kockmann, N.; Noël, T.; Wang, Q. ChemSusChem 2013, 
6, 746–789. 
(35)  Jiménez-González, C.; Ponder, C. S.; Broxterman, Q. B.; Manley, J. B. Org. 
Process Res. Dev. 2011, 15, 912–917. 
(36)  Wiles, C.; Watts, P. Chem. Commun. 2011, 47, 6512–6535. 
(37)  Wiles, C.; Watts, P. Micro Reaction Technology in Organic Synthesis; 1st ed.; 
CRC Press: Boca Raton, Florida, 2011. 
(38)  Hessel, V. Chem. Eng. Technol. 2009, 32, 1655–1681. 
(39)  Mascia, S.; Heider, P. L.; Zhang, H.; Lakerveld, R.; Benyahia, B.; Barton, P. I.; 
Braatz, R. D.; Cooney, C. L.; Evans, J. M. B.; Jamison, T. F.; Jensen, K. F.; 
Myerson, A. S.; Trout, B. L. Angew. Chemie Int. Ed. 2013, 52, 12359–12363. 
(40)  Heider, P. L.; Born, S. C.; Basak, S.; Benyahia, B.; Lakerveld, R.; Zhang, H.; 
Hogan, R.; Buchbinder, L.; Wolfe, A.; Mascia, S.; Evans, J. M. B.; Jamison, T. F.; 
Jensen, K. F. Org. Process Res. Dev. 2014, 18, 402–409. 
(41)  Webb, D.; Jamison, T. F. Chem. Sci. 2010, 1, 675–680. 
(42)  Ley, S. V. Chem. Rec. 2012, 12, 378–390. 
(43)  Anderson, N. G. Org. Process Res. Dev. 2012, 16, 852–869. 
(44)  Popov, V. V. Pharm. Chem. J. 1973, 7, 263–266. 
(45)  Henderson, R. K.; Jiménez-González, C.; Constable, D. J. C.; Alston, S. R.; Inglis, 
G. G. A.; Fisher, G.; Sherwood, J.; Binks, S. P.; Curzons, A. D. Green Chem. 
2011, 13, 854–862. 
(46)  Constable, D. J. C.; Jiménez-González, C.; Henderson, R. K. Org. Process Res. 
Dev. 2007, 11, 133–137. 
(47)  Adams, J. P.; Alder, C. M.; Andrews, I.; Bullion, A. M.; Campbell-Crawford, M.; 
Darcy, M. G.; Hayler, J. D.; Henderson, R. K.; Oare, C. A.; Pendrak, I.; Redman, 
A. M.; Shuster, L. E.; Sneddon, H. F.; Walker, M. D. Green Chem. 2013, 15, 
1542–1549. 
(48)  Sheldon, R. A. Green Chem. 2007, 9, 1273–1283. 
(49)  Watson, W. J. W. Green Chem. 2012, 14, 251–259. 
(50)  Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Org. Biomol. Chem. 2006, 
4, 2337–2347. 
(51)  Roughley, S. D.; Jordan, A. M. J. Med. Chem. 2011, 54, 3451–3479. 
(52)  Dugger, R. W.; Ragan, J. A.; Ripin, D. H. B. Org. Process Res. Dev. 2005, 9, 253–
258. 
(53)  Roberge, D. M. Org. Process Res. Dev. 2004, 8, 1049–1053. 
(54)  Roberge, D. M.; Bieler, N.; Thalmann, M. PharmaChem 2006, 5, 14–17. 
(55)  Wiles, C.; Watts, P. Green Chem. 2012, 14, 38–54. 
(56)  Pashkova, A.; Greiner, L. Chemie Ing. Tech. 2011, 83, 1337–1342. 
(57)  Calabrese, G. S.; Pissavini, S. AIChE J. 2011, 57, 828–834. 
(58)  Schaber, S. D.; Gerogiorgis, D. I.; Ramachandran, R.; Evans, J. M. B.; Barton, P. 
I.; Trout, B. L. Ind. Eng. Chem. Res. 2011, 50, 10083–10092. 
(59)  Fogler, H. S. Elements of Chemical Reaction Engineering; 4th ed.; Pearson 
Education: Upper Saddle River, New Jersey, 2006. 
(60)  Levenspiel, O. Chemical Reaction Engineering; 3rd ed.; John Wiley & Sons, Inc: 
Hoboken, New Jersey, 1999. 
(61)  Thakur, R. K.; Vial, C.; Nigam, K. D. P.; Nauman, E. B.; Djelveh, G. Chem. Eng. 
Res. Des. 2003, 81, 787–826. 
(62)  Falk, L.; Commenge, J.-M. Chem. Eng. Sci. 2010, 65, 405–411. 
146
References 
121 
(63)  Schwolow, S.; Hollmann, J.; Schenkel, B.; Röder, T. Org. Process Res. Dev. 2012, 
16, 1513–1522. 
(64)  Brechtelsbauer, C.; Ricard, F. Org. Process Res. Dev. 2001, 5, 646–651. 
(65)  Choe, J.; Kim, Y.; Song, K. H. Org. Process Res. Dev. 2003, 7, 187–190. 
(66)  Bird, R. B.; Stewart, W. E.; Lightfoot, E. N. Transport Phenomena; 2nd ed.; Wiley 
& Sons, Inc.: New York, New York, 2007. 
(67)  Paul, E. L.; Atiemo-Obeng, V. A.; Kresta, S. M. Handbook of Industrial Mixing; 
2nd ed.; Wiley & Sons, Inc.: Hoboken, New Jersey, 2004. 
(68)  Lomel, S.; Falk, L.; Commenge, J. M.; Houzelot, J. L.; Ramdani, K. Chem. Eng. 
Res. Des. 2006, 84, 363–369. 
(69)  Nagy, K. D.; Shen, B.; Jamison, T. F.; Jensen, K. F. Org. Process Res. Dev. 2012, 
16, 976–981. 
(70)  Shah, S. I. A.; Kostiuk, L. W.; Kresta, S. M. Int. J. Chem. Eng. 2012, 2012, 1–13. 
(71)  Zaborenko, N.; Bedore, M. W.; Jamison, T. F.; Jensen, K. F. Org. Process Res. 
Dev. 2011, 15, 131–139. 
(72)  Bourne, J. R. Org. Process Res. Dev. 2003, 7, 471–508. 
(73)  Levien, K. L.; Levenspiel, O. Chem. Eng. Sci. 1999, 54, 2453–2458. 
(74)  Čatipović, N.; Levenspiel, O. Ind. Eng. Chem. Prod. Res. Dev. 1979, 18, 558–561. 
(75)  Hamel, C.; Thomas, S.; Schädlich, K.; Seidel-Morgenstern, A. Chem. Eng. Sci. 
2003, 58, 4483–4492. 
(76)  Tóta, Á.; Hamel, C.; Thomas, S.; Joshi, M.; Klose, F.; Seidel-Morgenstern, A. 
Chem. Eng. Res. Des. 2004, 82, 236–244. 
(77)  Kockmann, N.; Roberge, D. M. Chem. Eng. Technol. 2009, 32, 1682–1694. 
(78)  Barthe, P.; Guermeur, C.; Lobet, O.; Moreno, M.; Woehl, P.; Roberge, D. M.; 
Bieler, N.; Zimmermann, B. Chem. Eng. Technol. 2008, 31, 1146–1154. 
(79)  Roberge, D. M.; Bieler, N.; Mathier, M.; Eyholzer, M.; Zimmermann, B.; Barthe, 
P.; Guermeur, C.; Lobet, O.; Moreno, M.; Woehl, P. Chem. Eng. Technol. 2008, 
31, 1155–1161. 
(80)  Haber, J.; Kashid, M. N.; Renken, a.; Kiwi-Minsker, L. Ind. Eng. Chem. Res. 2012, 
51, 1474–1489. 
(81)  Wong, S.-W.; Berglund, K. D.; Viswanath, S. K. Org. Process Res. Dev. 2014, In 
Print. 
(82)  Kamble, S. P.; Barve, P. P.; Joshi, J. B.; Rahman, I.; Kulkarni, B. D. Ind. Eng. 
Chem. Res. 2012, 51, 1506–1514. 
(83)  Stonestreet, P.; Harvey, A. P. Chem. Eng. Res. Des. 2002, 80, 31–44. 
(84)  Phan, A. N.; Harvey, A. Chem. Eng. J. 2010, 159, 212–219. 
(85)  Harvey, A. P.; Mackley, M. R.; Stonestreet, P. Ind. Eng. Chem. Res. 2001, 40, 
5371–5377. 
(86)  Liguori, L.; Bjørsvik, H.-R. Org. Process Res. Dev. 2011, 15, 997–1009. 
(87)  Lawton, S.; Steele, G.; Shering, P.; Zhao, L.; Laird, I.; Ni, X.-W. Org. Process 
Res. Dev. 2009, 13, 1357–1363. 
(88)  Pedersen, M. J.; Holm, T. L.; Rahbek, J. P.; Skovby, T.; Mealy, M. J.; Dam-
Johansen, K.; Kiil, S. Org. Process Res. Dev. 2013, 17, 1142–1148. 
(89)  Cervera-Padrell, A. E.; Nielsen, J. P.; Pedersen, M. J.; Christensen, K. M.; 
Mortensen, A. R.; Skovby, T.; Dam-Johansen, K.; Kiil, S.; Gernaey, K. V. Org. 
Process Res. Dev. 2012, 16, 901–914. 
(90)  Christensen, K. M.; Pedersen, M. J.; Dam-Johansen, K.; Holm, T. L.; Skovby, T.; 
Kiil, S. Chem. Eng. Sci. 2012, 71, 111–117. 
(91)  Caygill, G.; Zanfir, M.; Gavriilidis, A. Org. Process Res. Dev. 2006, 10, 1773–
1782. 
147
References 
122 
(92)  Barbier, P. C. R. Hebd. Seances Acad. Sci. 1899, 128, 110–111. 
(93)  Grignard, V. C. R. Hebd. Seances Acad. Sci. 1900, 130, 1322–1324. 
(94)  Silverman, G. S.; Rakita, P. E. Handbook of Grignard Reagents; Silverman, G. S.; 
Rakita, P. E., Eds.; Marcel Dekker: New York, New York, 1996. 
(95)  Entemann, Jr., C. E.; Johnson, J. R. J. Am. Chem. Soc. 1933, 55, 2900–2903. 
(96)  Eisch, J. J. Organometallics 2002, 21, 5439–5463. 
(97)  Luderer, M. R.; Bailey, W. F.; Luderer, M. R.; Fair, J. D.; Dancer, R. J.; Sommer, 
M. B. Tetrahedron: Asymmetry 2009, 20, 981–998. 
(98)  Banno, T.; Hayakawa, Y.; Umeno, M. J. Organomet. Chem. 2002, 653, 288–291. 
(99)  Kadam, A.; Nguyen, M.; Kopach, M.; Richardson, P.; Gallou, F.; Wan, Z.-K.; 
Zhang, W. Green Chem. 2013, 15, 1880–1888. 
(100)  Richey, Jr., H. G. Grignard Reagents New Developments; Richey, H. G. J., Ed.; 
John Wiley & Sons, Ltd: West Sussex, England, 2000. 
(101)  Ackermann, L.; Althammer, A. Chemie unserer Zeit 2009, 43, 74–83. 
(102)  Christensen, S. H.; Holm, T.; Madsen, R. Tetrahedron 2014, 70, 4942–4946. 
(103)  Kryk, H.; Hessel, G.; Schmitt, W.; Tefera, N. Chem. Eng. Sci. 2007, 62, 5198–
5200. 
(104)  Wedlich, R. C.; Carey, B. J.; Kohn, D. Y. In Systematic Risk Analysis of a 
Grignard Reaction; Houston, Texas, 1999; pp. 1–10. 
(105)  Pace, V.; Hoyos, P.; Castoldi, L.; Domínguez de María, P.; Alcántara, A. R. 
ChemSusChem 2012, 5, 1369–1379. 
(106)  Holm, T. J. Organomet. Chem. 1973, 56, 87–93. 
(107)  Chen, Z.-N.; Fu, G.; Xu, X. Org. Biomol. Chem. 2012, 10, 9491–9500. 
(108)  Van Klink, G. P. M.; de Boer, H. J. R.; Schat, G.; Akkerman, O. S.; Bickelhaupt, 
F.; Spek, A. L. Organometallics 2002, 21, 2119–2135. 
(109)  Garst, J. F.; Soriaga, M. P. Coord. Chem. Rev. 2004, 248, 623–652. 
(110)  Tilstam, U.; Weinmann, H. Org. Process Res. Dev. 2002, 6, 906–910. 
(111)  am Ende, D. J.; Clifford, P. J.; Deantonis, D. M.; Santamaria, C.; Brenek, S. J. Org. 
Process Res. Dev. 1999, 3, 319–329. 
(112)  Brodmann, T.; Koos, P.; Metzger, A.; Knochel, P.; Ley, S. V. Org. Process Res. 
Dev. 2012, 16, 1102–1113. 
(113)  Wiss, J.; Länzlinger, M.; Wermuth, M. Org. Process Res. Dev. 2005, 9, 205–208. 
(114)  Wiss, J.; Ermini, G. Org. Process Res. Dev. 2006, 10, 1282–1286. 
(115)  Lai, Y.-H. Synthesis (Stuttg). 1981, 8, 585–604. 
(116)  Ashby, E. C.; Laemmle, J.; Neumann, H. M. J. Am. Chem. Soc. 1972, 94, 5421–
5434. 
(117)  Meisenheimer, J.; Casper, J. Chem. Ber. 1921, 54, 1655–1665. 
(118)  Swain, C. G.; Boyles, H. B. J. Am. Chem. Soc. 1951, 73, 870–872. 
(119)  Bruice, P. Y. Organic Chemistry; 5th ed.; Pearson Education: Upper Saddle River, 
New Jersey, 2007. 
(120)  Nicaise, O. J.-C.; Mans, D. M.; Morrow, A. D.; Hefti, E. V.; Palkovacs, E. M.; 
Singh, R. K.; Zukowska, M. A.; Morin, M. D. Tetrahedron 2003, 59, 6433–6443. 
(121)  Nicaise, O. J.; Ostrom, K. F.; Dalke, B. J. J. Chem. Educ. 2005, 82, 1059–1064. 
(122)  Smith, J. G.; Wikman, R. T. Tetrahedron 1974, 30, 2603–2611. 
(123)  Hillery, P. S.; Cohen, L. A. Bioorg. Chem. 1992, 20, 313–322. 
(124)  Natelson, S.; Pearl, A. J. Am. Chem. Soc. 1936, 58, 2448–2449. 
(125)  Nahm, S.; Weinreb, S. M. Tetrahedron Lett. 1981, 22, 3815–3818. 
(126)  Bechara, W. S.; Pelletier, G.; Charette, A. B. Nat. Chem. 2012, 4, 228–234. 
(127)  Yue, M.; Sharkey, J. J.; Leung, J. C. J. Loss Prev. Process Ind. 1994, 7, 413–418. 
148
References 
123 
(128)  Kramer, D. A. Magnesium Compounds. Kirk-Othmer Encyclopedia of Chemical 
Technology, 2004. 
(129)  Kramer, D. A. Magnesium and Magnesium Alloys. Kirk-Othmer Encyclopedia of 
Chemical Technology, 2010. 
(130)  Rakita, P. E. Grignard Reactions. Kirk-Othmer Encyclopedia of Chemical 
Technology, 2005, 12. 
(131)  Seeger, M.; Otto, W.; Flick, W.; Bickelhaupt, F.; Akkerman, O. S. Magnesium 
Compounds. Ullmann’s Encyclopedia of Industrial Chemistry, 2011. 
(132)  Amundsen, K.; Aune, T. K.; Bakke, P.; Eklund, H. R.; Haagensen, J. Ö.; Nicolas, 
C.; Rosenkilde, C.; Van den Bremt, S.; Wallevik, O. Magnesium. Ullmann’s 
Encyclopedia of Industrial Chemistry, 2003. 
(133)  Haynes, W. M. Handbook of Chemistry and Physics; 95th ed.; Taylor and Francis 
Group, LLC, 2014. 
(134)  Shand, M. A. The Chemistry and Technology of Magnesia; John Wiley & Sons, 
Inc: Hoboken, New Jersey, 2006. 
(135)  Schlenk, W.; Schlenk, Jr., W. Berichte der Dtsch. Chem. Gesellschaft 1929, 62, 
920–924. 
(136)  Johnson, G. O.; Adkins, H. J. Am. Chem. Soc. 1932, 54, 1943–1947. 
(137)  Oldham, J. W. H.; Ubbelohde, A. R. J. Chem. Soc. 1938, 1, 201–206. 
(138)  Reid, T. J.; Ubbelohde, A. R. J. Chem. Soc. 1948, 1, 1597–1601. 
(139)  Holm, T. Tetrahedron Lett. 1966, 7, 3329–3336. 
(140)  Seyferth, D. Organometallics 2009, 28, 1598–1605. 
(141)  Osztrovszky, G.; Holm, T.; Madsen, R. Org. Biomol. Chem. 2010, 8, 3402–3404. 
(142)  The European Commission. Off. J. Eur. Union 2012, 179, 3–10. 
(143)  Langer, J.; Krieck, S.; Fischer, R.; Görls, H.; Walther, D.; Westerhausen, M. 
Organometallics 2009, 28, 5814–5820. 
(144)  Holm, T. Acta Chem. Scand. 1965, 19, 1819–1826. 
(145)  Holm, T. Acta Chem. Scand. 1966, 20, 2821–2828. 
(146)  Holm, T. Acta Chem. Scand. 1966, 20, 1139–1144. 
(147)  Holm, T. J. Organomet. Chem. 1971, 29, C45–C48. 
(148)  Holm, T. Acta Chem. Scand. 1974, 28B, 809–812. 
(149)  Holm, A.; Holm, T.; Huge-Jensen, E. Acta Chem. Scand. 1974, 28B, 781–786. 
(150)  Holm, T. Acta Chem. Scand. 1973, 27, 1552–1556. 
(151)  Holm, T.; Crossland, I. Acta Chem. Scand. 1971, 25, 59–69. 
(152)  Holm, T. Acta Chem. Scand. 1969, 23, 579–586. 
(153)  Holm, T. Acta Chem. Scand. 1967, 21, 2753–2758. 
(154)  Holm, T.; Blankholm, I. Acta Chem. Scand. 1968, 22, 708–710. 
(155)  Krummradt, H.; Koop, U.; Stoldt, J. In Experiences with the use of Microreactors 
in Organic Synthesis; Ehrfeld, W., Ed.; Springer-Verlag: Berlin, Germany, 2000; 
pp. 181–186. 
(156)  Koop, U.; Krummradt, H.; Schwarz, M.; Stoldt, J.; Eckstein, J.; Zehner, S. 
Reaktion von Carbonylverbindungen mit Metallirganischen Reagenzien. 
DE10001317A1, 2000. 
(157)  Koch, M.; Wehle, D.; Scherer, S.; Forstinger, K.; Meudt, A.; Hessel, V.; Werner, 
B.; Löwe, H. Verfahren zur Herstellung von Aryl- und Alkyl-Bor-Verbindungen in 
Mikroreaktoren. EP1285924A1, 2003. 
(158)  Pennemann, H.; Hessel, V.; Löwe, H. Chem. Eng. Sci. 2004, 59, 4789–4794. 
(159)  Hessel, V.; Hofmann, C.; Löwe, H.; Meudt, A.; Scherer, S.; Schönfeld, F.; Werner, 
B. Org. Process Res. Dev. 2004, 8, 511–523. 
149
References 
124 
(160)  Roberge, D. M.; Zimmermann, B.; Rainone, F.; Gottsponer, M.; Eyholzer, M.; 
Kockmann, N. Org. Process Res. Dev. 2008, 12, 905–910. 
(161)  Kockmann, N.; Roberge, D. M. Chem. Eng. Process. 2011, 50, 1017–1026. 
(162)  Golbig, K.; Hohmann, M.; Kursawe, A.; Schwalbe, T. Chemie Ing. Tech. 2004, 76, 
598–603. 
(163)  Schwalbe, T.; Kursawe, A.; Sommer, J. Chem. Eng. Technol. 2005, 28, 408–419. 
(164)  Riva, E.; Gagliardi, S.; Martinelli, M.; Passarella, D.; Vigo, D.; Rencurosi, A. 
Tetrahedron 2010, 66, 3242–3247. 
(165)  Mateos, C.; Rincón, J. A.; Villanueva, J. Tetrahedron Lett. 2013, 54, 2226–2230. 
(166)  Polyzos, A.; O’Brien, M.; Petersen, T. P.; Baxendale, I. R.; Ley, S. V. Angew. 
Chemie Int. Ed. 2011, 50, 1190–1193. 
(167)  Murray, P. R. D.; Browne, D. L.; Pastre, J. C.; Butters, C.; Guthrie, D.; Ley, S. V. 
Org. Process Res. Dev. 2013, 17, 1192–1208. 
(168)  Wu, J.; Yang, X.; He, Z.; Mao, X.; Hatton, T. A.; Jamison, T. F. Angew. Chemie 
Int. Ed. 2014, In Print. 
(169)  He, Z.; Jamison, T. F. Angew. Chemie Int. Ed. 2014, 53, 3353–3357. 
(170)  Kupracz, L.; Kirschning, A. Adv. Synth. Catal. 2013, 355, 3375–3380. 
(171)  Nwosu, S. O.; Johnson, M. D.; Adler, J. J.; Schafer, J. P.; Braden, T. M.; Kerr, M. 
S.; Seibert, K. D.; Kopach, M. In AIChE Meeting: Pharmaceutical Discovery, 
Development and Manufacturing Forum; San Francisco, California, 2013. 
(172)  Kopach, M. E.; Roberts, D. J.; Johnson, M. D.; McClary Groh, J.; Adler, J. J.; 
Schafer, J. P.; Kobierski, M. E.; Trankle, W. G. Green Chem. 2012, 14, 1524–
1536. 
(173)  Anteunis, M. J. Org. Chem. 1961, 26, 4214–4217. 
(174)  Aycock, D. F. Org. Process Res. Dev. 2007, 11, 156–159. 
(175)  Yamazaki, T.; Terajima, T.; Kawasaki-Taskasuka, T. Tetrahedron 2008, 64, 2419–
2424. 
(176)  Wojciechowski, B. W.; Rice, N. M. Experimental Methods in Kinetic Studies; 2nd 
ed.; Elsevier: Amsterdam, The Netherlands, 2003. 
(177)  Valera, F. E.; Quaranta, M.; Moran, A.; Blacker, J.; Armstrong, A.; Cabral, J. T.; 
Blackmond, D. G. Angew. Chemie Int. Ed. 2010, 49, 2478–2485. 
(178)  Skoog, D. A.; West, D. M.; Holler, F. J.; Crouch, S. R. Fundamentals of Analytical 
Chemistry; 8th ed.; Thomson Brooks/Cole: Belmont, Canada, 2004. 
(179)  Yue, J.; Schouten, J. C.; Nijhuis, T. A. Ind. Eng. Chem. Res. 2012, 51, 14583–
14609. 
(180)  McMullen, J. P.; Jensen, K. F. Org. Process Res. Dev. 2011, 15, 398–407. 
(181)  Moore, J. S.; Jensen, K. F. Org. Process Res. Dev. 2012, 16, 1409–1415. 
(182)  Moore, J. S.; Jensen, K. F. Angew. Chemie Int. Ed. 2014, 53, 470–473. 
(183)  Mozharov, S.; Nordon, A.; Littlejohn, D.; Wiles, C.; Watts, P.; Dallin, P.; Girkin, 
J. M. J. Am. Chem. Soc. 2011, 133, 3601–3608. 
(184)  Alfa Laval. Quantitative Conversion with Undiluted reactants, 2005, 1–2. 
(185)  Wakami, H.; Yoshida, J. Org. Process Res. Dev. 2005, 9, 787–791. 
(186)  Petersen, T. P.; Becker, M. R.; Knochel, P. Angew. Chemie Int. Ed. 2014, In Print. 
(187)  Tricotet, T.; O’Shea, D. F. Chem. A Eur. J. 2010, 16, 6678–6686. 
(188)  Muñoz, J. D. M.; Alcázar, J.; de la Hoz, A.; Díaz-Ortiz, Á.; Alonso de Diego, S.-A. 
Green Chem. 2012, 14, 1335–1341. 
(189)  Yoshida, J.; Kim, H.; Nagaki, A. ChemSusChem 2011, 4, 331–340. 
(190)  Chinnusamy, T.; Yudha, S. S.; Hager, M.; Kreitmeier, P.; Reiser, O. 
ChemSusChem 2012, 5, 247–255. 
(191)  Holmes, A. B.; Sporikou, C. N. Org. Synth. 1987, 65, 61–67. 
150
References 
125 
(192)  Gaussian 09, Revision A.02, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; 
Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; 
Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. 
P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; 
Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, 
O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; 
Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; 
Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, 
S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N. J.; Klene, M.; Knox, J. E.; Cross, 
J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; 
Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; 
Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; 
Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, 
J.; Fox, D. J. Gaussian, Inc., Wallingford CT, 2009. 
(193)  Becke, A. D. J. Chem. Phys. 1993, 98, 5648–5652. 
(194)  Becke, A. D. J. Chem. Phys. 1992, 96, 2155–2160. 
(195)  Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785–789. 
(196)  Gilman, H.; Fothergill, R. E. J. Am. Chem. Soc. 1929, 51, 3149–3157. 
(197)  Neuenschwander, U.; Meier, E.; Hermans, I. ChemSusChem 2011, 4, 1613–1621. 
(198)  Yamazaki, S.; Yamabe, S. J. Org. Chem. 2002, 67, 9346–9353. 
(199)  Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Textbook of 
Practical Organic Synthesis; 5th ed.; Pearson Prentice Hall: Essex, England, 1998. 
(200)  Székely, G.; Gil, M.; Sellergren, B.; Heggie, W.; Ferreira, F. C. Green Chem. 
2013, 15, 210–225. 
(201)  Remenar, J. F.; Macphee, J. M.; Larson, B. K.; Tyagi, V. A.; Ho, J. H.; Mcilroy, D. 
A.; Hickey, M. B.; Shaw, P. B. Org. Process Res. Dev. 2003, 7, 990–996. 
(202)  Murugesan, S.; Hallow, D. M.; Vernille, J. P.; Tom, J. W.; Tabora, J. E. Org. 
Process Res. Dev. 2012, 16, 42–48. 
(203)  Bastin, R. J.; Bowker, M. J.; Slater, B. J. Org. Process Res. Dev. 2000, 4, 427–435. 
(204)  Schaefer, T. L.; Grace, C. E.; Skelton, M. R.; Graham, D. L.; Gudelsky, G. A.; 
Vorhees, C. V.; Williams, M. T. ACS Chem. Neurosci. 2012, 3, 12–21. 
(205)  Artigas, F. ACS Chem. Neurosci. 2013, 4, 5–8. 
(206)  Wooster, T. J.; Johanson, K. M.; Fraser, K. J.; MacFarlane, D. R.; Scott, J. L. 
Green Chem. 2006, 8, 691–696. 
(207)  Sasson, Y. Handbook of Phase Transfer Catalysis; Chapman & Hall: London, 
United Kingdom, 1997. 
(208)  Petrowsky, M.; Glatzhofer, D. T.; Frech, R. J. Phys. Chem. B 2013, 117, 14432–
14437. 
(209)  Shaik, S.; Ioffe, A.; Reddy, A. C.; Pross, A. J. Am. Chem. Soc. 2006, 116, 262–
273. 
(210)  Maton, C.; De Vos, N.; Stevens, C. V. Chem. Soc. Rev. 2013, 42, 5963–5977. 
(211)  Acevedo, O.; Jorgensen, W. L.; Iodide, E. J. Phys. Chem. B 2010, 114, 8425–8430. 
(212)  Stanger, K. J.; Lee, J.-J.; Smith, B. D. J. Org. Chem. 2007, 72, 9663–9668. 
(213)  Varughese, P. J. Chem. Educ. 1977, 54, 666–669. 
(214)  Kohjiya, S.; Ohtsuki, T.; Yamashita, S. Makromol. Chemie 1990, 191, 397–403. 
(215)  Jiménez-González, C.; Ollech, C.; Pyrz, W.; Hughes, D.; Broxterman, Q. B.; 
Bhathela, N. Org. Process Res. Dev. 2013, 17, 239–246. 
(216)  Poechlauer, P.; Colberg, J.; Fisher, E.; Jansen, M.; Johnson, M. D.; Koenig, S. G.; 
Lawler, M.; Laporte, T.; Manley, J.; Martin, B.; O’Kearney-McMullan, A. Org. 
Process Res. Dev. 2013, 17, 1472–1478. 
151
References 
126 
(217)  Fringuelli, F.; Lanari, D.; Pizzo, F.; Vaccaro, L. Green Chem. 2010, 12, 1301–
1305. 
(218)  Bonollo, S.; Lanari, D.; Longo, J. M.; Vaccaro, L. Green Chem. 2012, 14, 164–
169. 
(219)  Constable, D. J. C.; Curzons, A. D.; Cunningham, V. L. Green Chem. 2002, 4, 
521–527. 
(220)  Bryan, M. C.; Dillon, B.; Hamann, L. G.; Hughes, G. J.; Kopach, M. E.; Peterson, 
E. A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; Sneddon, H. F. J. 
Med. Chem. 2013, 56, 6007–6021. 
(221)  Zhang, W.; Cue, B. W. Green Techniques for Organic Synthesis and Medical 
Chemistry; John Wiley & Sons, Ltd: Chichester, United Kingdom, 2012. 
(222)  Lapkin, A.; Constable, D. J. C. Green Chemistry Metrics: Measuring and 
Monitoring Sustainable Processes; John Wiley & Sons, Ltd: Chichester, United 
Kingdom, 2009. 
(223)  Trost, B. M. Angew. Chemie Int. Ed. English 1995, 34, 259–281. 
(224)  Adamo, A.; Heider, P. L.; Weeranoppanant, N.; Jensen, K. F. Ind. Eng. Chem. Res. 
2013, 52, 10802–10808. 
(225)  Cervera-Padrell, A. E.; Morthensen, S. T.; Lewandowski, D. J.; Skovby, T.; Kiil, 
S.; Gernaey, K. V. Org. Process Res. Dev. 2012, 16, 888–900. 
(226)  Williams, D. B. G.; Lawton, M. J. Org. Chem. 2010, 75, 8351–8354. 
(227)  Merck KGaA. Dry and Safe Drying Agents from Merck Millipore, 2013. 
(228)  Newman, S. G.; Jensen, K. F. Green Chem. 2013, 15, 1456–1472. 
(229)  Sreenath, K.; Pushpavanam, S. Chem. Eng. J. 2009, 155, 312–319. 
(230)  Kollonitsch, J. Ann. N. Y. Acad. Sci. 1965, 125, 161–171. 
(231)  Kortagere, S.; Ekins, S.; Welsh, W. J. J. Mol. Graph. Model. 2008, 27, 170–177. 
(232)  Bolt, H. M.; Gansewendt, B. Crit. Rev. Toxicol. 1993, 23, 237–253. 
(233)  Fishbein, L. Potential Industrial Carcinogens and Mutagens; 2nd ed.; Elsevie: 
New York, New York, 1981. 
(234)  Pearson, D. E.; Cowan, D.; Beckler, J. D. J. Org. Chem. 1959, 24, 504–509. 
(235)  Blackmar, G. E.; Wight, R. C.; Smith, R. B. Continuous Grignard Reactors. 
US3.911.037, 1975. 
(236)  Browne, D. L.; Deadman, B. J.; Ashe, R.; Baxendale, I. R.; Ley, S. V. Org. 
Process Res. Dev. 2011, 15, 693–697. 
(237)  Federsel, H.-J. Bioorg. Med. Chem. 2010, 18, 5775–5794. 
(238)  Jayadev, A.; Stiglitz, J. Health Aff. 2008, 28, 165–168. 
(239)  Aitken, M.; Berndt, E. R.; Cutler, D. M. Health Aff. 28, 151–160. 
(240)  Anderson, N. G.; Burdick, D. C.; Reeve, M. M. Org. Process Res. Dev. 2011, 15, 
162–172. 
(241)  Chew, W.; Sharratt, P. Anal. Methods 2010, 2, 1412–1438. 
(242)  Snead, D. R.; Jamison, T. F. Chem. Sci. 2013, 4, 2822–2827. 
(243)  Hartman, R. L. Org. Process Res. Dev. 2012, 16, 870–887. 
(244)  Pastre, J. C.; Browne, D. L.; O’Brien, M.; Ley, S. V. Org. Process Res. Dev. 2013, 
17, 1183–1191. 
(245)  Bogaert-Alvarez, R. J.; Demena, P.; Kodersha, G.; Polomski, R. E.; Soundararajan, 
N.; Wang, S. S. Y. Org. Process Res. Dev. 2001, 5, 636–645. 
(246)  Zhang, X.; Stefanick, S.; Villani, F. J. Org. Process Res. Dev. 2004, 8, 455–460. 
(247)  Bech Sommer, M.; Nielsen, O.; Petersen, H.; Ahmadian, H.; Pedersen, H.; Brøsen, 
P.; Geiser, F.; Lee, J.; Cox, G.; Dapremont, O.; Suteu, C.; Assenza, S. P.; 
Hariharan, S.; Nair, U. Methods for the Preparation of Escitalopram. 
WO03006449A1, 2003. 
152
References 
127 
(248)  Kirschneck, D.; Tekautz, G. Chem. Eng. Technol. 2007, 30, 305–308. 
(249)  White, T. D.; Berglund, K. D.; Groh, J. M.; Johnson, M. D.; Miller, R. D.; Yates, 
M. H. Org. Process Res. Dev. 2012, 16, 939–957. 
(250)  Johnson, M. D.; May, S. A.; Calvin, J. R.; Remacle, J.; Stout, J. R.; Diseroad, W. 
D.; Zaborenko, N.; Haeberle, B. D.; Sun, W.-M.; Miller, M. T.; Brennan, J. Org. 
Process Res. Dev. 2012, 16, 1017–1038. 
(251)  Grongsaard, P.; Bulger, P. G.; Wallace, D. J.; Tan, L.; Chen, Q.; Dolman, S. J.; 
Nyrop, J.; Hoerrner, R. S.; Weisel, M.; Arredondo, J.; Itoh, T.; Xie, C.; Wen, X.; 
Zhao, D.; Muzzio, D. J.; Bassan, E. M.; Shultz, C. S. Org. Process Res. Dev. 2012, 
16, 1069–1081. 
(252)  Gage, J. R.; Guo, X.; Tao, J.; Zheng, C. Org. Process Res. Dev. 2012, 16, 930–933. 
(253)  Loh, G.; Tanigawara, R.; Shaik, S. M.; Sa-ei, K.; Wong, L.; Sharratt, P. N. Org. 
Process Res. Dev. 2012, 16, 958–966. 
(254)  Mckenzie, P.; Kiang, S.; Tom, J.; Rubin, A. E.; Futran, M. AIChE J. 2006, 52, 
3990–3994. 
(255)  Cooper, T. W. J.; Campbell, I. B.; Macdonald, S. J. F. Angew. Chemie Int. Ed. 
2010, 49, 8082–8091. 
(256)  Rubin, A. E.; Tummala, S.; Both, D. A.; Wang, C.; Delaney, E. J. Chem. Rev. 
2006, 106, 2794–2810. 
(257)  Lombardino, J. G.; Lowe, J. A. Nat. Rev. Drug Discov. 2004, 3, 853–862. 
(258)  Baraldi, P. T.; Hessel, V. Green Process. Synth. 2012, 1, 149–167. 
(259)  Leng, R. B.; Emonds, M. V. M.; Hamilton, C. T.; Ringer, J. W. Org. Process Res. 
Dev. 2012, 16, 415–424. 
(260)  Dach, R.; Song, J. J.; Roschangar, F.; Samstag, W.; Senanayake, C. H. Org. 
Process Res. Dev. 2012, 16, 1697–1706. 
(261)  Poechlauer, P.; Manley, J.; Broxterman, R.; Gregertsen, B.; Ridemark, M. Org. 
Process Res. Dev. 2012, 16, 1586–1590. 
(262)  Muller, F. L.; Latimer, J. M. Comput. Chem. Eng. 2009, 33, 1051–1055. 
(263)  Federsel, H.-J. Nat. Rev. Drug Discov. 2003, 2, 654–664. 
(264)  Van Gerven, T.; Stankiewicz, A. Ind. Eng. Chem. Res. 2009, 48, 2465–2474. 
(265)  Laufer, S.; Holzgrabe, U.; Steinhilber, D. Angew. Chemie Int. Ed. 2013, 52, 4072–
4076. 
(266)  Tirronen, E.; Salmi, T. Chem. Eng. J. 2003, 91, 103–114. 
(267)  Buchholz, S. Chem. Eng. Process. 2010, 49, 993–995. 
(268)  Obenndip, D. A.; Sharratt, P. N. Chem. Eng. Res. Des. 2005, 83, 655–661. 
(269)  Papavasileiou, V.; Koulouris, A.; Siletti, C.; Petrides, D. Chem. Eng. Res. Des. 
2007, 85, 1086–1097. 
(270)  Carpenter, K. J. Chem. Eng. Sci. 2001, 56, 305–322. 
(271)  Levenspiel, O. Chem. Eng. Sci. 2002, 57, 4691–4696. 
(272)  Shah, N. Comput. Chem. Eng. 2004, 28, 929–941. 
(273)  Gernaey, K. V.; Cervera-Padrell, A. E.; Woodley, J. M. Comput. Chem. Eng. 2012, 
42, 15–29. 
(274)  Laínez, J. M.; Schaefer, E.; Reklaitis, G. V. Comput. Chem. Eng. 2012, 47, 19–28. 
(275)  Troup, G. M.; Georgakis, C. Comput. Chem. Eng. 2013, 51, 157–171. 
(276)  Wu, H.; White, M.; Khan, M. A. Int. J. Pharm. 2011, 405, 63–78. 
(277)  Tomba, E.; Facco, P.; Bezzo, F.; Barolo, M. Int. J. Pharm. 2013, 457, 283–297. 
(278)  Dunn, R. F.; El-Halwagi, M. M. J. Chem. Technol. Biotechnol. 2003, 78, 1011–
1021. 
(279)  Yu, L. X. Pharm. Res. 2008, 25, 781–791. 
(280)  Miller, D. C.; Davis, J. F. Ind. Eng. Chem. Res. 2000, 39, 2954–2969. 
153
References 
128 
(281)  Cervera-Padrell, A. E.; Skovby, T.; Kiil, S.; Gani, R.; Gernaey, K. V. Eur. J. 
Pharm. Biopharm. 2012, 82, 437–456. 
(282)  Parker, J. S.; Moseley, J. D. Org. Process Res. Dev. 2008, 12, 1041–1043. 
(283)  Moseley, J. D.; Brown, D.; Firkin, C. R.; Jenkin, S. L.; Patel, B.; Snape, E. W. 
Org. Process Res. Dev. 2008, 12, 1044–1059. 
(284)  Watanabe, K.; Yamagiwa, N.; Torisawa, Y. Org. Process Res. Dev. 2007, 11, 251–
258. 
(285)  Hefter, G. T.; Tomkins, R. P. T. The Experimental Determination of Solubilities; 
John Wiley & Sons, Ltd: West Sussex, England, 2004. 
(286)  Myerson, A. S. Handbook of Industrial Crystallization; 2nd ed.; Butterworth-
Heinemann: Woburn, 2002. 
(287)  Atkins, P.; De Paula, J. Physical Chemistry; 8th ed.; Oxford University Press: 
Oxford, 2006. 
(288)  Aksu, B.; De Beer, T.; Folestad, S.; Ketolainen, J.; Lindén, H.; Lopes, J. A.; de 
Matas, M.; Oostra, W.; Rantanen, J.; Weimer, M. Eur. J. Pharm. Sci. 2012, 47, 
402–405.  
 
 
154

Centre of Combustion and Harmful Emission Control 
Department of Chemical and 
Biochemical Engineering
Technical University of Denmark
Søltofts Plads, Building 229
DK-2800 Kgs. Lyngby
Denmark
Phone: +45 4525 2800
Fax: +45 4525 4588
Web:  www.chec.kt.dtu.dk
ISBN : 978-87-93054-53-0
